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ABSTRACT 
 
Conditional mutagenesis allows the introduction of tissue specific mutations in the mouse and is 
of  crucial  importance  in  converting  genome  sequence  information  into  functional  data  for 
biomedical research. Mice expressing the Cre recombinase in a spatially controlled manner are 
essential  in  creating  such  conditional  knock-outs.  A  wide  variety  of  Cre  mice  have  been 
generated, but there is a distinct lack of models expressing the recombinase faithfully and at 
high levels in cells of the innate immune system.  To address this need, three target genes, 
Itgb2l,  Marco  and  Msr1,  were  chosen  to  create  novel  neutrophil  and  macrophage  specific 
knock-in models harbouring iCre2, a recombinase engineered for increased expression levels. 
Two strategies were employed. Initially gene specific bacterial artificial chromosomes in which 
the iCre2 fragment replaced the endogenous translation start codon were created by Red/ET 
recombineering. Utilization of these BAC vectors for embryonic stem cell targeting successfully 
created knock-ins but the identification of homologous recombinants was complicated by the 
vectors’ large size. As the discovery of mutations impeding iCre2 functionality in the knock-in 
lines necessitated repeating the vector creation process, novel shorter vectors were designed. 
These vectors achieved targeting frequencies of around 10% and facilitated the isolation and 
verification of 9 Itgb2l and Marco specific iCre2 knock-in murine embryonic stem cell lines on 
the 129 genetic background. To determine tissue specific iCre2 expression before generating 
mouse models,  an in vitro haematopoietic differentiation system, utilising three-dimensional 
embryoid body formation and selective expansion of progenitors in the presence of IL-3 and 
MCSF, was adapted. Embryonic stem cells were successfully differentiated into macrophages 
as assessed by CD11b and F4/80 marker expression. Collectively, this work has established the 
foundations for obtaining viable myeloid specific Cre producer mouse strains and discusses the 
potential of their future application in elucidating the role of macrophages and neutrophils in 
innate immune function. 
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OVERVIEW 
 
Among the currently available Cre expressing mouse models for conditional mutagenesis in the 
haematopoietic  systems,  those  mediating  recombination  in  the  lymphoid  compartment 
dominate. The few models available targeting cells of the innate immune compartment largely 
suffer  from  low  expression  levels  and/or  additional  ectopic  recombination  in  non-myeloid 
tissues. The GE-Cre strain previously created by this lab, for example, designed to express the 
enzyme from the pro-myelocyte restricted ela2 locus (Tkalcevic et al., 2000), achieved less than 
50% deletion levels in macrophages and granulocytes in a model devised to remove the TGF-β 
receptor type II (S.Mahbub et al, unpublished data). With such low recombination frequencies 
resulting in mixed cell populations no phenotype was observed, highlighting the need for new 
and improved models. The objective of this work is therefore to create such mice utilizing the 
novel engineered recombinase iCre2,  which, through the integration of heterologous mouse 
introns, reaches significantly higher expression levels (Lacy-Hulbert et al., 2001). 
 
As no available myeloid Cre strain can selectively mediate recombination in either neutrophils 
or macrophages, three novel target loci were chosen as locales for iCre2 knock-in. Itgb2l is 
expressed in all neutrophils, Msr1 in all macrophages and Marco in subsets of tissue resident 
macrophages.  The  knock-in  strategy  is  set  up  such  that  iCre2  replaces  the  endogenous 
translation start codon ensuring minimal interference with the host gene’s regulatory sequences. 
 
The first three chapters of the introduction focus on the technical evolution of the Cre/loxP 
system,  the  essentials  in  creating  a  new  mouse  model  and  the  particulars  of  conditional 
mutagenesis in the haematopoietic compartment respectively. The final introductory Chapter 4 
briefly covers basics in stem cell biology and blood development from the embryo in vivo and 
in vitro as a macrophage differentiation assay was utilized to assess tissue specific recombinase 
expression prior to the creation of a murine model. 
 
After a brief summary of employed techniques in Chapter 5; Chapters 6 to 9 summarize and 
discuss  the  experimental  findings  of  this  project,  with  the  key  individual  objectives  and 
achievements recapitulated here: 
 
Chapter 6: The First Generation of iCre2 Knock-ins 
Objectives  Key Achievements 
• Identification of Homologous 
Recombinants Among Previously 
Created G418 Resistant ES Cell 
Colonies Using Gene Specific 
BAC Knock-ins 
• Design of PCR Strategies to Reduce Number of Candidate 
Clones 
• Application of Southern Blots to Identify Knock-in Lines 
for Itgb2l 
• Discovery of Faulty loxP Sites in All Vectors and Targeted 
Clones, Precluding Removal of the Resistance Marker   17 
Chapter 7: Constructing the Second Generation iCre2 Targeting Vectors 
Objectives  Key Achievements 
• Redesigning of 
Targeting Vectors to 
Utilize Shorter 
Homology Arms 
• Vector Construction in 
Two Rounds of Red/ET 
Recombinogenic 
Engineering 
• Successful Construction of BAC knock-ins by First Round of 
Recombineering 
• Discovery and Repair of Several Interfering Mutations 
• Construction and Verification of Plasmid Targeting Vectors 
Harbouring iCre2, a Selection Cassette and 4kb and 7kb Homology 
Arms for Itgb2l, Marco and Msr1 
 
Chapter 8: Creating 2
nd Generation iCre2 Embryonic Stem Cell Knock-ins 
Objectives  Key Achievements 
• Establishment of Knock-
in 129 ES Cell Lines 
• Removal of the G418 
Selection Marker 
• Isolation of 650 Drug Resistant Clones 
• Application of PCRs & Southern Blots to Identify 9 Knock-ins for 
Itgb2l and Marco 
• Removal of Neo
R 
• Discovery of Basal Marco Expression in Undifferentiated Embryonic 
Stem Cells 
 
Chapter 9: Generating Embryonic Stem Cell Derived Macrophages 
Objectives  Key Achievements 
• Implementation of a 
Haematopoietic 
Differentiation Protocol 
to Test iCre2 Expression 
in vitro 
• Testing, Analysis & Optimisation of Conditions to Produce Embryonic 
Macrophages 
• Creation of a Reporter Cell Line to Trace iCre2 Expression 
• Discovery of Dysregulated Marco Expression in Knock-in Cell Lines 
 
Finally, the closing Chapter 10 provides further discussion of the next steps required to produce 
the novel murine models, including possibilities for resolving technical obstacles encountered in 
the course of this project and for verifying tissue specific iCre2 expression in vivo. The Chapter 
also supplies a brief overview of potential applications. In the context of the models’ original 
intent, the cell specific ablation of TGF-β receptor type II, the current knowledge about TGF-β 
function  in  neutrophils  and  macrophages  is  reviewed  and  other  interesting  avenues  for 
conditional mutagenesis in the innate immune system are explored.   18 
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CHAPTER 1: CONDITIONAL GENE TARGETING IN THE MOUSE  
 
Mutational modification or inactivation of genes followed by phenotypic analysis remains the 
perhaps  most  important  method  in  elucidating  gene  function  in  mammals.  Prior  to  the 
development of directed mutagenesis, this technique was restricted to phenotypes resulting from 
rare spontaneous mutations, for example those causing hereditary diseases (Capecchi, 1989). 
The establishment of mouse embryonic stem cell technology (Bradley et al., 1984) allowed the 
targeted  introduction  of  mutations,  a  method  previously  restricted  to  bacteria,  into  more 
complex organisms (Thomas and Capecchi, 1987). The classical experiment (for further details 
see Chapter 2) uses homologous recombination to deactivate a chosen gene in all cells of the 
organism. Several disadvantages arise from this approach. About 15% of complete knock-outs 
prove to be lethal during mouse embryonic development (Copp, 1995), leaving no viable model 
for studying. Furthermore, genes may play important roles at various stages of ontogeny; but 
conventional knock-outs show only the target gene’s earliest purpose. Gene function can also 
vary among tissues, which can make organism-wide null phenotypes too complex to analyse. 
Conditional  gene  targeting  (Rajewsky  et  al.,  1996)  utilises  the  properties  of  site  specific 
recombinases,  in  particular  the  Cre/loxP  system,  to  circumvent  these  difficulties.  Genes  of 
interest can be inactivated in a spatially and/or temporally controlled manner. The technicalities, 
advantages and drawbacks of this method are described in the following chapter, together with 
available alternatives for the conditional control of gene expression in the mouse system. 
 
1.1  Site-specific Recombination 
 
Site-specific  recombination  is  a  process  of  breaking  and  re-connecting  DNA  segments  that 
commonly results in the integration, excision or inversion of sequences. The exchange of DNA 
strands  is  mediated  by  a  protein,  the  site-specific  recombinase,  which  recognizes  a  pair  of 
distinct recombination sites (Grindley et al., 2006). Many site-specific recombinases have been 
described,  all  of  which  are  responsible  for  maintaining  genetic  stability,  altering  gene 
expression  or  inducing  genetic  diversity in  their  host  organisms.  Site-specific  recombinases 
have evolved from topoisomerases; enzymes controlling the winding and unwinding of DNA 
(Cheng et al., 1998; Van Duyne, 2009). They fall in two distinct families depending on whether 
the amino acid forming an intermediate bond with the DNA’s phosphodiester backbone during 
recombination is a tyrosine or  a serine. Site-specific recombinases need no  energy  rich co-
factors such as ATP, because the energy released during the breakage of the phosphodiester 
bonds is sufficient to drive recombination. 
 
The tyrosine recombinase family (Argos et al., 1986; Nunes-Düby et al., 1998), also called λ 
integrase  family,  contains  Cre  and  Flp,  both  of  which  have  been  used  in  conditional   20 
mutagenesis in the murine system. A generalized mechanism of action is illustrated in Figure 
1.1. φ31, a member of the serine recombinase family (Smith and Thorpe, 2002), also known as 
the resolvase family, has also been utilised, particularly in order to facilitate integrations in 
mammalian genomes. 
 
Figure 1.1 Tyrosine Recombinase Mechanism 
Four recombinase subunits (white & yellow) and two DNA duplexes (red and blue) form a 
synaptic complex. Cleavage (blue stars) of one strand each by a nucleophilic tyrosine initiates 
recombination. The cleaved strands are exchanged and re-ligated forming a Holliday junction. 
Isomerization  of  the  complex  enables  the  second  strand  to  undergo  the  same  process  and 
resolves the junction. Illustration taken from (Grindley et al., 2006). 
 
1.2  The Cre/loxP System 
 
The  Cre  recombinase  was  first  described  in  1981  as  the  factor  responsible  for  mediating 
recombination  in  the  filamentous  bacteriophage  P1  (Sternberg  and  Hamilton,  1981).  The 
enzyme catalyses site-specific recombination between sites termed loxP (locus of X over P1) 
(Hoess  et  al.,  1982).  The  system  plays  an  important  role  in  maintaining  genetic  stability 
throughout  the  phage’s  life  cycle  by  controlling  the  integration  into  and  the  excision  from 
bacterial chromosomes as well as recombination aimed at increasing genetic diversity (Austin et 
al., 1981). 
 
The loxP sites are 34 base pairs (bp) long and are characterised by an 8bp asymmetric core 
sequence defining orientation (Hoess et al., 1986) flanked by 13bp long palindromic inverted 
repeats (Figure 1.2A). The recombination process can have three distinct outcomes depending 
on the spatial position of the loxP sites (Figure 1.2B). Two parallel loxP sites on the same 
double-stranded DNA molecule result in deletion of the intermediate segment, with one loxP 
site, made from the two halves of the pre-recombinatory sites, left behind. LoxP sites with an 
anti-parallel configuration, however, cause the intervening DNA stretch to be excised, inverted   21 
and re-inserted at the same location (Abremski et al., 1983). Sites located on different DNA 
molecules cause translocation or integration depending on whether both fragments are linear or 
one  is  linear  and  one  circular  (Sternberg  et  al.,  1981).  Excision  and  reintegration  form  an 
equilibrium, favouring excision in presence of the enzyme (Baer and Bode, 2001).  
 
Several groups have attempted to analyze the role of loxP sequence in recombination. Spacer 
length, but not sequence, is considered essential for efficient recombination (Hoess et al., 1986). 
Nucleotides 2 to 7 of the 8bp spacer were found to be crucial in recombination. Mutations at 
these positions abolished Cre mediated strand exchange between wild type and mutant sites. 
Base pairs 1 and 8 could be mutated without affecting recombination too severely (Lee and 
Saito, 1998). Several mutant loxP sites with single or double base pair changes in the spacer 
region  are  able  to  efficiently  recombine  with  each  other  but  not  with  the  wild  type  site. 
Contrariwise,  another  study  demonstrated  that  only  spacer  positions  4  and  5  are  essential, 
whereas all other nucleotides could be mutated with recombination still taking place, if at a 
lower frequency (Araki et al., 2002).  Mutations in the left and right inverted repeats have also 
been  described  as  functional,  particularly  those  involving  the  initial  and  terminal  5bp.  The 
TATA  sequence,  immediately  adjacent  to  the  spacer  on  the  left  and  right,  however,  seems 
indispensable for recombination as mutations of that area have not been reported (Missirlis et 
al., 2006). Modified loxP sites are useful when multiple genes in the same model are to be 
targeted or the rapid re-excision of an integrated product is to be avoided (Hoess et al., 1986). 
For an overview of loxP variants commonly used see Figure 1.2C. 
 
The  Cre  enzyme is a 38.5kDa protein that binds the inverted repeats of loxP sites  with its 
carboxy-terminal fragment (Hoess et al., 1990). The resolution of the Cre protein structure (Guo 
et al., 1997) revealed that the enzyme is folded in two distinct domains consisting primarily of 
α-helices. The enzyme’s active site is made up of a catalytic triad with arginines at positions 
173  and  292  and  histidine  at  position  289,  as  well  as  a  conserved  nucleophilic  tyrosine  at 
position 324 and a tryptophan at 315. Two Cre monomers bind to one loxP site forming a C-
shaped clamp around the DNA and subsequently aggregate as a tetramer with the Cre molecules 
bound to the second loxP site to initiate recombination (Figure 1.2D) (Gopaul et al., 1998). 
 
Recently, it was discovered that Cre recombination occurs primarily during the early S-phase of 
the  mammalian  cell  cycle  (Hashimoto  et  al.,  2008),  similar  to  the    endogenous  process  of 
double-stranded DNA break repair by homologous recombination (Mao et al., 2008). Since its 
first  successful  expression  in  a  mouse  cell  line  (Sauer  and  Henderson,  1989),  the  Cre/loxP 
system has been widely used to modify mouse genomes (Branda and Dymecki, 2004; Orban et 
al., 1992). Furthermore the system has been applied in yeast (Sauer, 1987), drosophila (Siegal 
and Hartl, 2000), zebrafish (Pan et al., 2005) and plants (Sieburth et al., 1998).    22 
 
Figure 1.2 The Cre/loxP System 
LoxP sites consist of 34bp (A) with an orientation-defining 8bp spacer flanked by 13bp-inverted 
repeats.  The  spatial  orientation  of  loxP  sites  (B)  determines  whether  excisions,  insertions, 
translocations or inversions occur. Several loxP mutants (C), carrying one or more mutated 
nucleotides (underlined), are in use. The Cre protein binds to the inverted repeats and forms a 
tetramer. This juxtaposes the DNA strands and makes recombination possible (D). Illustration D is 
taken from (Ennifar et al., 2003). 
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1.2.1  Modifications of the Cre Recombinase 
 
The  Cre  enzyme  has  been  modified  extensively  in  order  to  enhance  its  functionality. 
Modifications  are  typically  either  meant  to  increase  expression  levels  of  the  protein  in 
experimental models or to enable inducibility of expression. 
 
1.2.1.1  Modifications of the Cre Coding Sequence 
 
The  Cre  gene  originates  from  a  prokaryotic  background.  Codon  usage  differs  between 
prokaryotes and eukaryotes and high CpG contents typically found in prokaryotic genes can 
lead to epigenetic silencing by methylation in mammals (Cohen-Tannoudji et al., 2000). Silent 
mutations have been employed to adapt the Cre sequence to mammalian codon usage and to 
minimize GC pairs (Koresawa et al., 2000; Shimshek et al., 2002). Protein expression levels and 
recombination events observed increased by about 50% and 80% respectively. 
 
The Cre version used in this work (Figure 1.3) has further been optimized by the insertion of 
introns. Introns have been shown to enhance gene expression in transgenic mice considerably 
(Palmiter et al., 1991) by creating a spliceable structure reminiscent of mammalian genes, which 
improves mRNA stability. Short introns from the inmunoglobulin loci, more specifically from 
genes encoding the heavy chains of IgM and IgE, were inserted into a partially codon-improved 
Cre version lacking GC pairs (Lacy-Hulbert et al., 2001). The intronic sequences, 109 and 89bp 
in size, are compatible with high expression levels and do not increase the size of the Cre gene 
significantly. mRNA expression levels of this construct termed iCre2 were 30 fold higher than 
observed  with  the  codon  improved  Cre  version  alone.  iCre2  also  contains  an  E1α  nuclear 
localisation signal (NLS) at its 5’ end to enhance transfer into the nucleus, the location of Cre-
catalysed recombination. It has recently been shown, however, that Cre is able to cross the 
nuclear membrane without an extra NLS (Will et al., 2002). This is possibly due to Cre being a 
basic protein carrying an intrinsic, bipartite NLS-like structure (Andreas et al., 2002). 
 
 
 
 
 
 
Figure 1.3 Gene Structure of iCre2 
The Cre version applied in this work has been engineered to remove GC pairs and adapt the 
codon usage to mammals. Furthermore two heterologous introns (i1:109bp; i2:89bp) have been 
inserted  to  create  an  artificial  exon  structure  (E1:567bp;  E2:213bp;  E3:264bp).  In  addition, 
iCre2  carries  a  NLS  for  better  translocation  into  the  nucleus  and  a  polyA/pause  (pAp)  for 
efficient  termination  of  transcription.  The  inducible  version  is  fused  to  a  human  estrogen 
receptor fragment (ER
T2) and does not carry the NLS. Figure modified from (Lacy-Hulbert et al., 2001).   24 
1.2.1.2  Inducible Cre Fusion Constructs 
 
Numerous  attempts  have  been  made  to  render  Cre  temporally  inducible.  Though  the  34bp 
recognition site is stochastically unlikely to occur randomly in mammalian genomes, similar 
“pseudo-loxP”  sites  have  been  found  in  both  mouse  (Schmidt  et  al.,  2000)  and  human 
(Thyagarajan et al., 2000). In murine genomes, pseudo-loxP sites occur every 1.2 Megabases 
and,  while  having  a  much  lower  Cre  affinity,  can  promote  illegitimate  recombination 
compromising  chromosomal  integrity  (Semprini  et  al.,  2007).  In  cell  culture,  prolonged 
exposure to high doses of Cre can be cytotoxic due to chromosomal degradation (Loonstra et 
al., 2001). Some Cre mice, like the pancreas specific RIP-Cre that is glucose intolerant (Lee et 
al., 2006), show phenotypic abnormalities, though whether this is due to the transgene, insertion 
locus or a result of Cre toxicity is unknown. 
 
Temporal inducibility can be partly achieved by coupling Cre expression to a promoter only 
active during a certain period of development or regulable by endogenous molecules. The first 
inducible  Cre  model  was  the  Mx1-Cre  mouse,  in  which  expression  was  coupled  to  the 
interferon-responsive promoter Mx1 (Kuhn et al., 1995). As this system is potentially leaky, 
others, using hormone-inducible receptor fragments, have been conceived. Fusion constructs 
between  Cre  and  steroid  receptor  ligand  binding  domains  (LBD)  are  popular.  The  mouse 
(Zhang et al., 1996) and human (Metzger et al., 1995) estrogen receptor LBDs have been widely 
used. Without induction the fusion construct is held in the cytoplasm bound to Hsp90, not able 
to translocate to the nucleus and is therefore not able to mediate site-specific recombination.  
 
Initial  attempts  utilized  wild-type  receptor  fragments  whose  interactions  with  endogenous 
estrogen  were  deleterious.  Later  constructs  employed  mutated  receptors,  particularly  the 
G400V/M543A/L544A (Feil et al., 1997) version of the human estrogen LBD, designated ER
T2. 
Induction  only  occurs  via  the  estrogen  antagonist  tamoxifen  or  its  metabolic  derivate  4-
Hydroxytamoxifen (OHT) (Williams et al., 1994). In cell culture, the system is able to achieve 
100%  recombination  (Zhang  et  al.,  1996).  In  vivo,  mouse  models  are  fed  or  injected  with 
tamoxifen or OHT over a course of several days at differing stages of development. Background 
Cre function could not be observed, but recombination levels following induction typically do 
not reach 100% and are highly tissue dependent (Casanova et al., 2002; Hayashi and McMahon, 
2002). In the initial stages of this project a fusion construct between iCre2 and ER
T2 (Figure 
1.3), was used to achieve inducibility. 
 
Other inducible Cre systems include fusion constructs with mutant human progesterone receptor 
LBD (Wunderlich et al., 2001), mutant human glucocorticoid receptor LBD (Brocard et al., 
1998), or doxycycline inducible Cre (DAI-Cre; also see section 1.6.1.) (Holzenberger et al.,   25 
2000b), regulated by the prokaryotic tetracycline repression system (Belteki et al., 2005). A 
conceptually  new  approach  mediates  inducibility  by  splitting  the  Cre  recombinase  in  two 
inactive parts, each fused to proteins that are able to dimerize (DiCre) and thus activate Cre 
function in the presence of rapamycin (Jullien et al., 2007). Most recent efforts rely on Cre 
induction by light. Coupling the nucleophilic tyrosine residue in the enzyme’s active centre to 
an  o-nitro  benzyl  residue  renders  the  recombinase  inactive.  UVA  radiation  removes  the 
inhibitory group and activates Cre function (Edwards et al., 2009). 
 
1.3  The Flp/FRT System 
 
Flp is a site-specific recombinase originally discovered in the yeast Saccharomyces cerevisiae 
(Broach and Hicks, 1980). The 43kDa enzyme recognizes FRT sites, which have a topology 
similar to the loxP sites. An 8bp spacer is flanked by two 13bp inverted repeats. However, a 
further 13bp direct repeat is necessary for complete Flp function. Shorter FRT sites lacking the 
direct repeat can  mediate  excision but not integration. Three  Flp molecules, one bound per 
repeat, are required for DNA cleavage (Bode et al., 2000). 
 
Flp is used to a somewhat lesser extent than Cre, possibly due to its lower temperature stability. 
Cre is fully active at 37˚C and can survive temperatures of up to 46˚C. Flp on the other hand, 
has a thermo optimum of 30˚C and is labile above 39˚C. Flp also has been reported to need 
higher expression levels than Cre in order to function (Buchholz et al., 1996). Engineered Flp 
versions,  exhibiting  higher  temperature  stability  (Buchholz  et  al.,  1998)  and  improved 
expression  levels  following  codon  optimization  (Kondo  et  al.,  2009),  help  overcome  these 
drawbacks.  In  an  assay  analyzing  codon  improved  Flp  recombination  activity  on  a 
chromosomal target, however, it only reached 10% of the recombination levels observed with 
Cre (Andreas et al., 2002). Ligand-inducible versions of Flp, similar to those described for Cre, 
have  also  become  available  (Hunter  et  al.,  2005).  Flp  has  been  successfully  utilized  in 
mammalian cell culture (O'Gorman et al., 1991), drosophila (Theodosiou and Xu, 1998), plants 
(Luo and Kausch, 2002) and mice. 
 
1.4  The φ31/attP/attB System 
 
The φ31 integrase is derived from a streptomyces phage (Kuhstoss and Rao, 1991). It mediates 
recombination between dissimilar attachment (attB/attP) recognition sites. AttP is found in the 
phage genome and attB on the bacterial chromosome. Recombination results in the phage being 
integrated into its host genome, which generates two chimeric sites; attL and attR. The minimal 
sizes for recombination are 39bp (attP) and 34bp (attB) in size respectively, characterized by 
inverted repeats resembling the loxP and FRT sites, and a core consisting of the 3 nucleotides   26 
TTG. Whereas integrations catalysed by Cre and Flp are reversible due to the creation of two 
identical  parallel  sites  which  undergo  rapid  re-excision,  integration  carried  out  by  φ31  is 
unidirectional (Groth et al., 2000). 
 
Mammalian  genomes  have  been  shown  to  possess  a  significant  number  of  pseudo-att  sites 
(about 100-1000 in both mouse and human), which are also recognized by the integrase and 
could  serve  as  targets  for  the  directed  integration  of  genes  without  having  to  introduce 
attachment sites first (Thyagarajan et al., 2001). φ31 functions in both human and mouse ES 
cells and could be stably integrated and transmitted via the germline (Belteki et al., 2003).  
 
1.5  Creating Conditional Knock-outs 
 
In practice the creation of conditional knock-outs requires a Cre producer mouse, expressing the 
recombinase, and a Cre responder mouse carrying a floxed (flanked by loxP sites) version of the 
gene of interest (Branda and Dymecki, 2004). Crossing a female homozygous for the floxed 
allele to a male heterozygous for Cre results in 50% of the offspring carrying the Cre allele. All 
F1 offspring are heterozygous for the floxed allele. A F2 generation obtained by intercrossing 
the Cre positive F1 animals establishes the conditional knock-out (Figure 1.4). When Cre is 
transmitted maternally, deletions have sometimes been observed without inheritance of the Cre 
allele due to maternal imprinting, e.g. when Cre mRNA or protein were transferred into the 
oocyte (Cochrane et al., 2007; Matthaei, 2007). 
 
Cre mice are created by random transgenesis or targeted insertion of Cre into an endogenous 
locus  (knock-in;  further  details  in  Chapter  2).  Cre  expressing  strains  are  classified  by  their 
deletion patterns as tissue specific; inducible; deleter and balancer (Kuhn and Schwenk, 1997). 
Tissue specific and/or inducible strains are supposed to mediate target gene deletion only in 
defined cells at a given time in development. Deleters possess an ubiquitously expressed Cre, 
active from the early stages of embryonic development and are consequently able to generate 
organism wide deletions that resemble conventional knock-outs. Balancer mice create mosaic 
knock-outs as their Cre recombinase is active in various tissues at levels below maximum.  
 
Numerous  Cre  expressing  mice  have  been  created  over  the  past  15  years,  the  recently 
established Cre-X-database (Nagy et al., 2009) lists several hundred entries with specificities 
spanning virtually all tissues and developmental periods. About half are Cre knock-ins with the 
other half being randomly inserted transgenes. The number of Cre strains is too broad for a 
complete detailed discussion. Mice used for studying the immune system, in particular myeloid 
tissues, like the models proposed by this thesis, are discussed in Chapter 3.    27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Generation of Conditional Knock-outs 
F1  Offspring  from  heterozygous  Cre  mice  (Gen1
+/Cre/Gen2
+/+)  and  homozygous  floxed  
(Gen1
+/+/Gen2
flox/flox) mice are all heterozygous for the flox allele. 50% also carry the Cre allele 
heterozygously. Inter-crossing Cre+ F1 individuals is necessary to obtain conditional knock-
outs  in  F2.  The  chance  of  obtaining  the  shown  phenotype,  heterozygous  for  Cre  and 
homozygous for the floxed allele is 1 in 8 or 12.5%. Temporal and/or spatial restriction of Cre 
expression will be reflected in the observed deletion pattern. Gen1 represents the Cre knock-in 
site, whereas Gen2 is the chosen floxed target gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Options for the Generation of Floxed Alleles 
Exons can be flanked by loxP sites with several strategies based on homologous recombination. 
Replacement  vectors  carrying  the  recombinase  sites,  positive  (+)  and  negative  (-)  selection 
marker recombine with the target locus. After isolating correctly targeted clones, floxed alleles 
are generated by transient expression of a recombinase. In the Dual Recombinase Strategy the 
exon is flanked by loxP sites, whereas the positive selection marker is surrounded by FRT sites. 
Flp action deletes the marker leaves the floxed exon and one FRT site behind (A). The Triple 
LoxP Strategy relies on three loxP sites encircling exon and marker. Transient Cre action results 
in three possible alleles. If the whole construct is deleted; a null allele is left behind. Similarly, 
either the exon or the selection marker can be removed. The latter results in a floxed allele. The 
graphic is modified from (Branda and Dymecki, 2004). 
A  Dual Recombinase Strategy B  Triple loxP Strategy  28 
Likewise,  many  mouse strains carrying floxed versions of genes have been created, though 
these  have  yet  to  be  indexed.  Typically,  loxP  sites  are  placed  in  intron  sequences  by 
homologous  recombination  (Figure  1.5);  surrounding  one  or  more  exons  essential  for  gene 
function. Cre mediated deletion renders the gene inactive. So far intronic loxP sites have not 
been reported to influence the phenotype. The accessibility and distance of unidirectional loxP 
sites in the genome, however, play an important role in whether complete deletion is achievable. 
Floxed  alleles  for  Rb,  Brca2  and  p53,  for  example,  showed  very  different  and  also  tissue 
dependent  recombination  frequencies  (from  barely  detectable  to  100%)  when  crossed  to  a 
tamoxifen-inducible ubiquitous Cre deleter mouse. Therefore the usefulness of a particular Cre 
strain has to be assessed for each floxed target gene independently (Vooijs et al., 2001). 
 
Apart from using genetically engineered mice expressing Cre endogenously, several virus-based 
methods to deliver the recombinase have been described, especially for tissues like the brain or 
uterus  were  few  specific  promoters  are  known.  Temporal  and  spatial  control  is  commonly 
achieved  by  choosing  the  route  of  virus  administration,  varying  cellular  susceptibility  to 
infection, and the promoter driving expression.  
 
Adenoviral Cre, for example, transfused through the tail vein mediated target gene deletion in 
numerous  somatic  tissues  except  the  brain  (Akagi  et  al.,  1997).  Microinjections  of  similar 
vectors in the brain resulted in selective localized knock-outs (Sinnayah et al., 2004). Infused 
adenoviral Cre was used to restrict target gene deletion to the mouse uterus (Wang et al., 2006). 
Finally, adenoviral Cre served to delete the floxed G418 selection marker during embryonic 
development at the 16 cell morula stage (Kaartinen and Nagy, 2001). Retroviral Cre mediated 
recombination on a single cell level in adult mouse neurons after injection in the brain (Tashiro 
et al., 2006). Similarly, self deleting Cre lentiviruses were successfully directed to the brain 
(Pfeifer  et al., 2001) and trophoblast tissues of the  mammalian placenta (Georgiades et al., 
2007).  Drawbacks  of  viral  delivery  are  potential  unwanted  immune  side  effects  caused  by 
infection and targeting not being as precise as when Cre is expressed from an endogenous locus. 
 
Another  technique,  used  primarily  in  vitro  in  cell  culture,  utilizes  transducible  Cre  protein. 
Unmodified  Cre  recombinase  is  able  to  cross  the  plasma  membrane  and  to  facilitate  low 
recombination levels of around 10% depending on protein concentration (Will et al., 2002). 
Fusing Cre protein to HIV derived basic translocation peptide TAT improved recombination 
levels to more than 90% when added to the culture medium (Joshi et al., 2002; Nolden et al., 
2006; Nolden et al., 2007; Peitz et al., 2002). 
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1.6  Conditional Gene Expression as Alternative to Conditional Knock-outs 
 
Conditional knock-outs by site specific recombinases switch off gene expression by physically 
removing the target from the mouse genome. However, alternative methods exist to generate 
knock-out phenotypes on a transcriptional or post-transcriptional/translational level, preferably 
in a reversible switch-like manner.  
 
1.6.1  The TetR System 
 
The  most widely used system for transcriptional transactivation is based on the tetracycline 
operon  regulatory  system  originally  found  in  Escherichia  coli.  Similar  systems  include 
Gal4/UAS  from  Saccharomyces  cerevisiae  and  lac  from  E.  coli.  They  are  less  commonly 
applied in mouse models and are not further described here but are extensively reviewed in 
(Mallo, 2006).  
 
The TetR system was first shown to be functional in HeLa cells and consists of a mutant Tet 
repressor (TetR) fused to the Herpes simplex viral VP16 transcriptional transactivation domain. 
The repressor binds both tetracycline derivatives and the tetO operator sequences inserted in 
front of the target gene. The system exists in two versions, tet-off and tet-on. In the tet-off 
system (Figure 1.6A), the tetracycline controlled transactivator (tTA) does not bind the operator 
in the presence of tetracycline, thereby switching off transcription (Gossen and Bujard, 1992). 
The tet-on system (Figure 1.6B) works in a reciprocal manner. The transactivator is mutated 
(rtTA), so that it only binds the operator and induces transcription in presence of the inducer 
(Gossen and Bujard, 1992; Gossen et al., 1995). The current inducer of choice is doxycycline as 
it is cheap,  widely available,  reaches most tissues effectively and is active below cytotoxic 
levels.  The  kinetics  of  the  rtTA  system  are  much  faster  than  those  of  tTA,  with  induced 
expression occuring within an hour compared to as much as several days for tTA (Kistner et al., 
1996).  
 
Similar to Cre and loxP mice, a large number of tet-on/off mouse models have been generated 
where tissue specifity is mediated by the selected promoter controlling tTA or rtTA. Problems 
encountered are remarkably similar to the Cre/loxP system. Regulation in conditional mouse 
models can be leaky, resulting in incomplete gene activation or inactivation. High expression 
levels  of  the  transactivator  can  be  cytotoxic  due  to  pleiotropic  gene  regulation  effects 
(Morimoto and Kopan, 2009; Zhu et al., 2002). 
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Figure 1.6 Regulation of Gene Expression by the TetR System 
In the tet-off system (A) the transactivator (tTA) binds to the response element (7xtet0) and 
switches on gene expression. Doxycycline (red), bound to tTA, silences the gene of interest by 
inhibiting its binding to the response element. The mutated transactivator (rtTA) activates gene 
expression, only in the presence of doxycycline (B). Illustration taken from (Bockamp et al., 2008). 
 
The TetR system has also been used to render Cre temporally inducible. The LC-1 transgenic 
line (Schonig et al., 2002), for example, carries a bi-directional doxycycline inducible construct 
that expresses Cre and luciferase upon induction. When crossed to a transgenic line expressing 
rtTA  in  a  liver  specific  manner,  100%  tissue-specific  recombination  could  be  observed 
following induction in one out of five lines. Similar results were obtained for a cross of a TetR 
inducible transgenic Cre line with a tTA transgenic line expressing the transactivator from the 
brain-specific CAMKIIα promoter (Lindeberg et al., 2002). Here, Cre mediated recombination 
could be switched off effectively by continuously feeding the mice with doxycycline.  
 
In an inverse scenario, the expression of transactivators themselves has been engineered to be 
inducible by Cre, due to placing an excisable STOP cassette in front of rtTA. In a recently 
described triple transgenic model (Belteki et al., 2005), a knock-in mouse line carrying a STOP-
rtTA cassette controlled by the ubiquitously expressed ROSA26 promoter (Soriano, 1999) was 
crossed to a double transgenic line expressing tissue-specific Cre and tetracycline responsive 
vascular endothelial growth factor (VEGF-A). Cre-mediated recombination enabled spatial, and 
doxycycline administration conferred temporal control of transgene expression. Using a Cre 
activatable rtTA locus abrogates the need to create novel tissue-specific lines in cases where 
useful Cre lines already exist. In another lately described mouse model, however, where Cre and 
rtTA  were knocked into the ROSA26 locus, tightly controlled generalized expression could 
only be achieved during early embryonic development. Adult mice showed significant leakage 
of Cre activity and failure of doxycycline induction (Backman et al., 2009). 
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1.6.2  RNA Interference 
 
RNA  interference  (RNAi)  is  a  eukaryotic  mechanism  in  which  double-stranded  RNA  is 
degraded  in  a  sequence-specific  manner.  RNAi  evolved  to  protect  cells  from  viral  RNAs 
(Waterhouse et al., 2001) but has since also been implied in the endogenous regulation of gene 
expression. Double-stranded RNA (dsRNA) is rapidly broken down into short duplexes varying 
between  21  and  28  nucleotides,  which  ultimately  results  in  global  translational  silencing 
(Meister  and  Tuschl,  2004).  Several  types  of  small  RNAs  occuring  in  cells  have  been 
discovered:  siRNAs  (short  interfering  RNAs),  microRNAs  (miRNAs)  and  repeat-associated 
short interfering RNAs (rasiRNAs). rasiRNAs and siRNAs originate from viral sequences or 
overlapping  transcripts,  whereas  miRNAs  are  the  degradation  products  of  endogenous 
transcripts with 20-50bp sequence homology that form dsRNA hairpins.  
 
Since  the  first  report  of  gene  knock-down  in  mice,  where  small  siRNA  expressed  from  a 
transgene successfully silenced reporter GFP expression in all assayed tissues (Hasuwa et al., 
2002), RNAi has been popular as a means of achieving gene inactivation. In vivo mouse models 
usually rely on transiently infused or injected synthetic short siRNA oligonucelotides matched 
to an endogenous transcript, stably inserted DNA fragments expressing miRNAs ubiquitously 
from  tRNA  or  RNA  polymerase  III  promoters  or  shRNAs  (short  hairpin  RNAs)  expressed 
tissue-specifically  from  appropriate  promoters  (Gao  and  Zhang,  2007).  Drawbacks  of  this 
method include incomplete and variable knock-downs, non-specific silencing known as an off-
target effect (Denovan-Wright et al., 2008) and the induction of interferon responses usually 
only seen as an in vivo defence mechanism against viral infections (Cao et al., 2005). 
 
Several conditional knock-down models combining RNAi with the Cre/loxP or TetR systems 
have been established. For example, a transgenic mouse line harbouring RNA-PolIII promoter 
(U6) inactivated by the insertion of a floxed Neo
R gene was coupled to a RNAi construct for 
Fgrf2.  Crossing  to  a  deleter  Cre  mouse  (EIIa-Cre)  activated  RNAi  and  resulted  in  a  95% 
reduction of Fgrf2 transcripts, creating a lethal phenotype, just like the conventional Fgrf2 null 
knock-out. Crossing to a mesenchyme specific Cre line (AP2-Cre) generated a viable model 
with a distinct phenotype (Coumoul et al., 2005). The combination of two independent RNAi 
constructs inactivated by stop cassettes and flanked by distinct mutant loxP sites enabled the 
knock-down of two genes, Gsk-3α/Gsk-3β and Erk1/Erk2 simultaneously with a brain specific 
Cre  line  (Nestin-Cre)  (Steuber-Buchberger  et  al.,  2008).  Lentiviral  constructs  in  which  the 
RNAi inserts are antisense to the promoter, but invertible by Cre mediated recombination, have 
also been utilized successfully in a conditional p53 knock-down strategy (Stern et al., 2008).   32 
CHAPTER 2: MAKING GENETICALLY ENGINEERED MICE 
 
After the completion of the human and mouse genome projects, the need to transform genetic 
sequence information into functional data is currently the central issue in biomedical research. 
Traditionally,  spontaneous  mutation  provided  interesting  mouse  phenotypes  for  analysis. 
However, the spontaneous rate of mutagenesis (5x10
-6 per locus) (Stanford et al., 2001) proved 
far too low for extensive studies. Genetically engineered mice have consequently grown into a 
major tool for elucidating gene function. 
 
The first genetically engineered mouse model was created in 1980 by injecting a plasmid vector 
in the pro-nucleus of a fertilized egg. Mice born after implanting these embryos into pseudo-
pregnant  females  showed  stable  integration  of  the  extraneous  sequences  throughout 
development (Gordon et al., 1980). This pioneering work started the era of transgenesis, the 
random integration of genetic sequences into organisms. The next major development, gene 
targeting, occurred in the 1990s. The method allows the directed modification of the murine 
genome and was honoured with the 2007 Nobel Prize for Medicine. Two major discoveries 
paved  the  way  for  this  success.  First,  murine  embryonic  stem  cells  could  be  isolated 
successfully and were shown to contribute to the mouse germline when re-introduced into the 
embryo (Evans and Kaufman, 1981; Martin, 1981; Smithies et al., 1985). Second, homologous 
recombination was established in those cells, providing a technique to access and engineer any 
chosen gene (Smithies et al., 1985).  
 
Random transgenesis and targeted modification have been used to create thousands of modified 
mice.  They  include  both  loss-of-function  (knock-out)  and  gain-of  function  (knock-in, 
transgenes
1)  models.  Both  approaches  are  introduced  in  this  chapter  with  regards  to  their 
advantages, drawbacks and most recent developments. 
 
A  further  strategy  to  generate  mouse  models  is  random  chemical  mutagenesis.  Rather  than 
establishing defined genotypes, random mutations are introduced by treating mice with N-ethyl-
N-nitrosourea (ENU). A number of offspring mice will exhibit an interesting phenotype and 
reverse genotypic analysis is then used to illuminate gene function. The technique has no direct 
relevance to the herein presented  work and is therefore not discussed further, but has been 
extensively reviewed elsewhere (Acevedo-Arozena et al., 2008; Cook et al., 2006; Soewarto et 
al., 2009). All major mouse mutagenesis methods are summarized in section 2.4. 
 
                                                 
1 This work uses knock-in as a synonym for a gene inserted into a defined locus as a single copy by 
homologous recombination. Transgenes represent random, non-homologous recombinations.   33 
2.1  Transgenesis 
 
Classic  transgenesis  enables  the  over-expression  of  endogenous  or  heterologous  genes  and 
relies on relatively short plasmid or viral vectors that are injected into fertilized eggs. Vectors 
are no more than 10-20kb in length and carry the transgene together with a promoter-enhancer 
sequence  determining  expression  pattern  and  level  (Rulicke,  2004).  The  DNA  is  randomly 
inserted  into  the  genome  in  one,  or  more  typically,  multiple  copy  numbers  and  stably 
transmitted to offspring. The insertion of multiple copies, often hundreds, commonly results in a 
head to tail tandem structure. 
 
Such  transgenic  mouse  models  can  be  created  relatively  quickly.  The  major  drawbacks, 
however, are unpredictable expression patterns due to variegational position effects that have 
the  potential  to  disturb  the  chosen  promoter  (Williams  et  al.,  2008).  For  example,  when  a 
transgene integrates into a gene with a strong transcriptional control element, the endogenous 
site-specific regulatory region can interact with the transgenic promoter in a detrimental fashion. 
Integration  into  sites  of  genetic  silencing  during  development,  for  instance  through 
heterochromatin formation, can abolish expression of the transgene (Wilson et al., 1990). Co-
introduced prokaryotic fragments, left behind from assembling the vector in E. coli, can have 
significant  non-specific  inhibitory  effects  as  they  trigger  cellular  responses  such  as  genetic 
silencing by methylation or sequence deletion in somatic tissues, originally intended to protect 
the mammalian genome from foreign bacterial or viral DNA (Chada et al., 1985; Clark et al., 
1997; Scrable and Stambrook, 1999). Furthermore transgenes can modulate the expression of 
unrelated genes in the neighbourhood (Woychik and Alagramam, 1998). 
 
Advances in overcoming positional effects include the use of insulating sequences (Geyer and 
Clark,  2002)  that  reduce  transgene  interactions  with  neighbouring  regulatory  elements. 
Homologous (Brinster et al., 1988) and heterologous (Palmiter et al., 1991) introns have also 
been  utilized  in  order  to  increase  transgene  expression,  as  have  scaffold-matrix  attachment 
regions  (Gutierrez-Adan  and  Pintado,  2000)  and  locus  control  regions  (Festenstein  and 
Kioussis, 2000; Gutierrez-Adan and Pintado, 2000). 
 
In  1993  the  first  transgenic  mice  using  large  artificial  chromosome  vectors  were  reported 
(Jakobovits  et  al.,  1993;  Schedl  et  al.,  1993;  Strauss  et  al.,  1993).  Artificial  chromosomes 
derived  from  bacteria  (BAC);  yeast  (YAC)  and  the  P1  phage  (PAC)  have  a  vast  cloning 
capacity compared to plasmids and viruses. Thus much larger DNA fragments, including more 
regulatory sequences, can be used for gene transfer. BAC,  YAC and PAC transgenes show 
fewer  positional  effects  and  due  to  their  size  only  few  copies  (1-5)  are  typically  inserted. 
Expression levels from those transgenes are frequently comparable to the wild type (Giraldo   34 
and Montoliu, 2001). Due to these characteristics, BAC transgenic mice have sometimes been 
referred to a pseudo-knock-in models (Sparwasser et al., 2004). A drawback is, however, that 
other genes, present in the vector, are  co-introduced and  may  affect the phenotype.  As the 
inserts are large, intra-molecular re-arrangements can occur and affect genomic structure and 
expression (Kaufman et al., 1999).  
 
One problem with random transgene insertion remains, no matter what type of vector is used; 
the destruction of endogenous loci by insertional mutagenesis is a distinct possibility. Influences 
on the phenotype, or, in extreme cases lethality, are likely to be observed.  
 
2.1.1  Gene Trapping 
 
A  recent expansion of traditional transgenesis is gene trapping in  ES cells.  Introduced trap 
vectors integrate randomly into the genome and disrupt (knock-out) and concomitantly label 
endogenous genes (Stanford et al., 2001).  The  method is ideally suited for high-throughput 
projects, as one vector can be used genome-wide. (Nord et al., 2006). 
 
Trapping vectors are introduced into murine ES cells either by electroporation or as retroviruses 
(Stanford et al., 2006). Two main classes exist, promoter trap and gene trap vectors (Figure 
2.1A&B). Promoter trap vectors contain a promoter-less reporter gene – typically lacZ – that 
needs  to  insert  into  an  exon  to  produce  a  fusion  transcript.  Gene  trap  vectors  contain  an 
additional splice acceptor site immediately upstream of the reporter and can thus also create a 
fusion  transcript  when  inserted  into  introns  by  directing  the  splicing  process.  Due  to  low 
trapping  frequencies,  resistance  markers  are  commonly  used  in  addition  to  reporters.  Such 
vectors tag the trapped gene and thus facilitate its identification but can only be used for genes 
actively transcribed in undifferentiated ES cells. Trap vectors for non-transcribed genes direct a 
constitutively  expressed  resistance  marker  to  an  endogenous  polyA  signal  or  co-transfer 
enhancer sequences in order to up-regulate expression at the insertion site (Niwa et al., 1993; 
Schnutgen et  al., 2008).  The trapped gene is often rendered inactive and thus constitutes a 
knock-out,  though  alternative  splicing,  particularly  with  trap  vectors  inserted  in  introns  or 
towards the 3’ region of a gene, can result in maintained function or hypomorphic alleles (Voss 
et al., 1998).  
 
Of late, gene trap vectors have been engineered to  contain strategically placed site-specific 
recombinase sites (Figure 2.1C).  These vectors  enable sophisticated genetic  modification in 
conjunction with recombinase activity; like the switching between null-alleles and functionally 
restored conditional alleles (Floss and Schnutgen, 2008; Schnutgen and Ghyselinck, 2007; Xin 
et al., 2005). The sites can also be used for recombinase mediated cassette exchange (RMCE) in   35 
order to insert other fragments, for example those encoding Cre itself (Hardouin and Nagy, 
2000). 
 
Transposons, DNA fragments with the inherent ability to move around the genome, have also 
been adapted to serve as vectors for gene trapping in mice. Particularly the Sleeping Beauty and 
PiggyBac  systems,  which  are  transposons  of  zebrafish  and  insect  origin  respectively,  were 
modified  to  function  in  mammalian  organisms  (Ding  et  al.,  2005;  Ivics  et  al.,  1997). 
Transposons insert non-randomly as single copies with many hot and cold spots found across 
the genome and thus take a place between random mutagenesis and site-directed gene targeting 
(Ivics et al., 2009). 
 
2.2  Gene Targeting  
 
Gene targeting refers to the directed modification of a defined locus in the mouse genome. It 
can be used to delete gene function (knock-out), insert novel fragments (knock-in), engineer 
subtle changes like point mutations or create large chromosomal rearrangements. In case of a 
knock-in, only one copy of the selected gene is introduced and expression is typically regulated 
from an endogenous promoter, which solves virtually all problems arising from chromosomal 
position effects. The technique combines homologous recombination in embryonic stem cells 
with the ability of those cells to re-populate the mouse germ line. While a gene knock-in model 
is superior to a transgenic model  when looking at overall genetic integrity, creating such a 
mouse is much more costly and time intensive. 
 
2.2.1  Homologous Recombination 
 
The  targeted  insertion  of  sequences  relies  on  the  mammalian  enzymatic  machinery  that 
mediates exact recombination between identical, also called homologous, DNA fragments. In 
vivo  this  mechanism  is  one  of  the  central  processes  for  repairing  double-strand  breaks  and 
interstrand crosslinks during DNA replication in the S phase of the  cell cycle prior to cell 
division. As such homologous recombination (HR) is essential in maintaining chromosomal 
stability and avoiding tumorigenesis. Mouse knock-out models involving genes needed for HR 
largely exhibit early embryonic lethality (Thompson and Schild, 2001). 
 
One  of  the  mechanisms  of  HR  is  depicted  in  Figure  2.2.  Double  strand  breaks  initiate  the 
process followed by enzymatic degradation of the 5’ DNA ends. The new single strands then 
pair with homologous 3’ sequences resulting in Holliday junctions. DNA synthesis fills in the 
gaps and the junctions are resolved in either gene conversions or crossovers (Waldman, 2008).   36 
 
Figure 2.1 Trapping Vectors 
A and B illustrate the structure of promoter and gene trap vectors respectively. Provided the 
endogenous promoter (P) is active, the insertion into an exon (E) or, with the help of a vector 
provided splice acceptor site, into an intron, enables the production of fusion transcripts and 
proteins. In this example the lacZ gene product β galactosidase (β gal) and neomycin resistance 
(neo) are fused (β geo). A separate expression, however, is possible by providing neo with its 
own promoter. C shows an example for a switchable construct flanked by pairs of heterotypic 
lox and FRT sites.  As only identical sites can recombine  with each other, several complex 
alleles can be engineered. The trapped null allele can be inverted using the Flp recombinase. 
This re-establishes the wild type splicing pattern (dashed lines) and yields a conditional allele. 
A  second  Cre-recombinase  mediated  switch,  for  example  during  a  defined  period  of 
development, can re-generate the null allele. Illustrations A and B are adapted from (Stanford et al., 2001), 
whereas C is modified from (Schnutgen and Ghyselinck, 2007).   37 
The discovery that linear, cloned, modified DNA, introduced into mammalian cells, could also 
participate in HR resulted in the onset of gene targeting (Capecchi, 1989; Smithies et al., 1985). 
The  DNA,  in  form  of  a  targeting  vector,  is  transferred  into  cultured  ES  cells  using 
electroporation,  lipofection  or  microinjection.  If  cells  are  successfully  transfected,  three 
outcomes are possible. In the majority of cases the DNA is not inserted into the genome at all. If 
insertion takes places, it is most likely to be random following non-homologous recombination. 
Early  experiments  showed  that  microinjected  linear  DNA  encoding  the  Herpes  simplex 
thymidine kinase (TK) was incorporated by 20% of TK deficient mouse cells (Capecchi, 1980). 
In few cells, however, the targeting vector will pair with the cognate chromosomal segment and 
undergo successful homologous recombination. Frequencies have been estimated at between  
10
-5 to 10
-8 correct events per targeted cell (Donoho et al., 1998).  
 
It is accepted that the length of the homology regions flanking the desired insert impacts on the 
success rate of homologous recombination. Numerous attempts have been made to ascertain 
how long homology arms need to be to achieve high frequencies. In early experiments, designed 
to modify the mouse hprt gene in ES cells, for example, a five-fold increase of homology, from 
2.9kb to 14.3kb, resulted in a 100-fold higher targeting frequency, equalling one correct HR 
event per 30.000 cells (Capecchi, 1989). Saturation was observed for homologies in excess of 
14kb (Deng and Capecchi, 1992). Another similar study noted a 200-fold increase in targeting 
efficiency, when the total homology was lengthened from 1.3 to 6.8kb (Hasty et al., 1991). 
 
Selection strategies are essential in identifying and enriching correctly recombined cells and can 
also  help  to  increase  targeting  frequencies  several  hundred-fold.  Commonly  used  positive 
selection markers include the gene for the neomycin phosphotransferase (neo
R), driven by a 
strong promoter, which renders cells resistant to the antibiotic G418. Using the insertion of neo
R 
in conjunction with homologous recombination to modify the mouse gene en-2 resulted in one 
correctly  targeted  clone  per  300  analyzed  resistant  cells  (Joyner  et  al.,  1989).  A  negative 
selection marker, usually the TK gene from Herpes simplex virus (HSV-tk) can be combined 
with G418 selection to further enrich targeted clones. The negative selection marker is placed 
adjacent to the homology region and is thus only inserted when the whole vector undergoes 
random  integration.  The  selective  agent,  ganciclovir,  is  phosphorylated  by  HSV-tk  and 
endogenous kinases resulting in a nucleoside analogue that arrests DNA synthesis causing cells 
carrying  random  integrants  to  die.  In  one  study,  homologous  recombinant  clones  could  be 
enriched  up  to  2000-fold  (Mansour  et  al.,  1988),  though  10-20  fold  enrichments  are  more 
commonly  reported  (Zimmer,  1992).  An  alternative  marker  is  the  diphteria  toxin  A  gene 
(Yanagawa et al., 1999). Negative selection markers form a large fragment of non-homology 
flanking  one  or  both  homology  arms.  Nevertheless  they  appear  to  not  adversely  affect 
recombination efficiency (Deng and Capecchi, 1992).   38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Homologous Recombination  
A double strand break (A) initiates the repair process. 5’ ends are resected first (B) followed by 
pairing of the single stranded 3’ ends with their homologous counterparts on the cognate strand 
(C). DNA synthesis leads to the formation of Holliday junctions (D) and the single strand gaps 
are  filled  in  (E).  The  junctions  can  be  resolved  by  gene  conversion  or  crossover  (F).  The 
illustration is taken from (Waldman, 2008). 
 
A further enrichment possibility is a promoter-less neo
R gene. Vectors are designed such that 
neo
R  inserts  in-frame  with  an  exon  of  the  target  gene  upon  successful  homologous 
recombination – akin to the trapping approach. Expression of a fusion protein is driven by the 
endogenous  promoter  and  confers  G418  resistance.  Similar  strategies  rely  on  targeting  the 
resistance marker to endogenous polyadenylation (pA) signals or using artificial splice sites to 
direct resistance gene transcription. These approaches can only be employed if the target gene is 
expressed in the embryonic stem cell line (Ledermann, 2000).  
 
Homologous recombination frequency on the whole is dependent on the intended chromosomal 
targeting  site,  making  it  difficult  to  compare  individual  experiments.  The  local  chromatin 
structure influences the accessibility for the recombination machinery and may affect expression 
levels of the selection marker (te Riele et al., 1992). Hotspots for recombination impacting on 
gene-targeting have also been reported (Hasty et al., 1991). 
 
2.2.2  Vectors For Gene Targeting 
 
In general, two different types of vectors, for either insertion or sequence replacement are used 
(Figure 2.3). Most commonly utilized linear sequence replacement vectors carry the extraneous 
DNA segment and selection marker flanked by target specific homology arms. Precise HR is 
the result of two crossing over events towards the ends of the flanking sequences. Contrariwise, 
insertion vectors are linearized within the homology region and participate in a single cross 
over, which causes the insertion of the entire vector and thus the duplication of homologous   39 
sequences.  They  are  often  used  to  engineer  subtle  mutations  through  a  second  step  of 
intrachromosomal recombination (Morrow and Kucherlapati, 1993). 
 
The  universal  recommendation  is  to  use  isogenic  DNA  (matched  to  the  mouse  strain  from 
which the chosen ES cell line originates) for vector construction as non-isogenic DNA can lead 
to lower recombination rates due to localized polymorphisms causing mismatches. Isogenic 
targeting vectors directed towards exons 3 and 8 of the mouse hprt gene, were shown to be 4-5 
fold more efficient than non-isogenic vectors (Deng and Capecchi, 1992). Similarly, targeting 
vectors aimed at Rb in 129 embryonic stem cells were 20-fold more efficient when derived from 
129 DNA compared to BALB/c DNA. Targeting of the mu opioid receptor locus with non-
isogenic  constructs  in  129  and  C57BL/6  embryonic  stem  cells  revealed  a  15%  decrease  in 
targeting frequency. The intronic sequence between those two strains was found to possess a 
divergence  of  2.5%  (Zhou  et  al.,  2001).  The  presence  of  sufficiently  long  stretches  of 
homologous DNA, however, seems to be more important in enabling efficient HR than the 
overall number of mismatches (te Riele et al., 1992). Thus, if non-isogenic DNA constructs are 
used, longer targeting arms can compensate for the presence of polymorphisms. 
 
Sequence replacement vectors are typically designed to contain a short and a long homology 
arm. This asymmetry facilitates screening, for example by PCR, across the shorter end. The 
employed  vector  type  and  the  subsequent  screening  strategy  dictate  the  overall  length. 
Nevertheless, the short homology arm should be in excess of 1kb, as shorter fragments are 
linked to illegitimate recombination (Thomas et al., 1992). 
 
Conventional gene targeting vectors are relatively short and are assembled in standard plasmids 
by normal cloning techniques or derived from target specific cDNA. BAC vectors, however, 
have become more popular since several libraries covering the whole mouse genome became 
available as a result of the genome sequencing projects. Furthermore, methods for modifying 
large DNA molecules are more firmly established. The vector generation in this work also relied 
on modifying BACs, therefore these techniques are introduced in the next section.  
 
2.2.2.1  Engineering Large BAC Vectors 
 
The main method for BAC engineering utilizes bacterial and phage recombination systems and 
has been popularly termed recombinogenic engineering or simply recombineering (Copeland et 
al., 2001). Large molecules of DNA can be modified without relying on conventional restriction 
enzymes and DNA ligases.   40 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Insertion and Sequence Replacement Vectors 
A linear sequence replacement vector (A) undergoes two crossover events with the homologous 
sequences  (numbered  boxes).  The  positive  selection  marker  neo  is  introduced  whereas  the 
negative  selection  marker  HSV-tk  is  lost  in  the  modified  locus.  Insertion  type  vectors  (B) 
contain the double strand break within the homology region and consequently insert as a whole 
(Step 1). Partial gene duplications can be reversed by another round of recombination (Step 2). 
The second method is particularly suited to introduce subtle mutations (X), such as base pair 
exchanges. Common synonyms for this strategy are “hit and run” or “in and out”. The scheme is 
adapted from (Morrow and Kucherlapati, 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Red/ET Recombineering 
Using Red/ET recombineering, a linear  DNA  fragment carrying a positive selection marker 
flanked by short 50bp homology arms (hm) can be inserted into a target BAC (A). Necessary 
proteins are expressed from the pRed/ET plasmid vector. Sequential steps carried out by the 
Red (λ phage) or Rec (Rac prophage) proteins mediate a recombination process that is similar to 
the one observed in eukaryotes (B). Pictures were retrieved from www.genebridges.com. 
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The  presented  study  used  the  λ  phage  derived  Red/ET  recombineering  system  in  E.coli 
(Angrand et al., 1999; Muyrers et al., 2000; Muyrers et al., 1999; Testa et al., 2003; Zhang et 
al., 1998; Zhang et al., 2000). The strategy relies on heterologously expressing the Red proteins 
encoded by the phage RecA operon in E.coli to mediate recombination. 
 
The process is illustrated in Figure 2.4. A DNA fragment containing the desired modification is 
amplified by high fidelity PCR using primers that introduce 50bp homology arms (Zhang et al., 
2003) analogous to the desired BAC modification location. This linear DNA piece is partially 
digested by the 5’ – 3’ endonuclease Redα. The 3’ single strand is then bound by single stand 
binding  protein  Redβ  and  forms  a  joint  molecule  with  the  target  DNA  after  which 
recombination occurs. Redγ inhibits RecBCD function in E.coli, which stops the linear DNA 
fragment harbouring the modification being degraded prematurely (Muyrers et al., 2000). 
 
In the Red/ET system, the Red proteins are expressed from a commercially available plasmid 
(pRed/ET;  GeneBridges)  in  a  L-arabinose-inducible  and  temperature-dependent  manner 
providing  temporal  control  of  recombineering  activity.  More  process-related  details  can  be 
found in the Materials & Methods Chapter. Recombineering systems vary with regards to how 
the recombination proteins are expressed in E.coli (from a transformed plasmid or integrated 
prophage)  and  the  origin  of  the  recombinogenic  proteins  (aside  from  the  λ  function,  the 
analogous Rac phage system is popular) (Copeland et al., 2001). 
 
2.3  Making Mice From Embryonic Stem Cells 
 
Irrespective of the method used to engineer murine embryonic stem cells, a mouse model often 
needs to be created. The general procedure is outlined in this section and depicted in Figure 2.5. 
After the construction of a suitable targeting vector and its transfer into the stem cells, drug 
resistant colonies are isolated. The screening of those clones aims at establishing successful 
homologous recombination and the integrity of the targeted locus. Specific PCRs are frequently 
employed in a first round of analysis and allow the screening of large numbers of clones while 
being sensitive enough to use only a fraction of an embryonic stem cell colony. Follow-up 
Southern blot analysis confirms PCR results, excludes the possibility of additional inserts and 
ensures correct recombination especially at the break-points of crossing over. 
 
The neo
R resistance marker is commonly removed from the targeted embryonic stem cell line. 
Transient Cre or Flp transfection, depending on whether loxP or FRT sites were used to flank 
the neo
R cassette in the initial vector construction, can achieve this objective.  
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Figure 2.5 Producing Mice from Embryonic Stem Cells 
The  production  of  germline  chimera  and  subsequently  genetically  engineered  mice  is  a 
multistep process including vector generation, embryonic stem cell transfection and screening 
and blastocyst injection. Further details can be found in the text. Graphic taken from (Capecchi, 1989).   43 
The  step  was  introduced  after  neo
R  resistance  genes,  often  coupled  to  their  own  strong 
promoters such as that of the phosphoglycerate kinase (PGK), were shown to influence the gene 
expression  pattern  of  surrounding  genes  and  thus  impact  on  the  phenotype.  A  PGK-Neo 
cassette, inserted into the granzyme B and β–like globulin loci, for example, severely reduced 
the expression of other genes in the respective clusters, even at large distances of more than 
100kb. An insertion into cathepsin G residing in the same cluster, however, had no discernible 
effects  (Pham  et  al.,  1996).  Similarly,  three  independent  alleles  of  a  MRF4  knock-out, 
distinguished by the area targeted and the orientation of the selection cassette, showed gross 
differences in phenotype (Olson et al., 1996). In one published report, however, the removal of 
the  resistance  marker  from  the  CD19Cre  mice,  resulted  in  20%  lower  Cre-mediated 
recombination in the majority of B cell lineages. It has been suggested that the presence of the 
selection cassette improves  Cre expression in this particular  model,  either due to contained 
enhancer sequences or by conferring increased RNA stability (Schmidt-Supprian et al., 2007). 
 
Once all genomic modifications are complete, homologous recombinant clones are expanded 
and  re-integrated  into  an  early  mouse  embryo.  The  embryo  is  then  implanted  into  a  foster 
mother  and  chimeric  offspring  is  born.  Chimaera  whose  germline  is  derived  from  the 
engineered embryonic stem cells will transmit the genetic modification to their progeny. The 
most  popular  method  for  embryo  re-integration  is  blastocyst  injection,  where  the  cells  are 
injected into the cavity of 3.5d old blastocysts. The process is relatively complicated and time 
consuming,  needing  a  specialist  technical  setup.  Advantages,  however,  include  that  ES  cell 
clones can be carefully selected for morphologic criteria and blastocysts need not be cultured 
for  an  extended  period  of  time.  Another,  technically  less  demanding  technique,  is  morula 
aggregation where clumps of embryonic stem cells are aggregated with 2.5d old morula stage 
embryos. This method, however, requires longer periods of embryo culture and individual cells 
cannot be selected easily (Nagy et al., 2003).  
 
Embryos for either aggregation or injection are selected so that the coat-colour markers differ 
from those of the ES cells and that a high probability of germ line transmission is achieved. 129 
ES cells (agouti or chinchilla fur colour), for example, are commonly injected into C57BL/6 
(black fur colour) embryos. Chimeras can be easily identified by their mixed black and white 
coat. Chimeras  are crossed to each other to obtain germ line transmission, which,  again, is 
judged by fur colour.  
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2.4  Overview of Mouse Mutagenesis Strategies 
 
Strategy  Success 
Quota 
Possible 
Mutation Types 
Major 
Disadvantages 
Major 
Advantages 
Spontaneous  5x10
-6 per 
locus 
Point mutations; 
chromosomal re-
arrangements 
Very low 
frequencies; needs 
large mouse 
colonies 
Selection by 
distinct phenotype 
Chemical (ENU)  150x10
-5 
per locus 
Point mutations; 
small deletions 
Numerous 
mutations per 
mouse, needs large 
mouse colonies, 
Mapping of 
mutations difficult 
Fast; high-
throughput 
possible 
Micro-
injection 
10% of all 
animals 
Insertion of 
heterologous 
genes; disruption 
of endogenous 
genes 
Low frequencies; 
unpredictable 
phenotypes; 
positional effects 
Medium speed; 
overexpression of 
heterologous genes 
possible  Trans-
genesis 
 
Gene 
Trap 
up to 100% 
of all 
animals* 
Insertion of 
heterologous 
genes; disruption 
of endogenous 
genes 
Time and labour 
intensive; 
unpredictable 
phenotypes 
Slow; high-
throughput 
possible, disrupted 
genes are labelled; 
easy vector design 
Conven-
tional 
Time and labour 
intensive; 
complicated vector 
design & 
screening; 
no temporal or 
spatial control 
Highest level of 
genome integrity; 
any gene can be 
targeted 
Gene 
Targeting 
Condi-
tional 
up to 100% 
of all 
animals* 
Targeted 
insertion or 
deletion of 
endogenous/he-
terologous genes 
or complex 
chromosomal re-
arrangements 
Time and labour 
intensive; 
complicated 
vector design & 
screening; needs 
two mice – one 
floxed one Cre; 
potential leakiness 
Highest level of 
genome integrity; 
any gene can be 
targeted; temporal- 
and spatial control 
Table 2.1. Comparison of Mouse Mutagenesis Methods 
*following selection and screening 
 
2.5  Large Scale Mouse Mutagenesis Projects 
 
The creation of an individual mouse model is still time consuming, expensive and laborious. 
Therefore recent years have seen the emergence of several large scale international projects with 
the ambitious target of mutating all protein expressing mouse genes by 2011 and thus providing 
a  standardized  and  indexed  resource  for  biomedical  research  (Collins  et  al.,  2007;  Gondo, 
2008). Efforts have been made to streamline the model generation process, moving away from 
individual researchers producing single to few engineered mice with a wide array of methods in 
favour of a partially automated; high-throughput; centralized approach. 
 
Several  international  consortia,  for  example  the  International  Mouse  Knock-out  Consortium 
(IMKC)  consisting  of  European  EUCOMM  (European  Conditional  Mouse  Mutagenesis 
Programme), North American KOMP (Knock-Out Mouse Project), Canadian NORCOM (North   45 
American  Conditional  Mouse  Mutagenesis  Project)  or  ITGC  (International  Gene  Trap 
Consortium) are, together with commercial partners, in the process of establishing libraries for 
general access. The objective of these efforts is that, following completion of these resources, 
individual researchers can request a modified version of their gene of interest; as vector; ES cell 
line or completed mouse model, to either begin with phenotypic analysis directly or at least 
significantly shorten the time until a new model is available. 
 
Envisaged numbers are staggering, the three members of IMKC, for example aim to produce 
about 40.000 unique ES cell lines and 920 mouse models by the end of 2010. An evaluation of 
success will be difficult before the project is concluded and all created resources have been 
entered into the repositories. By looking at the published results of the EUCOMM partner to 
date, however, it would appear that the projected numbers were slightly optimistic. As of early 
2010 (Table 2.2), less than half of all projected ES cell lines and about 80% of mouse models 
were completed. 
 
Resource 
Type 
Type of 
Modification 
Projected 
Cumulative by 2011 
Projected Share 
EUCOMM by 2011 
Achieved EUCOMM 
Early 2010
(1 
ES cell  Trapped 
Conditional 
22.000  12.000  5724 
ES cell  Targeted 
Deletion 
3500  N/A  N/A 
ES cell  Targeted 
Conditional 
15.000  8000  2981 
Mouse  Mixed  920  420  380 
Table 2.2 Overview of Projected Resource Generation by the IMKC 
Divided by totals, share of EUCOMM partner and actually achieved numbers to date. Table 
adapted from (Collins et al., 2007). 
(1 Numbers are derived from EUCOMM website www.eucomm.org and 
are current as of March 2010. N/A not applicable 
 
According  to  the  Sanger  Institute  High  Throughput  Gene  Targeting  resource 
(www.sanger.ac.uk/htgt); the common problems are unsuccessful vector design, generation or 
purification; failed ES cell electroporation and homologous recombination; modified ES cell 
lines  not  meeting  quality  control  standards  for  injection;  and  unsuccessful  germ  line 
transmission. Nevertheless, the number of available resources for the production of genetically 
engineered mice is increasing drastically. Therefore it will become more and more important to 
search available repositories before embarking on a  project aimed at creating a new  mouse 
model. As a significant portion of the high throughput projects constructs conditional alleles, 
novel Cre expressing mouse strains, such as the ones proposed by this work, will become more 
important to obtain knock-outs for phenotypic analysis.   46 
CHAPTER  3:  CONDITIONAL  MUTAGENESIS  IN  THE  IMMUNE  SYSTEM: 
MACROPHAGES AND NEUTROPHILS 
 
As the envisioned iCre2 mouse strains are meant to enable neutrophil and macrophage specific 
conditional mutagenesis, this chapter very briefly introduces the basic biology of those cell 
types. The target genes chosen as knock-in sites are also discussed and contrasted to other Cre 
strains used in immunological research.  
 
3.1  Macrophages and Neutrophils: Phagocytes of the Immune System 
 
Macrophages and neutrophils are major phagocytic cell types in the immune system. As such 
they play an important role in innate immunity and provide the first line of defense against 
pathogens such as bacteria and fungi. In addition, they are involved in tissue homeostasis and 
link the innate to the adaptive immune system. 
 
Both cell types derive  from a common myeloid progenitor in the bone marrow.  In case of 
macrophages, this progenitor turns into a pro-monocyte and later a monocyte circulating within 
the  blood  stream.  Monocytes  migrating  into  tissues  become  long-lived  macrophages. 
Granulocytes, one of which is the polymorphonuclear neutrophil, develop when the common 
progenitor  induces  promyelocyte  differentiation.  Neutrophils  appear  as  cells  with  distinctly 
shaped nuclei and densely staining granules. In flow cytometry, two markers are predominantly 
used  to identify  them,  Gr-1  (Fleming  et  al.,  1993)  and  the  polymorphic  neutrophil specific 
antigen (Hirsch and Gordon, 1983). Similarly, monocytes and macrophages are characterized by 
Mac-1 (Springer et al., 1979) and F4/80 receptor expression (Austyn and Gordon, 1981).  
 
Both respond to a wide variety of pathogens via pattern recognition receptors (e.g. Toll-like 
receptors,  lectin  family  receptors)  or  via  the  Fc  mediated  recognition  of  antibody/antigen 
complexes. Resident tissue macrophages are the first cells to encounter pathogens, triggering 
phagocytosis and the secretion of pro-inflammatory cytokines and chemokines such as IL-1β, 
TNF- α, CXCL8 or IL-6 and establish a state of inflammation.  
 
Phagocytosis,  a  key  component  in  macrophage  and  neutrophil  biology,  describes  the 
engulfment  and  internalization  of  microorganisms  and  cellular  debris.  Phagocytosed 
microorganisms  can  subsequently  be  killed  and  degraded  in  an  enclosed  vesicle,  the 
phagosome. This process is supported by acidification (pH 3.5-4.0), the release of antimicrobial 
peptides  and  enzymes  (i.e.  defensins,  lysozyme,  proteases)  and  the  generation  of  reactive 
oxygen intermediates (ROI; i.e. superoxide, nitric oxide, oxygen radicals) by a respiratory burst. 
Peptides and enzymes are released when lysosomal storage granules merge with the phagosome,   47 
whereas  oxygen  intermediates  are  produced  by  designated  enzymes  such  as  the  membrane 
associated NADPH oxidase complex.  
 
Factors released by macrophages cause further leukocytes to be recruited to the site of infection. 
The first cells are circulating neutrophils, followed by monocytes, which enter the tissue by 
crossing the barrier between blood vessels and infected tissue. Extravasation, the migration of 
leukocytes from the blood vessels via the endothelium, occurs as a result of inflammation. First, 
endothelial  cells  lining  the  vessels  begin  expressing  adhesion  molecules  (i.e.  P-Selectin,  E-
Selectin)  that  allow  leukocytes  to  attach.  Both  selectins  are  recognized  by  leukocyte 
glycoproteins, like L-selectin, which cause them to reversibly adhere to and roll along the vessel 
wall.  Second,  leukocyte  integrins  interact  with  additional  adhesion  molecules  on  the 
endothelium to confer a tighter binding and to stop further rolling. Third, the leukocyte squeezes 
between endothelial cells in a process called diapedesis and migrates, in response to chemokine 
signals, to the location of infection. 
 
Once  within  the  tissue,  neutrophils  like  macrophages  are  avidly  phagocytic,  and  release  a 
battery of  microbicidal  molecules both  within the phagolysosome and into the extracellular 
spaces.  However,  unlike  macrophages,  neutrophils  are  short  lived,  and  after  phagocytosis 
rapidly die, and are themselves taken up and degraded by tissue macrophages. In addition, 
macrophages play essential roles in tissue homeostasis, for example by ingesting dead cells 
during  injury  and  normal  cell  turn  over  or  in  the  extensive  remodelling  needed  during 
embryogenesis (Murphy et al., 2008). 
 
3.2  Candidate Genes for Tissue-Specific iCre2 Expression 
 
Three target genes were chosen as loci for knocking-in iCre2, based on published reports of 
stringent tissue specific expression, which should render Cre mediated recombination restricted 
to  either  macrophages  (Marco  and  Msr1  genes)  or  neutrophils  (Itgb2l).  Furthermore, 
connventional knock-outs of all three genes exhibit no or only very mild phenotypes, indicating 
that  knock-in  mice,  still  carrying  one  functioning  allele,  should  develop  normally. 
Haploinsufficiency  has  not  been  reported  for  any  of  the  chosen  genes.  Target  gene 
characteristics are summarized in table 3.1. 
 
3.2.1  Itgb2l 
 
The mouse protein Pactolus, expressed by the Itgb2l genomic locus, was first discovered in 
1998 in bone marrow cells matured with stem cell factor (SCF) or IL-3. The protein’s similarity 
(~60%  identical)  to  the  CD18/β2  and  CD18//β7  integrin  subunits,  apart  from  lacking  the   48 
characteristic metal binding unit (Chen et al., 1998), suggests it as their evolutionary paralogue 
(Hale et al., 2006).  Humans, unlike rats, have no comparable gene. 
 
Itgb2l resides on murine chromosome 16 and consists of 16 exons encompassing 24kb. The 
translation  start  codon is  located  in  exon  2.  Three  transcripts  are  known  due  to  alternative 
splicing in exon 13 caused by a single base pair mutation found in certain mouse backgrounds. 
Transcript A encodes the full-length protein, B lacks the trans-membrane domain, and transcript 
C encodes a prematurely terminated protein only present during neonatal development (Margraf 
et  al.,  1999).  C57BL/6  mice  only  produce  the  full-length  transmembrane  form  whereas 
BALB/c, C3H/HeJ  and 129/Sv mice transcribe both full-length and truncated versions. The 
promoter strength does not vary between these alleles as there is no significant difference in the 
total amount of transcripts between the independent strains (Garrison et al., 2001).  
 
The promoter sequence is somewhat unusual as it lacks a TATA box. Other transcriptional sites, 
however, are present, for example AP-1, AP-4, ELK-1, C/EBP, E47, GATA-1 and NF-κB sites. 
The GATA-1 site is suspected to be a central regulator in Pactolus expression. GATA-1 is only 
expressed in cells of the haematopoietic line (Sposi et al., 1992) – thus the Pactolus expression 
is believed to be restricted to cells of this descent. Regulation by NF-κB suggests Pactolus can 
be  induced  following  inflammatory  stimuli  (Margraf  et  al.,  1999).  Two  tandem  PU.1 
transcription factor binding sites are present but appear to be strictly negatively controlled in 
non-neutrophilic cells. Snail and smad family transcription factors have also been implied in the 
regulation of Itgb2l expression (Hale et al., 2006). 
 
Literature data to date shows Pactolus expression as being restricted to mature neutrophils in the 
periphery and maturing neutrophils in the bone marrow. Its expression pattern is thus far more 
limited than that of the CD18 integrin subunits which are expressed in T- and B-cells as well as 
macrophages and granulocytes (Walzog et al., 1999). It has actually been suggested that the 
expression  of  Pactolus  in  cells  other  than  neutrophils  is  lethal  as  the  stable  transfection  of 
selectable Pactolus expression vectors into B- , T- and macrophage cell lines failed to yield drug 
resistant cells (Hale et al., 2006). The Pactolus protein consists of a single chain and varies in 
size depending on whether it is membrane bound (98kDa) or cytoplasmic (130kDa) (Garrison et 
al., 2001). Unlike the integrins, it does not associate with an α subunit to form a functional 
heterodimer as it contains a 24-29 amino acid deletion rendering it unable to dimerize (Sen and 
Legge, 2007; Takagi et al., 2002).  
 
Pactolus function has not been completely elucidated. The majority of the protein is held in 
dense granules and is heavily N- and O-glycosylated and sialylated. Similar to β2 integrins, it is 
released after inflammatory activation, when constitutively expressed Pactolus on the plasma   49 
membrane is cross-linked. Pactolus is stored in granules differing from those of the β2 integrins 
and does not respond to the same stimuli. It does not act as an activating phagocytic receptor 
and its membrane translocation does not increase total calcium flux or protein phosphorylation. 
Pactolus expression levels were up-regulated in mouse model of pneumonia (Rosseau et al., 
2007). It has been proposed that Pactolus serves as a ligand to mark dead and dying neutrophils 
as it translocates to the cell surface during necrotic or apoptotic neutrophil death without being 
shed (Garrison et al., 2003). Its extensive coverage with sialic acid residues suggests Pactolus 
could serve as a ligand for macrophage lectins, further implicating it as marker for phagocytic 
macrophages. 
 
Itgb2l knock-out mice show no aberrant phenotype suggesting redundant functional equivalents. 
Their neutrophils are present in normal numbers and perform appropriate migration and combat 
of  infections.  They  do,  however,  promote  the  loss  of  resident  cells  producing  chemokine 
CXCL13  from  the  peritoneal  cavity  following  inflammatory  response  by  an  unknown 
mechanism (Hojgaard et al., 2006). 
 
3.2.2  Msr1 
 
Msr1  (murine  scavenger  receptor  1)  is  a  mouse  gene  encoding  one  of  the  various  class  A 
scavenger  receptors  first  identified  in  the  murine  macrophage  cell  line  P388D1.  The  gene 
contains 11 exons spanning 60kb on chromosome 8. Two transcripts are known, one consists of 
exons 1-9, the other links exons 1-8 to 10 and 11, which results in two receptor variants I and II. 
The translation initiation codon is located in exon 2 (Aftring and Freeman, 1995). The gene’s 
promoter sequence contains no typical TATA box but is characterized by AP-1 and GATA-1 
sites, known to be cytokine response elements (Wu et al., 1994). 
 
Msr1 expression patterns identify the protein as a pan-macrophage marker. Expression levels 
depend  on  the  genetic  background  due  to  polymorphisms  that  cause  varying  glycosylation 
patterns and amino acid substitutions (Daugherty et al., 2000; Fortin et al., 2000). C57BL/6J 
mice, for example, exhibit 1.6-fold higher protein levels than A/J mice (Fulton et al., 2006). 
Expression has been found in the red pulp and marginal zone of normal adult mouse spleens, 
the  thymus  medulla,  the  subcapsular  region  of  the  lymphnodes,  Kupffer  cells  in  the  liver, 
alveolar macrophages and lamina propria macrophages in the gut. The only non-macrophage 
cell  types  where  low  level  expression  of  Msr1  could  be  observed  was  the  sinusoidal 
endothelium of the liver (Hughes et al., 1995). The rabbit orthologue of Msr1 is also expressed 
in smooth muscle cells (Li et al., 1995). Expression in endothelial and smooth muscle cells 
appear to be dependent on oxidative stress and endogenous growth factors such as TNF-α and 
IFN-γ  (Mietus-Snyder et al., 1997).  Exposure to lipoproteins increased expression levels of   50 
Msr1 in macrophages 12-17 fold (Han and Nicholson, 1998). IL-1, IL-4 and MCSF also appear 
to  upregulate  Msr1  levels  in  macrophages  (Cornicelli  et  al.,  2000).  Studies  of  the  human 
orthologue revealed that expression of receptor variant I is low in circulating monocytes, but 
significantly  upregulated  at  both  mRNA  and  protein  level  when  maturation  into  adherent 
macrophages occurred. Variant II is constitutively expressed at low levels in both monocytes 
and macrophages. In this study Msr1 could not be detected in peripheral human neutrophils and 
lymphocytes (Geng et al., 1994). 
 
Scavenger  receptors  are  trimeric  cell  surface  glycoproteins  whose  major  function  is  the 
recognition of molecules with polyanionic structure, such as LDL (low density lipoprotein), 
polyribonucleotides, polysaccharides, phospholipids, asbestos or silica (Freeman et al., 1990; 
Krieger and Herz, 1994; Platt and Gordon, 2001). Scavenger receptors, belonging to the pattern 
recognition receptors, are found in many mammalian species such as cattle, rabbits and humans, 
but  have  low  sequence  conservation  (Ashkenas  et  al.,  1993).  The  Msr1  protein  contains  6 
domains and carries a highly conserved cysteine-rich carboxyterminal fragment with a collagen-
like structure that mediates ligand binding (Kodama et al., 1990). 
 
Msr1 is involved in the regulation of anti-inflammatory processes as it induces IL-10 upon 
stimulation with LPS, which inhibits septic shock (Fulton et al., 2006; Manning-Tobin et al., 
2009;  Tsujita  et  al.,  2007).  Scavenger  receptors  have  also  been  implied  in  the  pathological 
deposition of cholesterol during atherogenesis by receptor-mediated uptake of modified low-
density lipoproteins by vessel-wall macrophages and smooth muscle cells (Linton and Fazio, 
2001). Furthermore Msr1 has been connected to clearing bacteria and apoptotic cells as well as 
to cell adhesion (Kosswig et al., 2003; Platt et al., 1996).  
 
Msr1  knock-out  mice  appear  to  be  normal  in  both  morphology  and  development  but  their 
macrophages exhibit impaired uptake and degradation of lipoproteins and apoptotic cells and 
adhere  slower  than  wild  type  cells  to  tissue  culture  plastic.  Msr1
-/-  animals  are  also  more 
susceptible to Listeria monocytogenes and herpes simplex virus type-1 infections (Kunjathoor et 
al., 2002; Ling et al., 1997; Suzuki et al., 1997). 
  
3.2.3  Marco 
 
The gene expressing Marco (Macrophage receptor  with collagenous structure) is located on 
chromosome 1. It consists of 17 exons encoding a 210kDa disulfide-trimeric protein (Kangas et 
al., 1999). The translation start codon lies at the end of exon 1 and is preceded by a Kozak 
sequence (Kraal et al., 2000).  Marco belongs, like  Msr1, to the class  A scavenger  receptor 
proteins and shares its binding specifities (Elomaa et al., 1995). The protein differs from Msr1   51 
in that it lacks an α helical coiled-coil domain and possesses a longer extracellular subunit of 
collagenous structure (Dahl et al., 2007). Successful protein folding and delivery to the cell 
membrane depend on chaperones in the endoplasmic reticulum (Kvell et al., 2006). 
 
Where Msr1 is expressed in all macrophages, Marco expression is restricted to certain subsets 
in distinct tissue compartments. It has been found on macrophages in the medullary cord of 
lymph  nodes,  the  marginal  zone  of  the  spleen,  peritoneum  and  particularly  in  alveolar 
macrophages. No further expression has been observed (Dahl et al., 2007; Hamilton et al., 2006; 
Kanno et al., 2007). Induced ectopic expression of Marco in other cell lines brought on changes 
of morphology, such as the formation of long dendritic processes, implying a role in adhesion 
and  migration  (Pikkarainen  et  al.,  1999).  LPS  binding  upregulates  Marco  expression 
independent of proinflammatory cytokines such as IFN-γ, IL-6, TNF- α and IL-1 (Kangas et al., 
1999). Following stimulation, Marco also appears transiently on macrophages in the liver, the 
red pulp of the spleen and Kupffer cells, where it is not normally found in healthy individuals. 
(Elomaa et al., 1995). LPS or bacterial activation has also been shown to switch on expression 
of  Marco  in  splenic  dendritic  cells  and  microglial  cells  in  the  brain,  which  are  otherwise 
negative for the protein. In these cells Marco appears to play a role in rearranging the actin 
cytoskeleton and thereby changing cellular adhesive properties (Granucci et al., 2003; Grolleau 
et al., 2003; Milne et al., 2005). Marco also performs a critical part in the protection against 
inhaled antigens by taking up and clearing of inhaled oxidized surfactant lipids and bacteria, 
thus forming a part of the lung innate immune system (Dahl et al., 2007). 
 
Marco knock-out mice display an impaired ability in clearing bacteria from the lungs, increased 
pulmonary  inflammation  and  diminished  survival  in  a  murine  model  of  pneumococcal 
pneumonia,  but  otherwise  appear  to  be  normal  (Arredouani  et  al.,  2004).  In  general,  their 
macrophages  possess  substantially  diminished  capabilities  in  the  uptake  of  bacteria  like 
Escherichia coli or Neisseria meningitidis as well as acetylated LDL (low density lipoproteins) 
(Mukhopadhyay et al., 2006) and exhibit a 2.7 fold lower production of IL-12 (Jozefowski et 
al., 2005). Reduced levels of Marco and resulting impaired clearance of apoptotic cells have 
recently  been  implicated  as  a  major  contributor  in  a  murine  model  of  Systemic  Lupus 
Erythematosus (Rogers et al., 2009). 
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  Itgb2l  Msr1  Marco 
Protein  Pactolus  Murine Scavenger 
Receptor 1 
Macrophage Receptor 
with Collagenous 
Structure 
Chromosomal 
Location 
16C4  8A4  1E4-5 
Gene 
Structure 
16 exons, start codon 
in exon 2 
11 exons, start codon in 
exon 2 
17 exons, start codon in 
exon 1 
Expression 
Pattern 
Maturing and mature 
neutrophils 
Macrophages in spleen, 
thymus, lymphnodes, liver, 
alveoli, gut 
Ectopic: liver endothelium 
Macrophages in 
spleen, lymphnodes, 
alveoli 
Function  Marker for dead and 
dying neutrophils 
Macrophage adhesion, 
uptake of bacteria and 
LDL 
Clearance of inhaled 
pathogens 
Knock-out 
phenotype 
Normal  Mild, impaired uptake and 
degradation of lipoproteins 
and phagocytosed cells; 
more susceptible to 
Listeria monocytogenes 
and herpes simplex 
Mild, increased 
susceptibility to 
pneumonia, impaired 
uptake of lipoproteins 
and bacteria 
Table 3.1 Summary of Target Gene Characteristics 
 
3.3  Cre Lines Used in Immunology 
 
A variety of immune-specific Cre lines have been generated in recent years. A selection, sorted 
by  tissue  specificity,  is  listed  in  Table  3.2.  The  majority  of  available  strains  direct  Cre 
expression to the lymphoid compartment. The novel Cre strains proposed in this work aim at 
providing myeloid specific recombination, in particular in neutrophils and macrophages. The 
thus far available Cre donor mice targeting myeloid cells; LysMCre  (Clausen et  al., 1999), 
CD11b-Cre  (Ferron  and  Vacher,  2005)  and  GE-Cre  (Thomas  et  al.,  2004),  all  suffer  from 
ectopic  expression  and  varying  expression  levels.  In  addition,  none  is  able  to  distinguish 
between neutrophils and macrophages. 
 
3.3.1  LysM-Cre 
 
The LysM-Cre mouse line is arguably the most widely used strain for conditional mutagenesis 
in granulocytes and macrophages. The model, based on a 129 background, was first developed 
in 1999 and carries the Cre cDNA knocked into the endogenous Lysozyme M locus (Clausen et 
al.,  1999).  In  mice  Lysozyme  M  (LysM)  is  specifically  expressed  in  cells  belonging  to  the 
myeloid lineage and is specifically up-regulated when tissue macrophages become activated 
(Keshav et al., 1991).  
 
In an approach similar to the one presented herein, the Cre cDNA carrying a NLS sequence was 
recombined into the ATG start codon in exon1 of LysM to avoid interference with the gene’s 
regulatory elements. The original paper showed high deletion levels using two floxed target   53 
genes. A floxed version of the β DNA polymerase was deleted in 95% and 99% of peritoneal 
macrophages  and  neutrophils  respectively,  while  deletion  levels  in  the  bone  marrow  were 
slightly lower with 75% and 79%. Deletion was also observed in 16% of splenic and 31% of 
bone marrow dendritic cells (DCs). This ectopic recombination is attributed to early expression 
in the myeloid DC progenitor. Low levels of deletion also occurred in lung and spleen, the 
authors, however, attribute this effect to resident tissue macrophages. A second floxed target, 
RFX5, a transcription factor involved in MHC II expression, showed lower deletion factors of 
83% in peritoneal macrophages, once more emphasizing the importance of the target locus in 
recombination  efficiency  (Clausen  et  al.,  1999).  Another  group  observed  additional  ectopic 
expression when a floxed SOCS1 allele was not only deleted in the myeloid lineage, but also in 
B and T lymphocytes (Chong et al., 2005). 
 
Due  to  its  comparatively  good  expression  levels,  the  LysM-Cre  model  has  been  broadly 
employed to scrutinize innate immune function. Many studies have been aimed at dissecting the 
signalling events occuring during inflammation processes. In a LysM-Cre conditional knock-out 
model of SOCS3 (suppressor of cytokine signalling), it became clear that SOCS3 plays a major 
role in negatively regulating G-CSF signalling in mature neutrophils, with deleted mice having 
more  neutrophils  than  wild-type  ones  due  to  lower  apoptosis  levels  (Kimura  et  al.,  2004). 
SOCS1 deficient macrophages were found to have a higher tumor killing ability (Hashimoto et 
al., 2009). Specific disruption of STAT3, confirmed its suspected role as a repressor in resident 
macrophages during acute inflammation in a mouse  peritonitis model in response to IL-10. 
STAT3 absence resulted in increased leukocyte infiltration and heightened production of pro-
inflammatory cytokines and chemokines such as TNFα and MIP-2 (Matsukawa et al., 2005). 
This  finding  was  also  confirmed  in  a  mouse  colitis  model,  where  it  was  shown  that  the 
interaction  of  STAT3  deficient  macrophages  with  lymphocytes  leads  to  a  more  severe 
inflammatory response (Reindl et al., 2007).  The conditional deletion of IL4-receptor α led to a 
higher arthritis incidence accompanied by an up-regulation of pro-inflammatory cytokines IL-
1β and IL-6 as well as chemokines MIP-1 and MIP-2, indicating IL-4 as another suppressor of 
chronic inflammation (Cao et al., 2007). The same deletion caused an increased mortality in a 
mouse model of schistosomiasis due to an impaired alternative macrophage activation process 
and increased TH1 response (Herbert et al., 2004).  
 
LysM-Cre has also been successfully used in a macrophage ablation study designed to analyse 
the role of macrophages during skin repair. Cre mediated recombination led to the myeloid 
specific activation of the diptheria toxin receptor, which renders cells susceptible to diptheria 
toxin. After toxin administration, skin wound macrophages were efficiently depleted, wounds 
were  infiltrated  by  large  numbers  of  neutrophils  resulting  in  high  persisting  levels  of  pro-  54 
inflammatory cytokines. Due to impaired neo-vascularisation and wound contraction, healing 
was seriously disturbed in non-sterile environments (Goren et al., 2009). 
 
3.3.2  CD11b-Cre 
 
The C57BL/6 derived CD11b-Cre mouse carries a plasmid transgene in which Cre expression is 
regulated by a 1.7kb long fragment of the human CD11b promoter (Ferron and Vacher, 2005). 
CD11b is expressed in myeloid cells, osteoclasts and subsets of T and B cells. Expression levels 
were shown to be highly dependent on the chromosomal insertion position as a transgenic line 
carrying only 4 copies achieved much higher frequencies than one harbouring 40. Transgene 
specificity  was  assessed  using  the  Z/EG  reporter  mouse  (Novak  et  al.,  2000)  in  which  the 
deletion of lacZ activates EGFP expression in targeted tissues. Flow cytometry analysis showed 
GFP activation in 38% of peritoneal macrophages and 35% of bone marrow granulocytes and 
macrophages. 50% of B220+ B cells in the spleen and 33% of CD4+ T cells in the thymus were 
also  fluorescent.  Interestingly,  DNA  quantitation  by  Southern  Blot  estimated  the  total 
recombination frequency in peritoneal macrophages to be 100% whereas very low levels in 
testis, kidney, liver, brain heart and lung were attributed to peripheral blood contamination. 
Microglial cells and osteoclasts, derived from the common macrophage progenitor, exhibited 
significant recombination as well (Ferron and Vacher, 2005).  
 
Unlike the LysM-Cre mouse, the CD11b-Cre model has not been extensively used in generating 
myeloid specific conditional knock-outs, very likely due to its lower levels of recombination 
and  significant  ectopic  activity.  In  one  study,  however,  the  strain  was  used  to  generate  an 
ostecoclast specific knock-out of the microRNA processing enzyme Dicer, which resulted in 
mild  osteopetrosis  caused  by  reduced  osteoclast  numbers  and  impaired  bone  resorption 
(Sugatani and Hruska, 2009). 
 
3.3.3  GE-Cre 
 
The 129 based GE-Cre mouse strain, previously designed in this lab, harbours Cre as a knock-in 
into the granulocyte elastase locus ela2 (Tkalcevic et al., 2000), which is expressed at the pro-
myelocyte stage. Crossing of GE-Cre to a mouse harbouring a floxed version of csk, the C 
terminal  Src  kinase,  resulted  in  55%  deletion  in  bone  marrow  and  peritoneal  granulocytes. 
Deletion could not be observed in resident peritoneal macrophages or lymphocytes, however, 
once macrophages became activated, they also displayed significant levels of recombination 
(Thomas et al., 2004). In another mouse model, carrying a floxed version of TβRII, a receptor 
subtype for TGFβ, recombination levels in bone marrow derived granulocytes only reached 
30%, climbing to 52% after stimulation (Mahbub et al, unpublished).   55 
 
The  GE-Cre mouse served to ascertain the role of csk in regulating phagocyte recruitment. 
Conditional  csk  deficiency  causes  enhanced  acute  inflammation  and  sensitivity  to  LPS  by 
rendering granulocytes hyperresponsive and -adhesive. Both phenotypes result from a dropped 
neutrophil activation threshold caused by spontaneous de-granulation and the localisation of 
integrins to the cell surface. Mice show acute inflammation of the skin and lung (Thomas et al., 
2004). In a model where the target was the conditional deletion of TβRII however, the low 
deletion levels precluded the study of a specific phenotype regarding the migratory capabilities 
of neutrophils in response to TGFβ (Mahbub et al, unpublished). 
 
In conclusion, the available blood specific Cre mouse models provide varied tools for studying 
the immune system. If one is interested in the myeloid cell lineage, the LysMCre mouse appears 
to be the most popular choice at present. That model, however, does not allow to selectively 
delete floxed target genes in myeloid subpopulations, as Cre is expressed in all macrophages 
and  granulocytes.  In  addition,  ectopic  expression  in  non-myeloid  compartments  has  been 
reported. The herein proposed models are an attempt to close this gap by providing Cre mice 
that enable selective and strong expression in neutrophils (Itgb2l) and macrophages (Marco and 
Msr1). We hope that Msr1 controlled Cre expression results in a superior model allowing pan-
macrophage  conditional  knock-outs.  The  Marco  model,  on  the  other  hand,  will  hopefully 
provide a superior tool to engineer deletions in macrophage subsets. 
 
Strain 
Name 
Target 
Gene/ 
Promoter 
Type  Main 
Expression in 
Ectopic 
Expression in 
Expression Levels  Reference 
Lymphoid specific Cre lines 
Lck-Cre  lck 
promoter 
Plasmid 
transgene 
Immature T 
cells 
Splenocytes  90%  (Orban et al., 
1992) 
CD19-
Cre 
CD19 
 
Knock-in  B 
lymphocytes 
None 
observed 
75-80% pre-B cells, 
90-95% splenic B 
cells 
(Rickert et al., 
1997) 
hCD2-
iCre 
hCD2 
LCR 
Plasmid 
transgene 
T and B cells  Testis and 
ovaries 
≈100% in all B and 
T Cells 
(de Boer et 
al., 2003) 
CD21-
Cre 
CD21  BAC 
transgene 
Mature B cells  Liver, 
pancreas, 
kidney, gut, 
ovary 
90% in mature B 
cells, 4-40% 
immature B cells, 
55-70% bone 
marrow B cells 
(Kraus et al., 
2004) 
Rag1-
Cre 
Rag1  Knock-in  T and B cells  n/a  100% spleen 
partial in bone 
marrow 
(McCormack 
et al., 2003) 
Foxp3
YFP
-Cre 
Foxp3  Knock-in  Regulatory T 
cells 
T and B cells, 
myeloid cells, 
bone marrow 
precursors 
100% in regulatory 
T cells 
2-10% in other 
tissues 
(Rubtsov et 
al., 2008) 
CD4-
Cre 
CD4 
promoter/ 
enhancer 
Plasmid 
transgene 
Maturing T 
cells 
Macrophages, 
B cells, 
Granulocytes, 
Microglia 
90% in T cells  (Lee et al., 
2001) 
Strain 
Name 
Target 
Gene/ 
Promoter 
Type  Main 
Expression in 
Ectopic 
Expression in 
Expression Levels  Reference 
Mb1- Mb1  Knock-in  B Cells  Low levels in  99% splenic B cells,  (Hobeika et   56 
Cre  kidney, liver, 
T cells 
97% bone marrow 
B cells, 100% pre B  
al., 2006) 
GZMB-
Cre 
Granzyme 
B 
promoter 
Plamsid 
transgene 
Activated 
CD4+ T cells 
n/a  n/a  (Jacob and 
Baltimore, 
1999) 
Cγ1-Cre  γ1 
constant 
region 
promoter 
Knock-in  Germinal B 
cells 
IgM+ B cells  >85%  (Casola et al., 
2006) 
Ox40-
Cre 
Ox40 
promoter 
Knock-in  Active T cells, 
regulatory T 
cells 
Testes, naive 
T cells 
90% in regulatory T 
cells, 8-70% in T 
cells 
(Klinger et al., 
2009) 
Aicda-
Cre 
AID 
promoter 
BAC 
Transgene 
Germinal B 
cells 
n/a  n/a  (Kwon et al., 
2008) 
E8I-Cre  CD8a 
Promoter 
E8I 
enhancer 
Plasmid 
transgene 
 
CD8+ T cells  n/a  n/a  (Maekawa et 
al., 2008) 
Myeloid Specific Cre Lines 
LysM-
Cre 
M 
Lysozyme 
Knock-in  Monocytes, 
macrophages, 
neutrophils 
Dendritic cells  95% peritoneal 
macrophages, 99% 
peritoneal 
neutrophils, 75% 
bone marrow, 
macrophages, 78% 
bone marrow 
granulocytes 
(Clausen et 
al., 1999) 
GE-Cre  Ela2  Knock-in  Granulocytes  Macrophages  55% granulocytes  (Thomas et 
al., 2004) 
CD11b-
Cre 
CD11b 
regulatory 
elements 
Plasmid 
transgene 
Macrophages, 
granulocytes, 
mature 
osteoclasts 
T and B cells,   100% peritoneal 
macrophages, 35% 
bone marrow, 35% 
thymic T cells 
(Ferron and 
Vacher, 2005) 
Mcpt5-
Cre 
Mcpt5 
regulatory 
elements 
BAC 
transgene 
Mast cells  None 
observed 
99.1% peritoneal 
mast cells 
(Scholten et 
al., 2008) 
Haematopoietic Stem Cell Specific Cre Lines 
vav-iCre  Vav 
promoter 
Plasmid 
transgene 
All hemato-
poietic tissues 
Testis and 
ovaries, gut, 
brain, muscle 
n/a  (de Boer et 
al., 2003) 
Fes-Cre  Human c-
fes 
promoter 
Plasmid 
Transgene 
Definitive 
hematopoietic 
stem cells 
Heart, muscle, 
lung, kidney, 
brain 
52% erythrocytes, 
69% granulocytes, 
56% B cells, 77% T 
cells 
(Keller et al., 
2001) 
Erythrocytes/Megakaryocyte Specific Cre Lines 
pEV-
Cre 
Erythroid 
specific β 
globin 
promoter 
and LCR 
Plasmid 
transgene 
Erythrocytes  Fetal mast 
cells, 
macrophages 
100% in fetal liver  (Gutierrez et 
al., 2004) 
Pf4-Cre  CXCL4 
regulatory 
elements 
BAC 
transgene 
Megakaryo-
cytes 
None 
oberserved 
100% in 
megakayocytes and 
platelets 
(Tiedt et al., 
2007) 
Gata1-
Cre 
Gata1 
promoter 
Plasmid 
transgene 
Erythrocytes 
  
Megakaryo-
cytes, eosino-
phils mast 
cells 
100% in peripheral 
erythrocytes 
(Jasinski et 
al., 2001) 
Dendritic Cell Specific Cre Lines 
CD11c-
Cre 
CD11c 
regulatory 
elements 
BAC 
transgene 
Dendritic cells  Lymphocytes, 
myeloid cells 
>95% splenic 
dendritic cells 
(Caton et al., 
2007) 
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CHAPTER 4: HAEMATOPOIETIC DIFFERENTIATION OF MURINE EMBRYONIC 
STEM CELLS 
 
Embryonic stem cells are able to give rise to almost any cell type. Recent years have seen major 
advances regarding in vitro culture protocols aimed at producing a multitude of tissues. It has 
become  clear  that  ES  cells  follow  some  of  the  key  regulatory  processes  governing  in  vivo 
embryonic  development.  Differentiation  can  consequently  serve  as  a  model  for  mammalian 
development  and  also  provide  cells  for  regenerative  medicine  (Murry  and  Keller,  2008). 
Simultaneously, the knowledge about the cellular processes distinguishing embryonic stem cells 
has evolved considerably. Haematopoietic differentiation was used as a method in the herein 
presented  work  to  assess  expression  of  the  knocked-in  Cre  recombinase  in  vitro  prior  to 
investing the time and resources in creating mouse models. The basics of murine stem cell 
biology  and  differentiation,  as  well  as  key  concepts  surrounding  in  vivo  and  in  vitro 
haematopoiesis are summarized in this final introductory chapter.  
 
4.1  Basic Stem Cell Biology: Pluripotency and Self-Renewal 
 
Murine  embryonic  stem  cells  are  derived  from  the  inner  cell  mass  (ICM)  of  the  3.5d  pre-
implantation blastocyst. They are able to differentiate into all three germ layers and can thus 
complement  embryos  that  give  rise  to  adult  mice.  The  key  characteristics  of  embryonic 
“stemness”  are  pluripotency
2  and  self-renewal  (Boheler,  2009).  By  definition,  pluripotency 
portrays a cell’s ability to form all cell types of the adult body without possessing the self-
organising capability needed to build a whole organism. Self-renewal describes the capacity to 
undergo repeated cell divisions while maintaining the undifferentiated state and not entering 
senescence (Niwa, 2007). So far “stemness” has been traced to three distinct cellular properties 
– a defined set of transcription factors, a unique epigenetic state and a shorter cell cycle – that 
differentiate embryonic stem cells from somatic cells.  
 
Of the transcription factors implicated in maintaining pluripotency, Oct3/4, Nanog and Sox2 are 
most important. Oct3/4 is essential for the initial development of pluripoteniality in the ICM. 
Oct3/4 knock-out mice die soon after implantation (Nichols et al., 1998). Suppression of Oct3/4 
in ES cells leads to trophoblast-like differentiation (Niwa et al., 2000). The mechanism of action 
seems  to  be  dose-dependent,  as  overexpression  results  in  mesodermal  and  endodermal 
differentiation  and  Oct3/4  has  also  been  linked  to  the  regulation  of  cardiac  differentiation 
(Stefanovic and Puceat, 2007; Zeineddine et al., 2006). Likewise, Nanog is expressed in pre-
implantation embryos but not in differentiated cells (Chambers et al., 2003; Mitsui et al., 2003). 
                                                 
2Pluripotent cells can create all embryonic and thus adult tissues, but not extraembryonic structures. Only 
the zygote is able to generate both and is therefore totipotent.   58 
The  factor acts as a dimer that suppresses endodermal differentiation (Wang et al., 2008a). 
Overexpression  of  Nanog  enables  in  vitro  embryonic  stem  cell  cultures  to  remain 
undifferentiated in the absence of leukemia inhibitory factor (LIF) and sera (Liu et al., 2009; 
Ying  et  al.,  2003).  The  third  factor,  Sox2  (Ivanova  et  al.,  2006;  Kopp  et  al.,  2008),  curbs 
throphoectoderm formation in a dose-dependent manner (Kopp et al., 2008) and is further able 
to dimerize with Oct3/4 in order to regulate gene expression (Chew et al., 2005). Sox2 deletion 
can be rescued by Oct3/4 administration, suggesting that its major role is governing Oct3/4 
(Masui et al., 2007). Oct3/4, NANOG and Sox2 interact in complex feedback loops and regulate 
each other’s expression as well as their target genes. 
 
Plenty  of  other  transcription  factors  have  been  connected  to  pluripotency  and  self-renewal, 
though they are not restricted to ES cells. These include, but are not limited to, c-Myc (Kidder 
et al., 2008), B-Myb (Kidder et al., 2008; Liu and Labosky, 2008), Foxd3 (Liu and Labosky, 
2008), Klf4 (Chan et al., 2009), Sall4 (Yuri et al., 2009), Zfp42 (Scotland et al., 2009) and Gbx2 
(Chapman  et  al.,  1997).  Overall,  the  maintenance  of  “stemness”  in  ES  cells  appears  to  be 
controlled by an intricate transcriptional network. 
 
The  transcriptional  network  is  complemented  by  elaborate  and,  in  the  context  of  stem  cell 
biology, poorly understood signalling pathways. Cultured murine ES cells, for example, are 
maintained  in  an  undifferentiated  state  through  growth  on  a  fibroblast  feeder  layer  in  the 
presence of extrinsic LIF (Williams et al., 1988). LIF has recently been shown to hierarchically 
affect Jak/STAT3; Grb2/MAPK and PI(3)K/Akt (Niwa et al., 2009) pathways. It has been long 
known that stimulation of the Jak/STAT3 pathway is sufficient to maintain pluripotency in 
culture (Matsuda et al., 1999). Signalling controls Klf4 and Tbx3 transcription factors, which in 
turn influence the major pluripotency markers Sox2, Oct3/4 and Nanog (Figure 4.1). Supporting 
evidence comes from the discovery that enhanced expression of Nanog (Chambers et al., 2003), 
renders  embryonic  stem  cells  independent  of  LIF.  Parallel  auxiliary  conduits  encompass 
signalling through BMP4 (bone morphogenetic protein 4) and Smad to activate the Id (inhibitor 
of differentiation) proteins that repress lineage specific commitment (Ying et al., 2003) as well 
as activation of the Wnt/β-catenin system (Ogawa et al., 2006; Sato et al., 2004). 
 
A recent study supporting the hierarchical structure of the signalling network postulates that 
embryonic  stem  cells  represent  a  basal  cellular  state,  which  self-maintains  if  shielded  from 
differentiation stimuli (Ying et al., 2008), as blocking cellular differentiation pathways (i.e. 
autocrine  stimulation  of  the  mitogen-activated  protein  kinase  ERK1/2  by  fibroblast  growth 
factor FGF4) with small molecule inhibitors maintains ES cells in the absence of LIF (Kunath et 
al., 2007; Stavridis et al., 2007).  
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ES  cells  have  a  distinct  pattern  of  histone  acetylation  and  methylation  as  well  as  DNA 
methylation,  comprising  a  unique  epigenetic  state.  Embryonic  stem  cell  chromatin  is  in  an 
active  shape,  poised  for  transcription,  which  is  evidenced  by  a  looser  structure  with  fewer 
tightly wound heterochromatin foci that can be  easily accessed by pluripotency-maintaining 
transcription factors; a higher proportion of loosely bound architectural proteins (Meshorer et 
al.,  2006)  and  increased  levels  of  acetylated  histones  implicated  in  rendering  chromatin 
transcriptionally  permissive  (Lee  et  al.,  2004).  Simultaneously,  discrete  patterns  of  histone 
lysine  methylation  and  the  co-operative  binding  of  polycomb  protein  complexes  efficiently 
repress lineage specific transcription factor expression (Boyer et al., 2006; Pietersen and van 
Lohuizen, 2008). Once differentiation commences; pluripotency markers such as Nanog and 
Oct3/4  are  rapidly  silenced  by  DNA  methylation  (Farthing  et  al.,  2008;  Li  et  al.,  2007). 
Furthermore,  embryonic  stem  cells  express  a  unique  set  of  microRNAs
3  which  are  down 
regulated  with the onset of differentiation (Houbaviy et al., 2003).  Their mode of action is 
unclear, they  might serve to silence pluripotency factors as embryonic stem cells leave the 
pluripotent  state  (Chivukula  and  Mendell,  2009).  Transcriptional  and  epigenetic  regulators 
interact extensively to maintain both pluripotency and the induction of differentiation (Figure 
4.2). 
 
A final defining feature of embryonic stem cells is their rapid division and thus comparatively 
short cell cycle  with a particularly short  G1 phase controlled by constitutively active Cdk2 
(Koledova et al., 2009). ES cells exhibit a non-functional mitotic-spindle checkpoint in G2 that 
normally induces apoptosis if chromosomal integrity is compromised. Consequently, embryonic 
stem cells are more likely to develop karyotypic abnormalities than adult cell lines, a trait that 
has been repeatedly observed in long term in vitro culture (Mantel et al., 2007). 
 
A direct result of understanding what governs stem cell biology is the recent development of the 
induced pluripotent stem (iPS) cell technology through which somatic cells are reprogrammed 
into an induced pluripotent state by overexpressing certain transcription factors, modifying the 
cell’s  epigenetic  state  and/or  altering  defined  signalling  pathways  (Muller  et  al.,  2009; 
Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Yu et al., 2007). 
                                                 
3 microRNAs are a 22nt long subset of mammalian transcriptomes, They have been found to regulate 
gene expression by degradation of transcripts or inhibition of translation.   60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 LIF-controlled Parallel Signalling in Cultured Embryonic Stem Cells 
LIF  interacts  with  its  receptor  gp130/LIFRβ  and  controls  three  pathways.  The  Jak/STAT3 
pathway  mainly  activates  Klf4,  whereas  the  PI(3)K/Akt  pathway  regulates  Tbx3.  The 
Grb2/MAPK pathway is proposed to have a balancing effect on Tbx3. Klf4 and Tbx3 interact in 
regulating Sox2 and Nanog, which then direct Oct3/4. Illustration taken from (Niwa et al., 2009). 
 
 
Figure 4.2 Regulatory Networks in Pluripotency and Differentiation 
Epigenetic  (blue)  and  pluripotency  regulators  (dark  pink)  interact  to  activate  pluripotency-
inducing  genes  (red)  and  suppress  lineage  specific  genes  (yellow)  when  the  cell  is  in  a 
pluripotent  state.  During  differentiation,  however,  the  epigenetic  regulators  activate 
transcription of defined developmental genes relevant for lineage commitment (red) and inhibit 
pluripotency  and  non-related  developmental  genes.  MicroRNAs  (miRNA)  serve  to  silence 
pluripotency transcripts (light pink). Cartoon taken from (Chen and Daley, 2008). 
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4.2  Embryonic Haematopoietic Differentiation in vivo and in vitro 
 
4.2.1  Basic Murine Embryonic Development 
 
Murine  pre-natal  development  has  been  studied  for  decades  as  a  model  for  vertebrate  and 
especially human embryogenesis. A brief summary, focussing on the early stages, is presented 
here, for more extensive reviews, the reader is referred to (Duranthon et al., 2008; Gridley, 
2006; Nagy et al., 2003; O'Shea, 2004; Rossant and Tam, 2009; Tam, 2004; Tam et al., 2006). 
 
Embryo development begins with the fertilization of an ovum resulting in the formation of a 
zygote covered by the zona pellucida. Progressing cell divisions commence the morula stage (4-
16 cells), with a compaction observed at the 8-cell phase around E2.5. The morula enters the 
uterine cavity via the fallopian tubes and forms a liquid-filled cavity, the blastocoel, at 32 cells 
or around E3.5. This period (40-150 cells) is called the blastocyst stage. The zona pellucida 
degenerates and is replaced by the trophoblast built from the outer layer of the blastocyst. The 
trophoblast  serves  to  generate  the  trophoectoderm,  an  epithelial-like  structure  essential  for 
implantation  and  later  placenta  development  (Watson  and  Barcroft,  2001).  The  blastocyst’s 
inner layer forms the embryoblast and is the embryo’s source pluripotency (i.e. inner cell mass; 
ICM) (Rossant, 2004; Yamanaka et al., 2006). It differentiates into an epiblast, adjacent to the 
trophoblast, and a hypoblast, next to the blastocyst cavity. The epiblast is the starting point for 
all three embryonic germ layers. The hypoblast gives rise to a primitive endoderm. 
 
The embryo implants into the uterine lining around E5 and forms a central pro-amniotic cavity. 
Shortly thereafter, around E5.5, epiblast cells loose their pluripotency. The primitive endoderm 
develops into the visceral endoderm at gastrulation and subsequently into the visceral yolk sac. 
Gastrulation,  the  invagination  of  the  blastocyst,  begins  with  the  formation  of  the  primitive 
streak at E6.5 and establishes the spatial organisation of the embryo. The process ultimately 
results  in  the  extraembryonic  mesoderm  and  the  three  definitive  germ  layers  mesoderm, 
endoderm and ectoderm (Rivera-Perez, 2007). The germ layers then begin with the complex 
course of organogenesis, with each layer, giving rise to a specific set of tissues until birth at 
E19.5 (Figure 4.3).  
 
4.2.2  In vivo Haematopoeitic Development 
 
A functioning cardiovascular system is essential for mammalian embryos to develop beyond 
implantation (Copp, 1995). Haematopoietic tissues are consequently, together with cardiac and 
vascular structures, the first to arise in the embryo. Early embryonic haematopoiesis begins with   62 
the onset of gastrulation. Future mesodermal cells move along the primitive streak
4 and exit at 
either the posterior or anterior end. The former contribute to several extraembryonic tissues 
including the yolk sac (Lawson et al., 1991). The latter serve to form an intraembryonic region 
called  the  para-aortic  splanchnopleura  (P-Sp),  which  later  develops  the  aorta,  gonads  and 
mesonephros (AGM) (de Bruijn et al., 2000; Medvinsky et al., 1993). Both of these sites play a 
vital role in embryonic blood production. Several other locales of haematopoietic potential have 
been  suggested.  These  include  the  allantois,  a  transient  sac-like  extraembryonic  structure 
involved in excretion (Lawson et al., 1991); aortic clusters in the vitelline and umbilical arteries 
which  supply  blood  to  the  yolk  sac  and  placenta  (de  Bruijn  et  al.,  2000)  and,  later  in 
development,  the  placenta  (Gekas  et  al.,  2005).  The  respective  tissues  and  time  frames  are 
summarized in Figure 4.4.  
 
The yolk sac produces haematopoietic tisssues in several staggered waves. The first generates 
primitive
5 erythroid cells from so-called blood islands, formed by blood cells and endothelium, 
starting from E7.25 (Palis et al., 1999) and plateauing by E12.5. These cells derive from a 
unique progenitor (EryP-CFC), enter circulation, mature and can be detected until several days 
after birth (Kingsley et al., 2004). The yolk sac also produces macrophages and megakaryocytes 
during  this  phase  (Xie  et  al.,  2003;  Xu  et  al.,  2001a).  The  second  wave  of  yolk  sac 
haematopoiesis  begins  at  E8.25  and  generates  definitive  erythroid  progenitors  (BFU-E  and 
CFU-E
6) which enter the blood stream and begin populating the fetal liver at E10 (Palis et al., 
1999). The liver becomes the main organ for the maturation of definitive erythrocytes which go 
into circulation around E11.5 (Kingsley et al., 2004). Mast cell and granulocyte-macrophage 
progenitors  appear  around  the  same  time  whereas  the  megakaryocyte  and  macrophage 
progenitors found during primitive yolk-sac haematopoiesis persist throughout the definitive 
stage (Keller et al., 1999). The yolk-sac thus provides myeloid and erythroid precursors to the 
fetus and helps to populate the liver with haematopoietic potential (McGrath and Palis, 2005). 
Whether or not yolk sac derived cells play a role in long-term haematopoiesis is still debated, 
though  it  sometimes  has  been  found  to  be  capable  of  forming  haematopoietic  stem  cells 
(Kumaravelu et al., 2002). 
 
After  E10  (Lux  et  al.,  2008)  the  AGM  region  begins  to  play  a  distinct  part  in  embryonic 
haematopoiesis. It is thought to provide haematopoietic stem cells, including those of lympho-
myeloid potential, that populate the liver, thymus, spleen and eventually initiate the switch to 
                                                 
4The primitive streak is the first sign of mammalian gastrulation. It forms as a transient furrow across the 
embryo and plays a role in defining the anterior and posterior orientation.  
5 Primitive erythrocytes are nucleated and resemble the red blood cells found in non-vertebrate species. 
In  addition,  they  are  much  larger  than  the  definitive  enucleated  erythrocytes  produced  later  during 
embryonic development or in the adult mammal.  
6 BFU-E (burst forming unit - erythroid) and CFU-E (colony forming unit – erythroid) are both progenitor 
cells for erythroblast and erythrocyte development. BFU-E differentiates into CFU-E when stimulated by 
Erythropoietin.    63 
long-term blood generation in the bone marrow. The involved mechanisms and cell types are 
not yet clearly elucidated (Cumano et al., 1996; Cumano et al., 2001). 
 
The early steps of embryonic haematopoiesis, irrespective of the locale, are still a matter of 
debate. It is well known that blood cells differentiate from the mesoderm, but exactly how is 
still under discussion. An established paradigm postulates the existence of the haemangioblast, a 
cell  type  capable  of  producing  both  endothelial  and  blood  cell  lineages  as  the  common 
mesodermal precursor. This assumption is supported by the finding that embryonic stem cells 
can differentiate into cells expressing the mesodermal marker Flk-1 which then mature into 
blast colony forming cells (BL-CFC) that in turn can develop into both haematopoietic and 
endothelial  cells  (Huber  et  al.,  2004).  Flk-1  is  also  expressed  during  embryonic  yolk-sac 
haematopoiesis. Yet, a newer theory suggests a haemogenic endothelium as the intermediate 
state. It is based on the discovery that Flk-1+ cells progress through a transient stage expressing 
exclusively endothelial markers before moving on to develop haematopoietic lineages (Lancrin 
et al., 2009). Furthermore it has been found that endothelial cells from the AGM region give 
rise to cells populating the fetal liver and bone marrow  (Zovein et al., 2008) in a  Runx-1
7 
controlled process (Chen et al., 2009) and that individual cells could be tracked in vitro from the 
mesodermal through the endothelial to the haematopoietic level (Eilken et al., 2009). 
 
4.2.3  In vitro Haematopoietic Differentiation from Embryonic Stem Cells 
 
Haematopoietic differentiation of ES cells is one of the best-studied differentiation processes 
and its investigation began as soon as embryonic stem cells had been isolated. It was shown 
early on that ES cells can differentiate in culture to generate several haematopoietic lineages 
(Doetschman et al., 1985). One of the central concepts of in vitro haematopoietic differentiation 
is to model the in-vivo haematopoietic niche. Several techniques have been employed in cell 
culture to mimic those surroundings: three-dimensional embryoid body culture in suspension 
(4.2.3.1), growth on feeder layers and matrices (4.2.3.2) and the application of soluble growth 
factors (4.2.3.3) (Orlovskaya et al., 2008). 
 
Experiments  have  shown  that  early  haematopoietic  cells,  primitive  and  definitive  erythroid; 
myeloid  and  endothelial  lineages,  reminiscent  of  in  vivo  yolk-sac  haematopoiesis,  can  be 
generated with comparative ease. In accordance with the dogma that all blood originates from 
mesoderm,  differentiation  cultures  begin to  express mesodermal  markers  such  as  Flk-1  and 
CD34, before haematopoietic markers appear (Keller et al., 1993). The gene expression patterns 
observed  during  in  vitro  differentiation  also  mimic  those  of  the  early  embryo  with  the 
                                                 
7 The transcription factor Runx-1 is needed for haematopoietic stem cell formation in the mouse embryo.   64 
transcription factors of the GATA family (Shimizu and Yamamoto, 2005; Tsai et al., 1994; 
Weiss et al., 1994) and SCL/tal-1 (Porcher et al., 1996) playing essential roles. 
 
Lymphoid, haematopoietic stem cell (HSC) populations and mature blood cell types such as 
neutrophils  are  much  more  difficult  to  derive  in  vitro.  This  is  in  part  due  to  their  later 
appearance in vivo. As such they are believed to require a more complex microenvironment, 
which is difficult to model in  culture.  One of the crucial factors appears to be the oxygen 
pressure, as one study found that lymphoid progenitors could only be derived in a low-oxygen 
environment  (Potocnik  et  al.,  1994).  Recent  years,  however,  have  seen  an  emergence  of 
complex; multi-step; long-term culture protocols, able to produce most blood cell lineages, if 
with low efficiencies (Wassarman and Keller, 2003). Figure 4.5 shows an overview of the order 
of differentiation seen in murine cultures. Early blood development in vitro was found to be 
independent  of  growth  factors  with  the  exception  of  those  provided  by  batch  tested  serum 
(Keller et al., 1993; Wiles and Keller, 1991) or, more recently, serum replacements (Ma et al., 
2008).  The  reproducible  creation  of  mature  lineages,  however,  heavily  depends  on  soluble 
growth factors, in particular cytokines and extracellular matrix proteins. 
 
4.2.3.1  Suspension Culture and Embryoid Body Formation 
 
ES cells cultured in suspension in the absence of pluripotency maintaining LIF  form small 
clumps surrounded by an visceral-endoderm like structure (Keller, 1995). These are referred to 
as embryoid bodies (EB). EBs are reminiscent of early in vivo post-implantation development 
when  considering  size,  gene  expression  patterns  and  differentiation  abilities.  They  contain 
precursors of all germ layers, including haemangioblast-like cells expressing Flk-1, which are 
commonly viewed as blood progenitors (Doetschman et al., 1985; Kabrun et al., 1997; Keller, 
1995). EBs cultured for more than 10d commonly develop a cystic structure, characterized by a 
liquid filled cavity and a polar morphology, much like the late blastocyst in vivo. 
 
Techniques for EB generation include liquid suspension culture in ultra-low attachment plates, 
culture in semisolid media (i.e.  methylcellulose, MCM), hanging drops or porous scaffolds. 
Formation efficiency depends on the cellular density, with dilute suspensions working better 
than  dense  ones  (Dang  et  al.,  2002).  Murine  embryonic  stem  cells  are,  unlike  their  human 
equivalent (Ng et al., 2005), capable of forming EBs with haematopoietic potential from single 
cells. Irrespective of the starting cell numbers, EBs grow to a threshold size in suspension, 
which is very likely due to them reaching a developmental block or not being able to extract 
enough nutrients and oxygen from the medium (Dang et al., 2002).   65 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Murine Germ Layers and Tissue Origination 
The three different germ layers endoderm (red), mesoderm (green) and ectoderm (blue) give 
rise  to  distinct  tissues  in  the  adult  organism.  Adult  blood  is  ultimately  derived  from  the 
mesoderm. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Stages of Murine Embryonic Haematopoiesis 
The upper panel illustrates active haematopoietic tissues during the embryonic development 
timeline (middle panel). The lower panel indicates the earliest time points (dashed arrows) at 
which  certain  blood  cell  types  appear  and  when  definitive  haematopoietic  organs  are  first 
colonized.  AGM: aorta-gonads-mesonephros;  HSCs: hematopoietic stem cells.  Figure  modified 
from (Dzierzak and Speck, 2008). 
 
 
Figure 4.5 Order of Haematopoietic Differentiation in Murine ES Culture 
The time-line indicates days from which onwards the first population of lineage progenitors can 
be  observed.  Timings  will  be  heavily  dependent  on  individual  culture  protocols.  Obtaining 
mature cells often requires further periods of maturation in the presence of specific growth 
factors. LTRHSC: long term repopulation haematopoietic stem cell, describes a transplantable 
population that can replace or supplement in-vivo haematopoiesis in the recipient. The graph is 
modified from (Keller et al., 1999).   66 
Keller  et  al  (Keller,  1995;  Wiles  and  Keller,  1991)  pioneered  the  EB  technology  for 
haematopoietic growth. In their cultures, based on semisolid methylcellulose supplemented with 
growth factors (Table 4.1), early erythrocytes were observed around day 7, as indicated by EBs 
turning red from produced haemoglobin. Early macrophages became apparent after 12-18d. At 
later  stages  mast  cells  and  very  few  neutrophils  appeared,  around  days  12-20.  The  initial 
experiments  proved  that  EBs  can  initiate  both  primitive  and  definitive  haematopoiesis.  The 
former, however, is quantitatively dominant, possibly due to the lack of anatomic complexity 
needed to expand the latter (Lengerke and Daley, 2005). In practical terms, this means that if 
mature  blood  cells  are  to  be  differentiated,  they  require  multifarious  and  lengthy  culture 
procedures beyond the formation of EBs. 
 
A key factor in the growth of haematopoietic EBs is culture in suspension. Attachment to cell 
culture  plastic  and  subsequent  spreading  abolishes  haematopoietic  potential,  possibly  by 
inhibiting the formation of early mesodermal precursors (Dang et al., 2002).  This theory is 
supported  by  the  observation  that  attached  EBs  exhibit  a  drastic  down-regulation  of  the 
mesodermal markers CD34 and Flk-1. Interestingly, this problem occurs only in early cultures. 
If  EBs  attach  after  4  days  or  later,  haematopoietic  development  is  not  compromised 
significantly  and  attachment  culture  of  late  EBs  is  indeed  widely  used  for  longer  term 
haematopoiesis in vitro (Bautch et al., 1996; Dang et al., 2002). 
 
4.2.3.2  Feeder Cells and Matrices 
 
Feeders and matrices model the stromal environment of the adult bone marrow and have been 
used particularly in differentiation assays aimed at creating haematopoietic populations that 
appear later in development, such as neutrophils, lymphocytes and re-populating stem cells. 
They are thought to support differentiation by providing soluble factors and extracellular matrix 
molecules. The OP9 cell line (see below), for example, has been shown to express IL-7 and 
SCF, both of which are relevant to granulopoiesis (Cho et al., 1999; Veiby et al., 1996). 
 
Several murine stromal-like fibroblast cells have been utilized. They are commonly isolated 
from the adult bone marrow, the fetal liver or intraembryonic regions of the early embryo. One 
of the first lines employed  was the  murine stromal  cell line  OP9, derived from adult bone 
marrow that is deficient in macrophage colony stimulating factor (Nakano et al., 1996). Due to 
the  lack  of  M-CSF,  it  is  still  popular  in  creating  non-macrophage  lineages  such  as 
megakaryocytes (Eto et al., 2002) and neutrophils (Lieber et al., 2004). Other described cell 
lines include S17, supporting B-lympho- and myelopoiesis (Collins and Dorshkind, 1987); MS-
5 (Issaad et al., 1993), AFT024 (Hackney et al., 2002) and AGM lines (Krassowska et al., 2006; 
Weisel et al., 2006) used in HSC maintenance.   67 
Collagen  IV  is  an  effective  matrix  protein  that  enables  the  production  of  Flk-1+  blood 
progenitors  without  the  step  of  three-dimensional  EB  formation  (Nishikawa  et  al.,  1998). 
Similarly,  the  portrayed  cell  lines  are  able  to  support  certain  haematopoietic  processes 
independently of EB formation. The majority of differentiation protocols, however, still rely on 
the  assembly  of  EBs  and  their  further  expansion,  either  as  whole  bodies  or  as  trypsin  or 
collagenase dissociated single cells, followed by maturation with the help of co-cultured cells 
and/or growth factors. 
 
4.2.3.3  Soluble Growth Factors and Differentiation 
 
Whereas the initial stages of differentiation, up to the formation of early mesoderm, appear to 
be  factor  independent,  soluble  growth  factors,  in  particular  cytokines  and  chemokines,  are 
broadly  used  to  maintain  longer  term  haematopoietic  differentiation  in  vitro.  Table  4.1 
summarizes combinations employed for a panel of murine differentiation experiments sorted by 
culture method and time frame. Murine haematopoietic differentiation is still heavily reliant on 
batch tested bovine serum. While this has been blamed for the high rate of variability between 
experiments (Keller, 2005), it is likely set to continue due to its cost-effectiveness. Also xeno-
free  culture  protocols  are  a  much  lower  priority  in  murine  experiments  compared  to  the 
differentiation of human embryonic stem cells for potential transplantation. Curiously, almost 
all protocols recommend the use of reducing agents, such as monothioglycerol (MTG), ascorbic 
acid  or  vitamin  E  due  to  their  beneficial  effects  on  haematopoietic  development.  The 
mechanism  through  which  these  substances  exert  their  influence  are  currently  unknown. 
Additionally, insulin is often added as it improves cell plating efficiency. 
 
4.2.4  In vitro Production of Murine Macrophages and Neutrophils 
 
4.2.4.1  Macrophages 
 
As  described  previously,  macrophages  are  the  first  murine  myeloid  lineage  to  appear  in 
differentiation cultures. Very low rates have even been seen without any added growth factors 
beyond those provided by the serum (Loureiro et al., 2008). The general protocol, however, 
relies on EB formation and expansion of macrophage progenitors by IL-1, IL-3 and M-CSF. 
Embryoid bodies cultured in liquid or semisolid suspension experience primitive and definitive 
erythropoiesis during the first 10 days illustrated by the EB core going red due to the production 
of  haemoglobin.  Macrophages  appear  over  the  following  10  days.  They  present  as  highly 
refractive cells forming a halo around the  EB and are eventually shed into the  cell culture 
medium.  Disrupted  EBs  can  also  be  expanded  as  attached  single  cell  cultures  in  which 
macrophages  appear  after  similar  time  frames.  Attached  EBs  were  shown  to  be  able  to   68 
continuously  produce  macrophages  for  several  weeks  (Wiles,  1993).  The  ES  derived 
macrophages express markers CD11b and F4/80 as well as RNA for lysozyme and for the M-
CSF receptor and are able to phagocytose (Inamdar et al., 1997; Wiles and Keller, 1991).  
 
4.2.4.2  Neutrophils 
 
Neutrophils appear late in embryonic development. Their derivation from murine embryonic 
stem cells is consequently much more difficult than for macrophages. Nevertheless, a complex 
three-step culture protocol, able to generate mature neutrophils with a yield of around 75%, has 
been  described  recently  (Lieber  et  al.,  2004).  First,  EBs  were  formed  in  liquid  suspension 
culture for several days. Day 8 EBs were trypsinized and plated onto semi-confluent OP9 cells 
with serum based medium supplemented by growth factors OSM, bFGF, LIF, KL, IL-6 and IL-
11. After two replating steps over the next 3 days, adherent cells were transferred into medium 
containing G-CSF, GM-CSF and IL-6 for maturation. Mature neutrophils could be harvested 
after additional 4-20 days, bringing the total culture period to 15-35 days. The phenotype of 
those  differentiated  cells  agrees  well  with  that  of  bone  marrow  derived  neutrophils.  They 
express neutrophil markers Gr-1 and the neutrophil specific antigen and a large fraction stains 
positive for gelatinase, a late stage neutrophil maturation marker. In addition, they are able to 
produce super oxide when stimulated and react chemotactically to MIP-2 (Lieber et al., 2004).  
 
Soluble Growth 
Factor 
Differentiation 
Protocol 
Predominant Cell 
Type 
Time 
Frame 
Reference 
Erythropoietin (Epo)  Embryoid 
body/MCM 
Erythrocytes  5-7 days  (Wiles and Keller, 
1991) 
IL-3  Embryoid 
body/MCM 
Macrophages, mast 
cells 
10-12 days  (Wiles and Keller, 
1991) 
IL-3 and/or IL-1; M-
CSF or GM-CSF 
Embryoid 
body/MCM 
Macrophages  8-14 days  (Wiles and Keller, 
1991) 
IL-3; IL-1; GM-CSF; 
Epo 
Embryoid 
body/MCM 
Broad range of colony 
forming cells 
(haematopoietic 
progenitors) 
8-14 days  (Keller et al., 1993) 
SCF and/or IL-11  Embryoid 
body/MCM 
M-CFC; E-CFC; GM-
CFC; mix CFC 
8-14 days  (Keller et al., 1993) 
IL-6; IL-11; 
Thrombopoietin (Tpo) 
OP9 co-culture  Megakaryocytes  8-12 days  (Eto et al., 2002) 
Epo  OP9 co-culture 
of Flk1+ cells, 
no serum 
Erythrocytes  7 days  (Otani et al., 2004) 
IL-3; IL-7; Epo  Embryoid 
body/MCM; 
ST2 co-culture 
Lymphoid precursors  18 days  (Nisitani et al., 1994) 
Tpo; FGF2; SCF; IL-3; 
IL-6; IL-11; G-CSF; 
Epo 
Embryoid body; 
MS-5 co-culture 
Myeloid progenitors, 
megakaryocytes 
>12 days  (Berthier et al., 1997; 
Uzan et al., 1996) 
OSM; bFGF; IL-6; IL-
11; LIF; SCF; G-CSF; 
GM-CSF; 
Embryoid body; 
OP9 co-culture 
Neutrophils  15-35 days  (Lieber et al., 2004) 
Flt-3L  OP9 co-culture  B-lymphocytes  19-28 days  (Cho et al., 1999) 
IL-3; GM-CSF  Embryoid body  Dendritic cells  >14 days  (Fairchild et al., 2003) 
Table 4.1 Cytokines Used in the Haematopoietic Differentiation of Murine ES Cells   69 
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CHAPTER 5: EXPERIMENTAL PROCEDURES  
 
5.1  Molecular Biology Methods 
 
5.1.1  Electrophoresis Related Methods 
 
5.1.1.1  Agarose Gel Electrophoresis 
 
Gel  concentrations  varied  between  0.7-2%  agarose  (Sigma)  depending  on  the  nucleic  acid 
fragment size to be visualized. Gels, containing 50µg/ml ethidium bromide, were poured and 
run in 1xTAE buffer. Samples were diluted in 6x loading buffer (20% Ficoll, 30mM EDTA, 
0.01% Bromphenolblue). Size standards (Promega) were run with every gel to estimate nucleic 
acid concentration and size. Gels were run at varying field strengths for a duration of 45min to 
1h. Samples were visualized using a UV transilluminator; pictures were taken using the Alpha 
Imager (Alpha Innotech). 
 
5.1.1.2  Pulse Field Gel Electrophoresis (PFGE) 
 
Pulse  field  gels  contained  0.8%  agarose  and  were  run  in  0.5xTBE  using  the  BioRad 
Chefmapper according to manufacturers protocols. All conditions were set to “AUTO“. Gels 
were  dyed  post-run  in  0.5xTBE  containing  50µg/ml  ethidium  bromide  for  15min  whilst 
shaking. To enhance contrast, gels were de-stained in water for further 10min. 
 
5.1.1.3  Gel Purification 
 
Samples to be isolated were run in low melting point agarose (Sigma) gels, excised, weighed 
and then purified with the Qiagen Mini Elute kit according to the manufacturer’s protocols. The 
protocol was modified to use doubled elution buffer volumes and eluting at 65˚C. 
 
5.1.2  PCR Related Methods 
 
Sequences of all primers used in this work can be found in Appendix A. Primers were designed 
using Primer3 (Rozen and Skaletsky, 2000).  Primers used were de-salted with the exception of 
targeting primers, which were gel and HPLC purified. 
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5.1.2.1  Standard PCR 
 
All PCRs designed to yield product sizes of up to 3kb and not requiring proofreading activity 
were carried out as follows. Reactions were performed in 10-50µl using the GoTaq Polymerase 
(Promega) according to the manufactures protocols. Primer (Sigma, MWG) concentrations were 
10  or  20pmol  per  reaction.  Nucleotides  (Invitrogen)  were  added  at  200µM.  Magnesium 
concentration  was  1.5mM.  The  template  amount  varied  from  100pg  in  case  of  plasmids  to 
200ng for genomic DNA per reaction. The annealing temperature was typically set about 5˚C 
below the melting temperature of the primer. 25-35 cycles were carried out. 
 
5.1.2.2  Long Range PCR 
 
PCRs  for  products  over  10kb  were  performed  using  the  Takara  LA  Taq  (Takara  Bio  Inc) 
according  to  the  manufacturer’s  protocols.  PCRs  were  performed  in  10µl  with  2.5mM 
Magnesium,  0.5U  enzyme,  10pmol  per  primer  and  20-50ng  template  genomic  DNA  per 
reaction. A special auto-segment extension programme (Ohler and Rose, 1992) was employed 
to  increase  product  yield.  All  PCRs  were  performed  as  Hot  Start.  Primer  annealing  and 
extension were combined in one step at 68˚C. 
 
5.1.2.3  Intermediate Length PCR 
 
PCRs  intended  to  generate  fragments  between  3kb  and  10kb,  those  for  sequencing  or 
subcloning  were  performed  mixing  the  previously  mentioned  GoTaq  polymerase  with 
proofreading polymerase  Pfu (Promega) to reduce errors at a ratio of 16:1. Reactions  were 
carried out in Pfu reaction buffer as described before. 
 
5.1.2.4  Colony PCR 
 
PCRs using mES colonies were carried out as follows. Cells were harvested and aliquoted into 
PCR tubes at 10
4, 2*10
4 or 5*10
4 cells/tube; alternatively one half of an ES cell colony provided 
the  PCR  template  with  the  other  half  enabling  further  expansion.  After  centrifugation  the 
medium  was  removed  and  the  pellet  was  washed  once  with  PBS.  Following  a  second 
centrifugation and removal of the supernatant, the cells were dislodged from the bottom of the 
tube and frozen overnight at -20˚C before being used as PCR template. Tubes intended for 
amplification were thawed and the cell pellet re-suspended in 20µl 1xPCR buffer supplemented 
with 100µg/ml ProteinaseK (Sigma). Cells were lysed for 30min at 55˚C in a thermocycler 
(MWG). 10min at 90˚C served to inactivate the proteinase. Tubes were held at 80˚C for a Hot 
Start PCR to add 30µl of PCR master-mix containing all other necessary components.   72 
5.1.2.5  RT PCR 
 
1µg of total RNA was treated with RQ1 DNAseI (Promega) according to the manufacturer’s 
protocols before being subjected to reverse transcription with either oligodT or random primers 
(both  Promega)  employing  the  Superscript  III  enzyme  (Invitrogen)  according  to  the 
manufacturer’s protocols. 1/20 of the reaction volume was used in PCR amplifications. 
 
5.1.2.6  DNA Sequencing 
 
The Wolfson Institute of Biomedical Sciences performed all sequencing analyses using the dye 
terminator sequencing method.  
 
5.2  Cloning Related Methods 
 
5.2.1  Bacterial Strains 
 
The following E.coli strains were used: DH10T-B1 (Invitrogen) (Narayanan et al., 1999) for 
BAC propagation and XL1BMR (Stratagene) for all other plasmid related work. 
DH10B-T1:   F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 lacX74 recAI endAI araD139 
Δ (araleu) 7697 galU galK rpsL nupGλ- tonA 
XL1BMR:   recAI endAI gyrA96 thi-1 hsdR17 supE44 relAI lac[F-proABlacI
qZΔM15 Tn10 
amy Cam
r] 
 
5.2.2  Bacterial Culture 
 
Bacteria  were  cultured  in  LB,  2xYT  or  TB  broth  containing  the  appropriate  antibiotics 
overnight at 37˚C whilst shaking. Initial cultures for plasmids usually were 1.5ml, miniprep 
cultures for BAC preparation 6ml and cultures for large scale production of plasmids/BACs 
about 150ml. 
 
Antibiotic  Supplier  Stock Solution  Working 
Concentration 
Ampicillin  Sigma  20mg/ml  100µg/ml 
Kanamycin  Sigma  30mg/ml  30µg/ml 
Tetracycline  Sigma  15mg/ml  3-12.5µg/ml 
Chloramphenicol  Sigma  10mg/ml  15µg/ml 
Table 5.1 Antibiotics for Prokaryotic Selection   73 
5.2.3  Bacteria Transformation 
 
5.2.3.1  Heat Shock 
 
CaCl2 competent XL1BMR E. coli were thawed on ice. Per transformation 80µl were mixed 
with  DNA  and  kept  on  ice  for  10min.  Following  incubation  at  42˚C  for  2min,  cells  were 
returned to the ice for further 10min. 1ml of LB medium was added to each transformation. 
Samples were incubated at 37˚C whilst shaking for 1h. Subsequently bacteria were plated in 
dilutions on agar plates containing the appropriate antibiotic and grown overnight at 37˚C. 
 
5.2.3.2  Electroporation 
 
Electrocompetent DH10T-B1 E. coli were thawed on ice. Desalted DNA was mixed with 70µl 
of  the  bacteria  and  transferred  into  a  0.1cm  electrocuvette  (Sigma).  Cells  were  shocked  at 
1.88kV, 25µF and 200Ω using an electroporator (BioRad) and immediately topped up with 1ml 
of LB medium. Bacteria were kept on ice for 10min before growing 1h at 37˚C whilst shaking 
and being plated in dilutions on agar plates containing the appropriate antibiotics to be grown 
overnight at 37˚C. 
   
5.2.4  Plasmid Mini Preparation 
 
Plasmids were isolated by alkaline lysis. 1ml of a TB or LB culture was spun down and re-
suspended in 100µl glucose buffer (50mM glucose, 25mM Tris, 10mM EDTA), mixed with 
200µl  lysis  buffer  (0.2N  NaOH,  1%  SDS)  and  precipitated  by  adding  150µl  neutralization 
buffer.  (3M KAc pH 5.2) After adding 400µl Phenol/Chloroform the sample was vortexed and 
centrifuged. The aqueous phase was separated, re-extracted with Chloroform and precipitated. 
Precipitates were dissolved in water containing 10µg/ml RNAse A (Sigma). 
 
5.2.5  Plasmid Midi & Maxi Preparation 
 
Large-scale plasmid preparation was carried out using Qiagen Midi and Maxi kits. For BAC 
preparation all lysis buffer volumes were doubled and elution was carried out with aliquots of 
buffer preheated to 65˚C to increase yield. 
 
5.2.6  Nucleic Acid Precipitation 
 
Samples were mixed with 1/10 3M NaAc pH 5.2 and 1 volume isopropanol or 2.5 volumes 
ethanol  before  centrifuging  them  30min  at  4˚C.  Precipitates  were  washed  twice  with  70%   74 
ethanol, dried at room temperature and re-suspended in an appropriate amount of 10mM Tris-Cl 
pH 8, TE or water. 
 
5.2.7  Nucleic Acid Quantitation 
 
DNA concentrations were either estimated by running samples on a gel and comparing band 
intensities to the λ HindIII size standard (Promega), or by measuring absorption at 260nm using 
the NanoDrop spectrophotometer (Thermo Fisher Scientific). 
 
5.2.8  Restriction Digest 
 
Enzymes were purchased from Promega, NEB or Sigma. DNA, at no more than 300ng/µl, was 
digested in the appropriate buffer at 37˚C for 1h to 16h. Enzymes were added at 5U per µg 
plasmid  DNA/PCR  product  or  10U  per  µg  genomic  DNA.  100µg/ml  acetylated  BSA  was 
present in all reactions. 
 
5.2.9  Dephosphorylation & Ligation 
 
DNA  was  dephosporylated  by  the  Shrimp  Alkaline  Phosphatase  (Promega).  Ligations  were 
performed  using  the  T4  DNA  Ligase  (Promega)  according  to  the  manufacturer’s  protocols. 
Ratios of vector to insert ranged from 1:1 to 1:6.  
 
5.2.10  Southern Blot 
 
DNA for Southern Blots was isolated from confluent ES cell cultures that had been transferred 
to gelatinized plates during the previous passage to minimize contamination with feeder cell 
DNA. Following harvest, cells were re-suspended at 5*10
6 cells/ml in lysis buffer (0.2%SDS, 
0.1M  Tris  pH  8.5,  5mM  EDTA,  200mM  NaCl,  200µg/ml  ProteinaseK)  and  incubated  in  a 
shaker at 55˚C for 4h or overnight. Subsequently, one volume of Phenol/Chloroform was added, 
and  samples  were  vortexed  before  being  centrifuged  to  separate  the  phases.  Following  re-
extraction with Chloroform, the aqueous phase was precipitated with 1 volume of isopropanol 
or 2.5 volumes of ethanol. The genomic DNA was removed with a yellow pipette tip, washed 
twice in 70% Ethanol and dried at room temperature. DNA was re-suspended in 1xTE buffer at 
no more than 300ng/µl. Following restriction digest and gel electrophoresis, Southern gels were 
blotted on a GeneScreen membrane (Perkin Elmer) using the salt transfer protocol (Sambrook et 
al., 1989). Membranes were pre-hybridized for 2h in Church Buffer (1% BSA fraction V, 1mM 
EDTA, 0.2M  NaHPO4 pH 7.2, 7%  SDS) containing 1µg/ml denatured salmon sperm  DNA 
65˚C. Southern probes were labelled with α
32P dCTP (Amersham) using the NEBlot kit (NEB)   75 
according  to  the  manufacturer’s  protocol.  Probes  were  purified  with  microspin  columns 
(Amersham)  to  remove  excess  radioactivity  and  denatured  at  95˚C  for  10min.  The  Church 
buffer was replaced, probes were added and the membranes were hybridized overnight at 65˚C. 
Membranes were washed using progressively more stringent conditions (1
st 2xSSC/0.1% SDS, 
2
nd 1xSSC/0.1% SDS, 3
rd 0.5xSSC/0.1%SDS, 4
th 0.2xSSC/0.1% SDS, 5
th 0.1xSSS/0.1% SDS, at 
50˚C or 65˚C) until the background radioactivity reached 10-20 cpm measured by a Geiger 
counter.  After  the  last  wash,  membranes  were  wrapped  in  plastic  foil  and  exposed  to  a 
PhosphorImager Storage Screen (Kodak) for 12h to 5 days. Screens were scanned with the 
Storm PhosphorImager (Molecular Dynamics). Band intensities were quantified using ImageJ 
(Abramoff et al., 2004). 
 
5.2.11  Red/ET Recombineering 
 
The  construction  of  the  targeting  vectors  was  accomplished  in  two  steps  by  Red/ET 
recombineering (Genebridges) according to the manufacturer’s protocol. First, a gene-specific 
BAC  iCre2  knock-in  was  created  followed  by  transfer  of  the  modified  insert  into  plasmid 
vectors. Further details can be found in Chapters 2, 6 and 7. Briefly, the iCre2-loxP-Neo-loxP 
cassette was amplified by PCR with primers introducing 50nt homology regions corresponding 
to the chosen BAC insertion point. The selection cassette (Genebridges)  carries procaryotic 
(Pgb2) and eucaryotic (PPGK) promoters and can thus be used in bacteria and mammalian cells. 
The PCR product was purified and electroporated into E.coli, together with the wild-type BAC 
and  pRED/ET,  which  expresses  all  proteins  necessary  for  recombination.  pRed/ET  is 
temperature sensitive and can be maintained at 30˚C but is lost at 37˚C. Expression is controlled 
by  a  sugar-inducible  promoter.  Recombineering  is  thus  induced  by  a  temperature  shift  and 
adding  L-arabinose.  Successfully  recombined  BACs  are  selected  for  their  newly  acquired 
kanamycin resistance and verified by PCR. To transfer the insert with appropriate homology 
arms into a plasmid vector, pUC19 was PCR amplified with primers adding 50nt homology 
regions corresponding to the gene-specific insert. The linear PCR product is transferred into the 
cells harbouring the knock-in BACs and a second recombination reaction is induced (illustrated 
in  Figure  5.1).  Correctly  recombined  clones  are  selected  for  acquiring  ampicillin  resistance 
(encoded from the pUC19 backbone) in addition to kanamycin resistance (from the insert). 
Plasmid vectors are isolated by miniprep and verified by restriction digest and sequencing.    76 
  Figure 5.1 Illustration of the Red/ET Recombineering Process 
The map at the top shows an iCre2 knock-in BAC. The homology regions used to create this 
knock-in are illustrated in yellow. The regions utilized for transferring the insert and adjacent 
homology arms are in green. The middle panel illustrates the linearized plasmid with attached 
homology  regions.  At  the  bottom,  the  rescued  targeting  plasmid  is  shown  after  successful 
recombination. 
 
5.3  Tissue Culture Methods 
 
All procedures were carried out in sterile tissue culture hoods. Tissue culture grade dishes and 
pipettes were from Nunc, Sterilin, or Costar. Reagents and media compositions are listed below. 
 
5.3.1  Reagents 
 
Dulbecco’s MEM    GibcoBRL, 41965-039 
Non-essential aminoacids 100x  GibcoBRL, 10829-018 
Sodium Pyruvate 100mM  GibcoRL, 11140-035 
ß-Mercaptoethanol    GibcoBRL, 31350-010 
L-Glutamin 200mM    GibcoBRL, 25030-024 
Penicillin/Streptomycin   GibcoBRL, 15140-114 
Trypsin/EDTA 10x    GibcoBRL, 35400-027 
FCS ES cell tested    Sigma, F-7524       
Mitomycin C      Sigma, M-0503 
G418 Sulphate      Roche-Boehringer, 1464981 
Gelatin       Sigma, G-1890 
HEPES 10mM      GibcoBRL 15630-056 
PBS        GibcoBRL, 14190-086 
LIF        Supernatant of LIF producing 293 cell line, titrated 
IMDM       GibcoBRL, 12440-079 
FBS for Differentiation   Kind gift from Alexandre Protocnik 
Monothioglycerol (MTG)  Sigma, M6145   77 
Ascorbic acid      Sigma, A4403 
Insulin        Sigma, I1882 
rIL-3        R&D Systems, 403-ML-010/CF 
rMCSF       R&D Systems, 416-ML-010/CF 
Collagenase IV     Sigma, C2674 
Methyl cellulose    Sigma, M7027 
 
5.3.2  Media Composition 
 
STO-NEO Medium  Dulbecco’s  MEM  supplemented  with  15%  FCS,  1x 
nonessential  amino  acids,  1mM  sodium  pyruvate,  0.1mM  ß-
Mercaptoethanol,  100i.E./ml  penicillin,  100µg/ml 
Streptomycin, 2mM Glutamin. 
ES Medium  STO-NEO Medium, but with 15% FCS and 1xLIF (leukemia 
inhibitory factor). 
Freezing Medium  STO-Neo  or  ES  Medium  supplemented  with  10mM  HEPES 
and 10% DMSO. 
ES Transition Medium  Iscove’s  MDM  supplemented  with  15%  differentiation  FCS, 
100i.E./ml penicillin, 100µg/ml Streptomycin, 2mM Glutamin. 
450µM  MTG  (added  fresh  from  stock),  50µg/ml  Ascorbic 
Acid, 10µg/ml Insulin, 1x LIF 
ES Differentiation Medium    ES  Transition  Medium  without  1xLIF,  1ng/ml  IL-3,  5ng/ml 
MCSF (for semisolid media 1% methyl cellulose was added) 
 
5.3.3  Cell Lines 
 
The mouse ES cell line used in this work is designated IB10. It is a subclone of the 129P2 E14 
line  and  has  the  genetic  background  129Ola/Hsd.  Embryonic  stem  cells  were  grown  on 
gelatinized  plates  on  top  of  growth  inhibited  STO-NEO  feeder  cells.  STO-NEO  is  an 
immortalised embryonic fibroblast cell line possessing G418 resistance. All cells were grown at 
37˚C, 5% CO2 in a humidified incubator. 
 
5.3.4  Passaging of Cell Lines 
 
Cells were passaged just before reaching confluency. The medium was aspirated and the cell 
layer washed once with PBS. Enough Trypsin was added to cover the cell layer and the dishes 
were returned to the incubator for 10min. STO-NEO cells were split 1/3 to 1/10 whereas ES 
cells were plated to yield densities of 1-7*10
4 cells/cm
2.   78 
5.3.5  Thawing and Freezing of Cells 
 
Cells  for  freezing  were  harvested  by  trypsinzation,  spun  down  and  re-suspended  at  1*10
7 
cells/ml  freezing  medium  and  transferred  to  cryovials  (Nunc).  Samples  were  placed  in  a 
polystyrene box at -20˚C overnight to facilitate slow freezing. After a few days, vials were 
transferred to liquid nitrogen for long-term storage. Cells to be thawed were incubated at 37˚C 
and  then  transferred  to  a  15ml  tube.  5ml  of  medium  were  added  drop-wise,  cells  were 
centrifuged, re-suspended and plated in the appropriate medium. 
 
5.3.6  Preparation of Feeder Layers for ES Cell Culture 
 
10µg/ml MitomycinC (Sigma) was added to the medium of confluent STO-NEO plates and 
incubated for 3h at 37˚C. After washing the cells thrice with PBS, they were trypsinized and 
plated at 1.5*10
4 cells/cm
2 on gelatinized dishes to serve as feeder layers. MitomycinC treated 
cells were aliquoted, frozen and thawed as needed during embryonic stem cell culture. 
 
5.3.7  Eukaryotic Cell Transfection & Selection 
 
mES cells were plated at 2*10
6 cells/6cm dish two days prior to transfection. On the day of 
transfection cells were harvested, washed once in medium and re-suspended at 0.5*10
6 – 1*10
7 
cells/ml transfection medium. The transfection medium consists of ES medium supplemented 
with 10mM HEPES. 2-10µg of the appropriate vector was added and cells were transferred into 
a  0.4cm  electrocuvette  (BioRad).  Cells  were  electroporated  at  a  voltage  of  625V/cm  and  a 
capacitance of 500µF. The cuvette was immediately topped up with 1ml of ES cell medium and 
left  at  room  temperature  for  10min.  Cells  were  subsequently  plated  in  varying  dilutions. 
Selection with the appropriate antibiotic was started after two days and selection medium was 
changed  every  three  days  until  resistant  colonies  could  be  observed.  Mass  cell  death  was 
observed  the  next  day  with  Puromycin  or  after  5  days  with  G418.  ES  cell  colonies  were 
typically isolated between days 10-12. 
 
Antibiotic  Supplier  Stock Solution  Concentration 
G418  Sigma  100mg/ml  175-250 µg/ml 
Puromycin  Sigma  30mg/ml  2µg/ml 
Table 5.2 Antibiotics for Eukaryotic Selection 
 
5.3.8  Embryonic Stem Cell Differentiation 
 
A method for macrophage differentiation of embryonic stem cells was adapted and established, 
details can be found in Chapter 9. Briefly, embryonic stem cells were transitioned into IMDM   79 
based medium by plating them at low densities (2.5*10E5/6cm dish) for 1-2 passages. ES cells 
were  then  harvested  and  washed  thrice  to  remove  LIF  and  re-suspended  in  differentiation 
medium. Embryoid body (EB) aggregation was carried out for 2 days in hanging drop culture. 
Then EBs were transferred into bacterial grade dishes for suspension culture for further growth 
with  added  growth  factors  Interleukin-3  (IL-3)  and  Macrophage  Colony  Stimulating  Factor 
(MCSF). After 7-10 days EBs were attached to tissue culture plastic either as whole structures 
or single cell suspension until macrophage formation was observed.  Single cell suspensions 
were obtained by protease digestion of embryoid bodies. 
 
5.3.9  RNA Isolation 
 
Total  RNA  from  embryonic  stem  cells  was  isolated  with  the  Qiagen  RNAeasy  mini  kit 
following the manufacturer’s protocol. Cellular samples were harvested and re-suspended in 
350µl lysis buffer and stored at -80˚C before extraction. 
 
5.4  Flow Cytometry 
 
5.4.1  Antibodies 
Antibody  Fluorophor  Isotype  Clone  Manufacturer 
F4/80 (rat anti mouse)  FITC  IgG2b  CI:A3-1  Serotec 
CD11b (rat anti mouse)  PE  IgG2b  M1/70  Pharmingen 
Marco (rat anti mouse)  none  IgG1  ED31  Serotec 
Star69 (goat anti rat)  FITC  IgG1  N/A  Serotec 
Gr-1 (rat anti mouse)  PE or FITC  IgG2b  B6-8C5  Pharmingen 
CD45R/B220 (rat anti mouse)  PE or FITC  IgG2a  RA3-6B2  Pharmingen 
CD31 (rat anti mouse)  PE  IgG2a  MEC13.3  Pharmingen 
CD117 (rat anti mouse)  PE  IgG2b  2B8  Pharmingen 
CD16/CD32 (rat anti mouse)  none  IgG2b  2.4G2  Pharmigen 
Table 5.3 Antibodies for Cell Stainings 
All antibodies  were used at pre-tested titrated quantities or diluted as recommended by the 
manufacturer. FITC: fluoresceine isothiocyanate; PE: phycoerythrine. 
 
5.4.2  Cell Surface Staining and Data Analysis 
 
Cells were harvested by protease digest and washed once in PBS. Single cells suspensions were 
aliquoted into 96well round bottom plates, spun down for 10min at 4˚C and 2000rpm and re-
suspended in FACS buffer (PBS pH 7.2, 0.5% BSA, 2mM EDTA, 0.01% sodium azide). Cells 
were blocked for 20min using 20% rat serum (Sigma) and CD16/CD32 antibody (FcBlock, 
Pharmingen) prior to staining. Cells were stained with the antibodies listed in Table 5.3. Briefly, 
directly conjugated antibodies were added at the appropriate concentrations and incubated for 
30min at 4˚C in the dark. Where a secondary antibody was used, the procedure was the same 
after a 30min incubation with the primary antibody and two rounds of washing. Finally, cells 
were washed twice and re-suspended in FACS buffer. Data was acquired on a FACS Calibur 
flow cytometer (Becton Dickinson). Data was analyzed with FlowJo (Treestar).   80 
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CHAPTER 6: THE FIRST GENERATION OF iCRE2 KNOCK-INS 
 
6.1  Setup of the Project 
 
The objective of presented work is the generation of neutrophil and macrophage specific Cre 
recombinase knock-in mice as novel tools for conditional mutagenesis. Therefore, prior to the 
start of this project, a total of 6 different targeting constructs (modified BACs) had been created 
and  verified  in  which  the  recombinase  is  inserted  into  neutrophil  (Itgb2l)  and  macrophage 
(Marco and Msr1) specific genes. BAC modification was carried out such that the recombinase 
replaces the endogenous translational start codon, an example map for Itgb2l can be found in 
Figure 6.2A. Details about the target genes are summarized in Chapter 3.2, whereas the process 
of generating BAC knock-ins is described in depth in Chapter 2.2.2.1 and Figure 2.4 as well as 
Chapter 5.2.12. For each of the 3 targets, two vectors were created, one carrying an improved 
Cre (iCre2) (Lacy-Hulbert et al., 2001) and the other one harbouring a tamoxifen-inducible 
version (iCre2ER
T2). BACs were used directly to target ES cells, as their long homology regions 
promised higher targeting frequencies
8. 
 
The vectors were designated as follows:   Itgb2l iCre2 
            Itgb2l iCre2ER
T2 
            Msr1 iCre2 
            Msr1 iCre2ER
T2 
            Marco iCre2 
            Marco iCre2ER
T2 
 
IB10  mES  cells  (a  subclone  of  E14-1)  (Hooper  et  al.,  1987;  Kuhn  et  al.,  1991)  had  been 
transfected with the linearized gene-specific knock-in BACs. 257 drug resistant clones had been 
isolated; a further breakdown is given in Table 6.1. The herein presented work started with the 
expansion of G418 resistant embryonic stem cell colonies, extraction of genomic DNA and the 
screening  employed  to  establish  homologous  recombinants,  all  of  which  is  covered  in  this 
chapter. Figure 6.1 on the next page gives an overview of the screening regime.  
                                                 
8 Unless otherwise specified, this work uses the term “targeting frequency” to describe the percentage of 
verified knock-in clones out of all drug resistant clones assayed.   82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Knock-in Screening Process 
The flowchart outlines the process used for generating iCre2 knock-ins in this project. mES cell 
transfection  and  selection  were  followed  by  PCR  and  Southern  Blot  screenings  to  identify 
homologous recombinants. The final step of mES cell manipulation is the deletion of the G418 
resistance marker. The positive (+) or negative (-) outcome of each screening step helped to 
classify  the  resistant  clones  into  knock-ins  or  random  integrants.  Only  clones  with  results            
-/+/+/+ (left to right) were assessed further. 
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6.2  PCR Screening Reveals Potential Homologous Recombinants 
 
The G418 resistant clones can either be the desired homologous recombinants, or, much more 
frequently, have inserted the entire BAC vector randomly into the genome. In an attempt to 
narrow down the 257 isolated clones, a two-tiered PCR strategy was employed (Figure 6.2A). 
 
The first step aimed at ascertaining whether clones carried the BAC backbone. Homologously 
recombined clones should have lost those sequences. Primers were designed to amplify a 692bp 
long fragment (backbone PCR) of pBACe3.6, from which all used BACs descend. An absence 
of a band was counted as a first indicator for successful knock-in. An example for backbone 
PCR of Itgb2l iCre2 is given in Figure 6.2B. A further PCR amplified a segment of iCre2 
(Figure 6.2C, results for the Marco targeting BAC). The appearance of this band is the second 
indicator for successful homologous recombination. 6.2D lists the identified candidate clones 
for the Itgb2l locus, as these are the focus in the remainder of this chapter. 
 
Only clones that have yielded the expected results in both PCRs were assayed further. As shown 
in Table 6.1, the fraction of potentially homologous recombinant clones varied considerably 
between targeted genes. About one third of the cells targeted with the Marco constructs yielded 
promising results after PCR screening, compared to a quarter of those targeted for Itgb2l. The 
lowest fraction was observed for  Msr1, only about  10% of  mES  cell clones  were knock-in 
candidates. Fractions observed for iCre2ER
T2 were only slightly lower for iCre2 alone, with the 
exception of Itgb2l iCre2ER
T2.  
 
Targeting 
construct 
Number of G418 
resistant clones isolated 
Number of knock-in 
candidates after PCR 
Fraction in 
% 
Itgb2l iCre2  38  9  24 
Itgb2l iCre2ER
T2  68  7  10 
Marco iCre2  30  10  33 
Marco iCre2ER
T2  31  9  29 
Msr1 iCre2  24  2  8 
Msr1 iCre2ER
T2  66  4  6 
Table 6.1 Number of Isolated Clones and Initial PCR Screening Results   84 
 
Figure 6.2 Initial PCR Screening of G418 Resistant Transfectants
9 
A  depicts  the  bMQ203N9  Itgb2l  BAC  before  and  after  modification.  Lines  underneath  the 
construct illustrate the placement of the backbone and Cre screening PCRs that were employed 
to determine  whether  ES cell clones  were potential homologous recombinants. Primer pairs 
used were bacbckgrd3’/backbckgrd5’ for the backbone PCR, and MaF;PactF;Msr1F/iCrecheck2 
for the Cre PCR. Expected product sizes were equivalent for both the iCre2 and iCre2ER
T2 
constructs. In B genomic DNA isolated from clones targeted with Itgb2l iCre2 was analyzed for 
presence of the backbone. The Cre PCR is shown for both Marco iCre2 (Ma2) and Marco 
iCre2ER
T2 (Ma1) in C. Positive controls (BAC) were the respective targeting vectors, negative 
controls either wild type genomic DNA of 129 mice or no template in the PCR reaction. D 
summarizes the candidate clones for Itgb2l. 
Numbers  indicate  individual  clones.  M1:  1kb  marker;  M2:  100bp  marker;  -  w/o  template, 
*indicates independent DNA preparations. 
 
                                                 
9 Maps in this document may contain elements that are not drawn to scale.   85 
6.3  Two Southern Blots Identify Homologous Recombinants for Itgb2l 
 
The previously described PCR exclusion strategy served to reduce the number of candidate 
clones from 257 to a more manageable 41. However, loss of the BAC backbone and presence of 
iCre2  alone  are  not  sufficient  to  prove  homologous  recombination.  For  instance,  random 
integrants could have lost the short stretch of backbone being used for PCR whilst containing 
iCre2.  Therefore,  the  correct  chromosomal  position  of  iCre2  needs  to  be  ascertained 
independently.  
 
To  achieve  this,  external  Southern  Blot  strategies  targeting  the  5’  homology  region  were 
devised for all 6 constructs (Figure 6.3). The approach relies on restriction enzymes cutting 
outside of the homology arm (between Sau3AI and the beginning of iCre2) and fragments are 
identified  by  hybridization  with  an  external  probe.  Only  homologous  recombinant  clones 
possess  juxtaposed  restriction  sites  that  result  in  the  expected  fragment  length.  The  long 
homology arms of the targeting BACs severely restrict the choice of restriction enzymes and 
also create large DNA fragments, which are difficult to resolve and visualize. 
 
To test the method, initially only Itgb2l knock-in candidate clones were assessed. An XhoI/SalI 
strategy (Figure 6.3A) generates 29kb wild type and 13kb/14kb mutant products. The technique 
proved to be challenging. In three independent experiments wild type bands could not be clearly 
distinguished. A re-occuring problem was incomplete digestion of genomic DNA, which may 
have been due to enzyme inhibition by genomic  methylation (data not shown).  Eventually, 
weak bands of the correct size (13kb) indicating homologous recombination (Figure 6.4E) could 
be observed in some of the Itgb2l iCre2, but none of the Itgb2l iCre2ER
T2 samples. Clones 
exhibiting this faint signal were 19, 107 and 141. 
 
As there were no feasible alternative enzyme choices for the external Southern Blot, an internal 
Southern blot strategy was devised for Itgb2l to generate additional data (Figure 6.3A). The 
approach relies on BamHI restriction sites. The expected wild type band has a size of 3.5kb, 
compared to 2kb for the iCre2 knock-in. Bands are visualized by hybridization with an internal 
probe. Both knock-ins and random integrants will exhibit either band. The analysis of relative 
band intensities, however, allows distinguishing properly targeted clones. A band intensity ratio 
- wild type to mutant - of 1:1 indicates successful homologous recombination, as one wild type 
allele corresponds to one mutant allele. Band intensity ratios deviating from 1 suggest random 
integration. One random integration, with two intact wild type alleles, would lead to a ratio of 
2:1. More than two random integrants would cause a ratio of less than 1.  
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The results of the BamHI Southern Blot are shown in Figures 6.4A and 6.4C. It was performed 
for all Itgb2l clones previously identified as candidates by PCR exclusion (top numbers). Some 
clones considered to be random integrants (bottom numbers) were also included for control 
purposes. As expected, the DNA of 129 wild type mice shows only the 3.5kb band, whereas 
both bands are present in the DNA isolated from most of the candidate ES cell clones. The 
exceptions were two of the Itgb2l iCre2 (38, 115 Figure 6.4A) and three of the Itgb2l iCre2ER
T2 
clones  (8,  28,  29;  Figure  6.4C)  that  had  no  discernible  mutant  band  and  were  not  further 
assayed. 
 
Relative band intensities were determined in all lanes exhibiting the wild type and mutant band 
by measuring integrated pixel densities and ratios are given in Figure 6.4B for Itgb2l iCre2 and 
6.4D for Itgb2l iCre2ER
T2. In case of Itgb2l iCre2, 3 of the candidate clones (BAC negative) 
were close to a ratio of 1: clones 19, 125 and 141. Most of the control samples (BAC positive) 
deviated from the ratio of 1 affirming them as likely random integrants. For Itgb2l iCre2ER
T2, 
all 4 clones that showed 2 bands in the Southern Blot (43, 47, 55 and 57) exhibited a band 
intensity ratio of approximately 1. Some of the Itgb2l iCre2ER
T2 control clones also showed this 
result. This can be partially explained by the low quality of the Itgb2l iCre2ER
T2 Southern Blot, 
which  makes  density  measurements  less  reliable.  Control  samples,  i.e.  random  integrants, 
reaching a ratio of 1, can occur when 2 random integrations correspond to 2 intact wild type 
alleles.  
 
Overall, the XhoI/SalI Southern Blot suggests Itgb2l iCre2 clones 19, 107 and 141 as knock-ins. 
Data for Itgb2l iCre2ER
T2 could not be obtained. The BamHI Southern Blot identifies Itgb2l 
iCre2  clones  19,  125  and  141  and  Itgb2l  iCre2ER
T2  clones  43,  47,  55  and  57  as  potential 
homologous recombinants. 
 
6.4  Long Range PCR Confirms Homologous Recombination in Itgb2l Clones 
 
Due to the technical difficulties encountered during Southern Blot screening and overall low 
data quality, a further PCR-based screening was used to corroborate homologous recombinants 
among the Itgb2l clones. It relies on a special polymerase designed to enable the amplification 
of very long PCR products (Takara LA Taq). Placing PCR primers in a way that allows the 
amplification of a genomic region from outside the 5’ homologous arm to within iCre2 enables 
the assessment of  correct chromosomal insertion (12.1kb external product, Figure 6.5A).  A 
second PCR, creating a slightly shorter product (internal product) of 10.5kb beginning within 
the homology region, serves as control. 
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Figure 6.3 Southern Blot Strategies for the Three Targeted Loci 
The structure of the genomic loci before and after homologous recombination is illustrated in A 
to C for Itgb2l, Marco and Msr1 respectively. Given are the chromosomal locations of the wild 
type genes or the corresponding Cre knock-ins, suggested restriction enzymes and expected 
fragment  sizes.  The  Sau3AI  restriction  sites  determine  the  borders  of  the  inserted  mouse 
genomic DNA as provided by the BACs used for targeting. Probe locations are depicted as bold 
black lines. Only maps for the iCre2 knock-ins are shown, the respective DNA fragment sizes 
and restriction enzymes for the iCre2ER
T2 constructs are as follows: Itgb2l iCre2ER
T2: 3.5kb 
(BamHI);  Itgb2l  iCre2ER
T2:  14kb  (XhoI/SalI);  Marco  iCre2ER
T2:  23kb  (SnaBI);
  Msr1 
iCre2ER
T2: 12.6kb (ScaI).   88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Southern Blot Results for Itgb2l Clones 
BamHI Southern Blots were performed for a selection of suspected Itgb2l iCre2 clones (A, B) 
Itgb2l iCre2ER
T2 and (C, D). Numbers at the top indicate samples that were previously screened 
as potential recombinants by PCR (BAC negative).  Lanes numbered  at the bottom indicate 
samples still harbouring the BAC backbone (BAC positive) and served as an internal control. 
The ratios of band intensities given in B and D indicate the copy number of wild type and 
targeted  loci.  Clones  closest  to  ratio  of  1  are  most  likely  to  have  undergone  homologous 
recombination.  Control  DNA  was  isolated  from  wild  type  129  ES  cells.  Examples  for  an 
XhoI/SalI Southern Blot of Itgb2l iCre2 clones are illustrated in E.   89 
All  clones  containing  the  target  sequence,  whether  as  random  integrant  or  homologous 
recombinant, should yield the internal PCR product. Only clones that have the insert in the right 
chromosomal  position,  however,  will  additionally  generate  the  external  PCR  product.  An 
example for this PCR is shown in Figure 6.5B. Clone Itgb2l iCre2 141 served as a template for 
both internal and external PCR products and thus is a homologous recombinant.  A  BamHI 
restriction digest of the PCR product (Figure 6.5C) generated the expected pattern. Notably, 
clone  19  initially  only  displayed  the  internal  PCR  product  (data  not  shown),  indicating  an 
unsuccessful  recombination  event.  After  further  optimization  of  the  reaction  conditions  (in 
particular reduction of template quantity) and repeated isolation of genomic DNA, however, 
clone 19 could also be identified as a homologous recombinant by long range PCR. Additional 
clones  yielding  this  positive  result  were  Itgb2l  iCre2  107  and  Itgb2l iCre2ER
T2  47  (Figure 
6.5D). All clones positive for the long range PCR were also positive by Southern Blot (Figure 
6.4).  
 
6.5  Cre-mediated Deletion of the Resistance Marker in Itgb2l iCre2 Knock-ins 
 
The combination of all obtained screening data allowed the identification of knock-in clones 
among the Itgb2l candidates (see section 6.6 and Table 6.3). The next step was the removal of 
the G418 selection marker. Neo
R is a fully functional expression unit with its own promoters 
(Figure 6.6A) and can have detrimental effects on iCre2 expression. To facilitate deletion, Neo
R 
is flanked by parallel loxP sites. Cre mediated recombination excises the intervening DNA and 
leaves just one loxP site behind.  
 
A PCR strategy was designed to screen for such deletion events. After excision of Neo
R, the size 
of the amplification product is reduced from 2.5kb to 1kb (Figure 6.6A).  The deletion was 
attempted using two different Cre expression vectors for transient transfection of ES cells: pIC-
Cre;  (Gu  et  al.,  1993)  and  pCre-Pac  (Taniguchi  et  al.,  1998).  Cells  of  two  Itgb2l  iCre2 
recombinant clones (19, 141) were electroporated with the expression plasmid. After 48h, cells 
were harvested for PCR to assess Cre activity at the level of bulk cultures before the isolation of 
individual  colonies.  In  case  of  pCre-Pac,  an  additional  transient  Puromycin  selection  was 
applied to enrich transfected cells. However, as shown in Figure 6.6B-D, deletion of the Neo
R 
gene  could  not  be  achieved  in  any  of  the  samples  despite  carrying  out  several  repeat 
experiments with varying amounts (1-10µg) of the expression vector.   90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Long Range PCR of Itgb2l Clones 
Map, primer locations (black arrows), product sizes and restriction enzyme sites for the Itgb2l 
iCre2  locus  are  depicted  in  A.  PCR  products  for  Itgb2l  iCre2  and  Itgb2l  iCre2ER
T2  are
 
equivalent. B illustrates the PCR results for Itgb2l iCre2 clone 141. The positive control was the 
targeting BAC. Wild type 129 genomic DNA or water served as negative controls. In and ex 
show where internal or external primer pairs have been used. The two-fold zoom illustrates the 
small size difference between internal and external PCR products. A BamHI restriction digest 
(C) resulted in expected fragment sizes. All other clones exhibiting both bands are illustrated in 
D. The external primer pair was Pacttarg/iCrecheck2; the internal pair was Pactin2/iCrecheck2. 
M1: 1kb marker; M3: λHindIII marker; - w/o template; +B: BamHI; BAC: bMQ203N9 iCre2; - 
no template DNA.   91 
Sequencing of the plasmid pSP72-iCre2-pAp-NeoLox revealed, that the loxP sites as defined by 
the central 8bp orientation-defining core sequences, had an inverted orientation relative to each 
other  (Figure  6.6E&F).  As  this  plasmid  had  initially  been  used  to  generate  every  targeting 
vector prior to the start of this project, all recombinant ES cell clones contain these antiparallel 
loxP sites. Neo
R can thus not be excised in any of the ES cell lines as antiparallel loxP sites 
cause Cre-mediated deletion, inversion and re-integration of the intervening DNA. The error 
was apparently introduced prior to the start of this project by the primer pair employed to tail 
the Neo
R fragment with loxP sites, before cloning it into the iCre2-containing vector pSP72-
iCre2-pAp-NeoLox. 
 
6.6  Discussion 
 
6.6.1  The Use of Linearized iCre2 Knock-in BAC as Targeting Vectors 
 
During the initial planning of the presented project, bacterial artificial chromosomes had been 
chosen as targeting vectors for several reasons: 
1. An indexed 129Sv based genomic library in BAC format spanning the entire mouse 
genome  had  just  become  available,  providing  a  public  isogenic  DNA  resource  for 
targeting  vector  construction  (Adams  et  al.,  2005).  Since  then  an  additional  library 
based on the 129/Ola background  and thus even  more closely  matched to the used 
E14.1 ES cells has been published (Ohtsuka et al., 2006). 
2.  Methods  for  the  recombinogenic  engineering  of  BACs  were  becoming  more 
accessible due to the emergence of new kits (Chapter 2.2.2.1). 
3.  The  very  long  homology  arms  (Table  6.2)  provided  by  BACs  were  expected  to 
positively  influence  homologous  recombination  and  consequently  increase  gene 
targeting frequencies. 
 
Gene  BAC  Upstream Homology in kb  Downstream Homology in kb 
Itgb2l  bMQ203N9  10.7  145 
Marco  bMQ294K23  16.7  64 
Msr1  bMQ239G13  5  144 
Table 6.2 Length of Homology Arms in BAC Vectors 
The area of homology is measured up- and downstream from the iCre2-loxP-Neo-loxP insertion 
point to the closest Sau3AI site. Sau3AI had been used to partially digest the genomic DNA and 
clone it into the BAC vector during the library creation process and thus marks the BAC insert 
end points (also see Chapter 7.2). The listed BACs for each target gene had been chosen for 
having the shortest upstream homology region of all available candidates.  
 
When this work started with screening the 257 isolated G418 resistant clones obtained after 
transfecting E14.1 mES cells with the targeting constructs (Table 6.1), however, it became clear 
that the use of BACs complicates the identification of homologous recombinants.    92 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 No Evidence for Neo
R Gene Excision 
The iCre2-loxP-Neo-loxP construct before and after Neo
R deletion is illustrated in A. iCre2 
consists of 3 exons (e) and 2 heterologous introns (i). Arrows indicate the orientation of both 
genes.  The Neo cassette has 2 promoters, one for prokaryotic (Pgb2) and one for eucaryotic 
(PPGK) expression. In order to screen for successful deletion, a PCR primer pair (small arrows) 
flanking  the  Neo
R  cassette,  resulting  in  1kb  or  2.5kb  products,  was  employed.  PCRs  were 
carried out using 10.000, 20.000 or 50.000 lysed mES cells per reaction as template. Positive 
and negative controls are same as before, except that clone specific genomic DNA (gDNA) 
isolated prior to transient transfection was used as an additional control. B to D shows clones 19 
and 141 of Itgb2l iCre2 after Cre mediated deletion with different Cre expression vectors. In B 
piCCre was used. C and D represent pCre-Pac without and with puromycin selection. Deletion 
of the Neo
R gene is not apparent in any sample. Sequencing of the pSP72-iCre2-pAp-NeoLox 
plasmid revealed the inverted orientation of the 5’ (E) and 3’ (F) loxP sites. The orientation-
defining  spacer  region  is  bold.  Sequencing  was  carried  out  using  NeoLoxFSeq  and  a  T7 
standard primer.   93 
The PCR exclusion study designed to discovers homologous recombination candidates by the 
absence of the BAC backbone and the presence of iCre2, worked very well, and successfully 
reduced  the  number  of  clones  to  analyze  from  257  to  41  (Figure  6.2).  This  method  has 
previously been described in the literature as being very effective in determining clones that 
warrant further screening (McDermott et al., 2004; Yang and Seed, 2003). On its own, however, 
it does not ascertain correct knock-in. A positive PCR result for iCre2 and negative result for 
the BAC can also occur in random integrants that have lost part of the BAC backbone in a non-
homologous recombination process. When looking at the fraction of candidates with favourable 
PCR results, Itgb2l and Marco have a high percentage with 10-24% and 29-33% depending on 
the  targeting  construct  used.  The  Itgb2l  and  Marco  targeting  vectors  also  have  the  longest 
upstream  homology  arms  with  10.7b  and  16.7kb  respectively.  For  Msr1  the  PCR  positive 
fraction is only 6-8% coinciding with the shortest upstream homology arm of 5kb. There is no 
such  correlation  with  the  overall  much  longer  downstream  homology  arms,  the  one  in  the 
Marco construct is actually shortest with 64kb whereas those in the Itgb2l and Msr1 vectors are 
of similar sizes around 145kb. The presence of ER
T2, which extends the iCre2 fragment to be 
inserted by around 2kb, but does not affect the homology arms, only had a noticeable influence 
in the Itgb2l vectors. With ER
T2, the fraction of candidate clones was about half as much (10%) 
than without (24%). 
 
Achieving good results in the more conclusive Southern Blot aimed at verifying the upstream 
homology region in Itgb2l clones was difficult. Due to the length of the upstream homology 
arm,  only  an  XhoI/SalI  combination  was  a  possible  choice  (Figure  6.3A),  due  to  all  other 
commonly used restriction enzymes cutting within the homology region.  Whilst weak 13kb 
knock-in bands could eventually be obtained for some of the suspected recombinant samples, 
the 29kb wild-type band could not be clearly distinguished in any of the blots (Figure 6.4E).  
 
In the meantime, the BamHI Southern Blot helped to exclude some of the candidate clones 
(Figures 6.4A&C). Whilst the method relies on measuring band intensities and is thus very 
dependent on blot quality, it allowed the exclusion of several samples that did either not exhibit 
the  expected  two  bands  (e.g.  Itgb2l  iCre2  38,  115  and  Itgb2l  iCre2ER
T2  8,  28,  29)  or  did 
significantly deviate from the band intensity ratio of 1 (e.g. Itgb2l iCre2 143, 147). 
 
Finally,  the  long  range  PCR  approach  (Lay  et  al.,  1998),  amplifying  across  the  entire  5’ 
homology arm, proved the most successful method to assess homologous recombination (Figure 
6.5). Four clones, Itgb2l iCre2 19, 107, 141 Itgb2l iCre2ER
T2 47 exhibited the PCR product 
agreeing with homologous recombination. An internal PCR control product amplifying both 
homologous recombinants and random integrants helped to avoid false negatives caused by 
PCR failure.    94 
Overall,  a  combination  of  all  screening  methods  (see  Table  6.3)  eventually  allowed 
discriminating  homologous  recombinants  from  random  integrants  among  the  Itgb2l  clones. 
Ultimately, 3 Itgb2l iCre2 clones and 1 Itgb2l iCre2ER
T2 clone could be identified as being 
knock-ins. This equals targeting frequencies of 8% and 1,5% respectively, much lower than the 
initial fraction of candidate clones listed in Table 6.1. 
 
    HR Indicating Result in   
Targeting 
Construct 
Clones 
selected by 
PCR exclusion 
XhoI/SalI 
Southern 
Blot 
BamHI 
Southern 
Blot 
Long 
Range 
PCR 
Considered 
Knock-in Clone 
14  NDA  NA  NO  NO 
19  YES  YES  YES  YES 
38  NDA  NO  NA  NO 
107  YES  NDA  YES  YES 
115  NDA  NO  NA  NO 
125  NDA  YES   NA  NO 
141  YES  YES  YES  YES 
143  NDA  NO  NA  NO 
Itgb2l-iCre2 
147  NDA  NO  NA  NO 
8  NDA  NO  NA  NO 
28  NDA  NO  NA  NO 
29  NDA  NO  NA  NO 
43  NDA  YES  NO  NO 
47  NDA  YES  YES  YES 
55  NDA  YES  NO  NO 
Itgb2l-
iCre2ER
T2 
57  NDA  YES  NO  NO 
Table 6.3 Identification of Homologous Recombinants among Itgb2l clones 
The table lists the screening results for the Itgb2l iCre2 and Itgb2l iCre2ER
T2 samples that were 
selected as candidates by PCR exclusion and whether they were eventually considered to be 
knock-ins. NDA – no data available; NA – not assessed; HR Homologous Recombination 
 
BAC vectors are not routinely used for gene targeting, therefore an assessment of targeting 
frequencies is difficult. In the first published study, a modified BAC was used to target two sites 
of  the  Mll  (myeloid/lymphoid  mixed  lineage  leukemia)  gene,  43kb  apart,  with  G418  and 
Hygromycin selection markers simultaneously. After double selection, a targeting frequency of 
6% was obtained (Testa et al., 2003). A similar approach, aimed at concurrently disrupting the 
adjacent Tec (encoding tyrosine protein kinase Tec) and Rlk (encoding receptor like kinase) 
genes with G418 and blasticidin selection markers, reported 9% of clones being the desired 
homologous recombinants (Gomez-Rodriguez et al., 2008). Both groups observed that BACs 
electroporated into ES cells mainly integrated intact, but also high-lighted the possibility of 
BAC  breakage  resulting  in  difficult  to  monitor  random  integration  of  fragments  within  the 
genome or rearrangements occuring at the integration site (Heaney et al., 2004). A further high 
throughput  approach  using  largely  automated  BAC  targeting  vector  creation,  reported  an 
average targeting frequency of 3,8% across 200 genes (Valenzuela et al., 2003). The study also 
reported, that long BAC homology  arms do not necessarily have  a beneficial effect on the 
targeting frequency. For one gene, for example frequencies were around 6%, irrespective of   95 
whether homology arms were long (80kb and 80kb) or short (5,5kb and 1,5kb). In a second 
example, frequencies could be increased from 2% to 6% with a BAC targeting vector (75kb and 
35kb homology instead of 4,7kb and 0,5kb). It has been reported previously, however, that 
homology arms under 1kb have a detrimental effect on homologous recombination (Thomas et 
al.,  1992).  Thus  far,  the  highest  reported  targeting  frequency  for  BAC  vectors  is  15%,  an 
average over 5 genes (Yang and Seed, 2003). 
 
Collectively, BAC vectors have not yet been shown to achieve significantly higher targeting 
frequencies  than  conventional  plasmid  vectors.  This  supports  the  theory  that  targeting 
frequencies  become  saturated  once  homology  arms  exceed  a  length  of  14kb  (Deng  and 
Capecchi, 1992). The confirmed frequencies in this study thus far, 8% for Itgb2l iCre2 clones 
and 1,5% for Itgb2l iCre2ER
T2, fall well within the reported ranges. Frequencies do not appear 
to  be  significantly  above  those  achieved  with  conventional  vectors  which  typically  range 
between 1-5% (Sorrell and Kolb, 2005). 
  
The  challenges  of  BAC  targeting  encountered  in  this  work,  the  difficult  Southern  Blot 
Screening  resulting  from  long  homology  arms,  has  also  been  discussed  in  the  literature. 
Alternative screening protocols include qPCR, which analyses the copy numbers of disrupted 
loci or selection markers. qPCR has been described as highly accurate in excluding random 
integrants  (Gomez-Rodriguez  et  al.,  2008;  Valenzuela  et  al.,  2003).  Another  alternative  is 
fluorescence in-situ hybridization (FISH), using the whole targeting BAC as a probe. FISH, 
however, has been linked to producing false positives but can be useful in monitoring partial 
random integrations of vector fragments (Gomez-Rodriguez et al., 2008; Yang and Seed, 2003). 
The gold standard for identifying targeted clones, however, is still Southern Blot. Therefore 
several groups have used BAC vectors with the modified regions sitting close to either end or 
“shaved”  homology  arms  by  recombineering  to  reduce  their  size  (Testa  et  al.,  2003).  A 
combination of all of these additional methods could significantly improve efficiency if BAC 
targeting was to be repeated. 
 
6.7  Conclusion 
 
The failure to remove the G148 resistance marker from Itgb2l iCre2 knock-ins revealed that all 
isolated ES cell clones contain inverse loxP sites. Because of that Marco and Msr1 clones were 
not  further  assessed  to  identify homologous  recombinants,  but  could  potentially  be  used  as 
transgenic  lines  to  create  “pseudo  knock-in”  mice  (Sparwasser  et  al.,  2004).  This  approach 
would be similar to models, in which faithful tissue-specific Cre expression was controlled from 
a  randomly  integrated  BAC  transgene,  including  IL-7Cre  (Repass  et  al.,  2009),  Mcpt5-Cre   96 
(Scholten et al., 2008) or CD11c-Cre (Caton et al., 2007). Further examples can be founds in 
Table 3.2. 
 
The identified Itgb2l iCre2 knock-ins could be used in an attempt to create knock-in mice as the 
presence  of  the  resistance  marker  does  not  necessarily  cause  deleterious  effects.  The 
assessment, however, could only be made after a lot of time and resources had been invested in 
creating the mouse, making this approach rather risky. As a mouse model in which the Neo
R 
gene can be removed if necessary is preferable to avoid the creation of hypomorphic alleles or 
dysregulated  expression  (see  Chapter  2.3),  the  iCre2  targeting  for  all  three  loci  was  to  be 
repeated. Work on the inducible iCre2 ER
T2 fusion constructs had to be discontinued due to lack 
of time and resources.  
 
BAC  knock-ins,  due  to  their  size,  have  proven  to  be  too  cumbersome  to  facilitate  easy 
identification  of  knock-ins  and  have  not  delivered  high  enough  homologous  recombination 
frequencies to warrant continued use. As such, the vector construction strategy was re-designed 
to  create  shorter  plasmid  based  targeting  vectors  of  around  16.7kb  total  size  with  shorter 
homology arms of 4kb and 7kb respectively (see Chapter 7). Such retrieval vectors, where the 
insert intended for gene targeting is rescued from the engineered BAC, have been successfully 
used  to  generate  knock-in  ES  cell  lines  and  mice  by  other  groups  (Adams  et  al.,  2005; 
Voehringer et al., 2009).  
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CHAPTER 7: CONSTRUCTING THE SECOND GENERATION iCRE2 TARGETING 
VECTORS 
 
Whilst  knock-ins  could  be  successfully  identified  after  using  the  BAC  targeting  approach 
described in Chapter 6, the size of the vectors complicated the screening regime and an error in 
the reverse loxP site precluded removal of the G418 selection cassette in targeted embryonic 
stem cell lines. Therefore it was decided to re-construct the vectors and repeat the embryonic 
stem cell targeting. 
 
First, the antiparallel loxP sites needed to be replaced by parallel loxP sites in the basic vector 
pSP72-iCre2-pAp-NeoLox  to  enable  Cre  mediated  selection  marker  deletion  in  the  final 
construct. The corrected plasmid served as template for the creation of second generation iCre2 
knock-in BACs by Red/ET recombineering. Shorter plasmid targeting vectors with homology 
arms  of  4kb  upstream  and  7kb  downstream  were  then  generated  by  a  second  round  of 
recombinogenic  engineering  in  which  the  gene-specific  knock-in  BACs  supply  the  starting 
template.  While  the  sequence  of  the  second  generation  targeting  vectors  was  confirmed,  a 
cryptic splice site in the iCre2 coding sequence was discovered. This site leads to incorrect 
splicing and consequently interferes with protein expression. Removing the cryptic splice site 
was the final step in obtaining correct plasmid targeting vectors for murine embryonic stem cell 
transfection (Chapter 8).  
 
7.1  Replacement of the Antiparallel loxP Site 
 
A  new  vector  containing  iCre2  and  floxed  Neo
R  cassette  was  constructed  by  replacing  the 
inverse 3’ loxP site, as outlined in Figure 7.1. First, a fragment of Neo
R was amplified; the 
reverse PCR primer introduced the parallel loxP site. This PCR product was cloned into the 
EagI/EcoRV sites of the original vector replacing the antiparallel loxP sites. An initial screening 
selected correctly ligated plasmids for the loss (due to blunt end ligation) of the EcoRV site 
(data not shown). The loxP sites were further confirmed by sequencing.  
 
7.2  Assembly of New BAC Maps 
 
The creation of new knock-in BACs required the assembly of accurate maps. All maps were 
created by retrieving the BAC insert sequence from ENSEMBL (Adams et al., 2005; Xose et 
al.,  2007).  All  sequences  are  based  on  the  ENSEMBL  Mus  musculus  assembly  47  of 
C57BL/6N, which is based on the NCBI assembly m37. Insert end points were derived from the 
sequencing trace file database as described in (Adams et al., 2005). The Sau3AI sites closest to 
the respective ends  were considered to be the border points between  mouse genomic  DNA   98 
insert and backbone pBACe3.6 (Frengen et al., 1999; Shizuya et al., 1992). The introns and 
exons of the respective target genes were annotated using the ENSEMBL Gene Report files and 
data described in the literature.  
 
The  respective  inserts  from  a  129Sv  background  are  deposited  as  bMQ203N9  for  Itgb2l, 
bMQ239G13 for Msr1 and bMQ294K23 for Marco in the ENSEMBL database (Adams et al., 
2005). The translation start codons and exons for Msr1 and Marco assigned in ENSEMBL 
differ  from  those  described  in  (Aftring  and  Freeman,  1995)  and  (Kangas  et  al.,  1999) 
respectively.  Targeting  primers  were  designed  according  to  start  codons  identified  in  the 
literature by functional studies rather than those deposited in the database (also see 7.15.1). A 
summary of the data used for map generation is given in the following table. 
 
  bMQ203N9  bMQ239G13  bMQ294K23 
5’ Trace 
sequence  bMQ203n09.p1kSP6  bMQ239g13.q1kT7  bMQ294k23.p1kSP6 
3’ Trace 
sequence  bMQ203n09.q1kT7  bMQ239g13.p1SP6  bMQ294k23.q1kT7 
Gene 
Report  ENSMUSG00000000157  ENSMUSG00000025044  ENSMUSG00000026390 
Total size 
in kb  166.5  157.4  89.5 
Table 7.1 Targeting BAC Data 
 
iCre2-loxP-Neo-loxP was positioned so that the Cre construct replaced the start codon of the 
respective target gene using the Red/ET Recombineering system (Angrand et al., 1999). An 
example for the Itg b2l BAC before and after targeting is shown in Figure 7.4A. Details of the 
individual experiments and confirmatory analyses can be found in the following sections. 
 
7.3  Confirmation of BAC Identity and Structural Integrity by PCR 
 
Prior to recombineering, a selection of short PCRs was employed to ensure the correct BACs 
were  used  for  each  loci.  Also,  this  step  helped  to  ensure  that  no  major  interfering  re-
arrangements  had  occurred  in  the  area  to  be  targeted.  All  3  BACs  (Figure  7.2)  could  be 
identified  and  the  PCR  product  sizes  were  as  expected.  Those  stock  BACs  were  then 
individually electroporated into competent DH10TB1 E. coli. Colonies were grown on LB agar 
containing  Chloramphenicol  for  BAC  maintenance  overnight  at  37˚C  and  then  kept  at  4˚C 
before individual clones were used for recombineering. 
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Figure 7.1 Generation of a Corrected iCre2-pAp-loxP-Neo-loxP Vector 
The construct containing the inverse 3’ loxP site (black triangles) is shown at the top. A PCR 
product, in which the new parallel loxP site is derived from the reverse primer was digested by 
EagI and cloned into the EagI/EcoRV sites of the original vector, resulting in the repaired vector 
(bottom) that was used for all further work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Confirmation of BAC Identity and Integrity 
10pg of stock BAC was used per PCR amplification. Lanes 1, 4, 6 show amplifications of a 
short fragment spanning the insertion point (start codon) of the  respective  BAC.  The same 
primer pairs were later used to identify knock-in BACs. Lane 2 shows a PCR product generated 
by amplifying a piece of the BAC backbone pBACe3.6 shared by all three vectors. Lanes 3, 5 
and 7 represent longer fragments from the respective targeting regions to further assure BAC 
structure.  
M2: 100bp marker; M1: 1kb marker 
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7.4  Amplification of the Targeting Fragment for bMQ203N9 Itgb2l  
 
Red/ET recombineering requires a linear DNA fragment containing the sequence that is to be 
inserted flanked by 50nt long homology arms and is usually produced by PCR. The primer pair 
used to amplify the 3.1kb iCre2 -loxP-Neo-loxP targeting fragment is shown in Figure 7.3A. 
Primers consist of a 24nt annealing region and a 50nt homology region corresponding to the 
sequences immediately adjacent of the respective start codon. A 5’-3’ proofreading polymerase 
(PrimeStar, Takara) was used to avoid the introduction of mutations. Curiously, Figure 7.3B 
shows that apart from the 3.1kb targeting band another band, approximately 1.6kb in size, was 
generated with a much higher efficiency. Various attempts at improving PCR specificity, i.e. by 
increasing the annealing temperature, did not prevent amplification of this product (data not 
shown).  
 
A closer look at the amplified sequence and a restriction digest (data not shown) revealed that 
the employed primer pair amplifies different segments of the template due to insufficient length 
of the reverse primer (Figure 7.3C). The homology region of the reverse primer contains 24bp 
of the 3’ loxP site. In the corrected vector (pSP72-iCre2-pAp-NeoLox_3), the loxP sites are, 
unlike the previously used inverted ones, direct repeats.  The reverse primer is now  able to 
anneal to the 5’ loxP site as well, generating, with the forward targeting primer, a 1.6kb large 
fragment containing iCre2-loxP. It is also possible, that the reverse primer anneals to the 5’ 
loxP site to create another 1.6kb large fragment containing loxP-Neo-loxP (Figure 7.3C). The 
primer annealing in such a manner, however, is not as specific due to a 6bp mismatch at the 5’ 
loxP site’s asymmetric central core. The sequence of a loxP site is given in Figure 7.3D for 
comparison. In order to avoid the production of multiple products in the future, the reverse 
targeting primer needs to be extended beyond the 3’ loxP site to enhance annealing specificity. 
 
7.5  New iCre2 Knock-in in Itgb2l BAC bMQ203N9  
 
A  first  round  of  Red/ET  recombineering  inserts  iCre2  into  bMQ203N9,  which  carries  the 
neutrophil-specific Itgb2l target gene. Bacteria are doubly selected for chlormaphenicol (BAC 
maintenance)  and  kanamycin  (resistance  obtained  from  incoming  fragment).  151  bacterial 
colonies were obtained. A screening PCR employing primers flanking the start codon (Figure 
7.4) indicated 7 out of 10 BAC clones had undergone recombination and showed the 3.3kb 
product size consistent with insertion of iCre2-loxP-Neo-LoxP. Several lanes, however, showed 
both the band resulting from insertion, and the smaller 329bp wild-type band indicating the 
presence of one or more copies of wild type BAC.  In order to avoid carryover of unmodified 
BAC, only clones IV, VII and VIII, showing no wild-type band, were used for further work. 
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Figure 7.3 Amplification of the Itgb2l Targeting Fragment 
The forward and reverse targeting primers are illustrated in A, the 50bp locus homology regions 
are shown in black, the annealing sequences for iCre2 and loxP in red. The iCre2 start codon in 
the forward primer and the loxP spacer in the reverse primer are underlined. The PCR, with 
100pg of pSP72-iCre2-pAp-NeoLox_3 as a template, resulted in a 3.1kb and 1.6kb fragment (B) 
due to the terminal primer annealing at both loxP sites. A schematic representation of generated 
products is shown in C, with the forward primer embodied by red; the reverse primer by black 
arrows. D illustrates the structure of a loxP site with 13bp inverted repeats and an underlined 
8bp asymmetric core region. 
   
 
 
   
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Generation of BACs bMQ203N9 Itgb2l iCre2 
A  Schematic  representation  of  the  BAC  locus  before  and  after  recombination.  Arrows  and 
dotted lines indicate primer positions and lengths of screening PCR products. B The screening 
PCR, employing primer pair PactF & PactR, was carried out using 1% of a BAC preparation 
generated  from  6ml  of  an  overnight  TB  culture.  Lanes  I  to  X  represent  individual  E.  coli 
colonies.  The  wild  type  (wt)  control  used  100pg  of the  unmodified  bMQ203N9  stock  as  a 
template.M1: 1kb marker; M3 λHindIII marker.   102 
7.6  Creating a Short Plasmid Targeting Vector for Itgb2l 
 
In a second round of recombineering, the iCre2-loxP-Neo-loxP insert flanked by 4kb and 7kb 
homology arms up- and downstream respectively, is transferred into a pUC19 plasmid to obtain 
a shorter targeting vector facilitating a more straightforward screening regime. To that end, the 
pUC19  vector  was  amplified  with  a  proofreading  polymerase.  A  primer  pair  (Figure  7.5A) 
introduced Itgb2l specific 50nt long homology arms, resulting in a linear DNA fragment that 
served as a template for recombineering.  The insert is strategically placed into the multiple 
cloning site (MCS) of pUC19, so that a unique upstream SalI site can later be used for vector 
linearization. Bacteria are selected for being doubly resistant to kanamycin (resistance provided 
by insert) and ampicillin (resistance provided by pUC19 backbone). Recombineering between 
the pUC19 PCR product and BAC bMQ203N9 iCre2-loxP-Neo-loxP clone VII resulted in 800 
colonies  potentially  harbouring  correctly  targeted  plasmid  vectors.  An  analytical  EcoRV 
restriction digest (Figure 7.5B, see map in 7.5C) revealed 3 out of 20 tested clones (numbers 3, 
5  and  7)  as  having  a  digest  pattern  of  6.3kb;  5.6kb  and  4.8kb  consistent  with  successful 
recombination. 
 
7.7  Sequencing Reveals a Cryptic Splice Site in the iCre2 Coding Sequence 
 
In order to verify the vectors independently prior to starting the ES cell work, the pUC19 Itgb2l 
iCre2 targeting plasmids were sequenced. Results exposed an inconsistency (Figure 7.6) in the 
reverse loxP site. All 3 clones, descendants of BAC knock-in clone VII, contained a 2bp TA 
deletion in the reverse loxP site. As the majority of the 5’ loxP sequence is introduced by the 
reverse targeting primer, the error must have arisen from a faulty primer molecule in the initial 
amplification of iCre2 -loxP-Neo-loxP. Mutations of those particular nucleotides in loxP sites 
have not been described and are therefore likely to render the loxP site non functional (Missirlis 
et al., 2006). 
 
New plasmid targeting vectors were then generated using BAC knock-in clones IV and VIII, 
assuming that the faulty primer molecules would only have been incorporated in a minority of 
targeted  BACs.  The  process  was  as  previously  described  (Chapter  7.6),  and  600  and  550 
resistant bacterial colonies were obtained respectively. 20 clones each were subjected to the 
diagnostic EcoRV restriction digest. 13 descendants from BAC VIII but only 1 from BAC IV 
showed the digestion pattern (data not shown) indicating successful homologous recombination. 
When 2 of the VIII derived vectors, clones p and i, were sequenced as before (Figure 7.7), it 
could be shown that the loxP site was indeed intact. 
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Figure 7.5 Creation of pUC19 Itgb2l iCre2 Targeting Vectors 
Targeting primers (A), consisting of 50bp long homology regions (black) and 24bp homologous 
to pUC19 (red) were used. Homology regions correspond to sequences 4kb upstream or 7kb 
downstream of the Itgb2l start codon. B Following recombineering, minipreps were carried out 
on  20  overnight  TB-cultures.  25%  of  the  DNA  was  subjected  to  an  EcoRV  digest  and 
electrophoresed. In case of correct recombination, 3 fragments, 6.3kb, 5.6kb and 4.8kb (C), are 
expected. Clones 3, 5 and 7 showed this pattern and are thus considered to be correctly targeted 
vectors. Unmodified pUC19 plasmid DNA was used as a control (c).  
M2: 1kb marker, M3 λHindIII marker. 
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Figure 7.6 Sequence Alignment of the 3’ loxP Site in BAC Clone VII Derived Vectors 
All 3 Itgb2l iCre2 targeting vectors were sequenced using primer PactR. The sequencing results 
for the individual clones are given in comparison to the reference and consensus sequences. The 
DNA sequence introduced by the reverse targeting primer is underlined. Only part of the loxP 
site is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7 Sequence Alignment of the 3’ loxP Site in BAC Clone VIII Derived Vectors 
Two pUC19 Itgb2l iCre2 targeting vectors, p and i, were sequenced using the primer PactR. 
Sequencing  showed  that  descendants  from  clone  VIII  carry  an  intact  loxP  site.  The  DNA 
sequence introduced by the reverse targeting primer is underlined. Only part of the loxP site is 
shown.   105 
Following verification of the loxP site, pUC19 Itgb2l iCre2 targeting vectors were also checked 
for integrity of the iCre2 coding sequence. It was discovered that all clones analyzed had 2 
codons in Exon 1 of iCre2 changed (CAA to CAG and CGG to CGT) in comparison to the 
reference sequence (Figure 7.8A). This mutation could eventually be traced back to the initial 
vector  assembly.  The  CAG/CGT  codons  are  consistent  with  the  enhanced  Cre  wild  type 
sequence designated Cre(x). Upon insertion of heterologous introns, however, a cryptic splice 
site was inadvertently created resulting in incorrect splicing of the Cre mRNA which deletes a 
fragment at the 5’ end (Figure 7.8B). By introducing silent mutations (CAG to CAA and CGT 
to CGG), the splice site had been removed without impacting on the Cre amino acid sequence 
(Lacy-Hulbert et al., 2001). 
 
The  splice  site-less  vector  was  designated  iCre2b.  Sequencing  of  iCre2b  during  this  work, 
however, revealed that it still carried the cryptic splice site. Since iCre2b had been used to 
generate all iCre2 carrying vectors prior to the start of the project, the mutation was introduced 
into all descendants and could consequently also be found in all 4 sequenced pUC19 Itgb2l 
iCre2 targeting vectors derived from BAC knock-in clone VIII. A vector designated mtiCre2, 
could finally be identified as having the splice site removed.  
 
7.8  Repair of the Cryptic Splice Site 
 
To rectify the cryptic splice, the plasmid vector carrying iCre2 -loxP-Neo-loxP was repaired as 
outlined in Figure 7.9A. BamHI and ClaI were used to excise a fragment containing the cryptic 
splice site. A fragment for replacement was amplified from  vector mtiCre2. Following ligation 
of those two pieces, 20 clones were isolated and sequencing of three of those (Figure 7.9B) 
revealed successful removal of the cryptic splice site. The clone designated pSP72-iCre2*-pAp-
NeoLox_20 was used for all further work. In this plasmid, the iCre2 coding sequence, including 
pause and polyA sites, the Neo
R gene and its double promoter were re-sequenced. No further 
significant sequence discrepancies were found (data not shown). 
 
7.9  Repair of the pUC19 Itgb2l iCre2 Targeting Vector  
 
In  order  to  avoid  repeating  the  entire  recombineering  process  for  the  pUC19  Itgb2l  iCre2 
targeting vectors, a cloning strategy (see Figure 7.10A) was devised to replace the cryptic splice 
site. In essence, the incorrect vector was digested with AgeI and ClaI. Three fragments were 
obtained,  the  smallest  of  which  (957bp)  contains  the  cryptic  splice  site.  The  same  957bp 
fragment was amplified from the vector mtiCre2 and re-ligated with the 1.8kb and 14kb pieces. 
Due to the low  efficiency of 3 piece ligations and the relatively large size (16.7kb) of the 
targeting vector, only 2 bacterial colonies were obtained.  Of those colonies, designated a and b,   106 
only b could be expanded in liquid culture for DNA isolation. Sequencing (Figure 7.10B) and 
PCR (data not shown) revealed that ligation had indeed occurred in the right orientation and the 
cryptic splice site was corrected successfully. 
 
7.10  Construction of iCre2 knock-in BACs for Msr1 and Marco 
 
Using the corrected vector pSP72-iCre2*-pAp-NeoLox_20 as a template, an attempt was made 
to also create knock-in BACs for Marco and Msr1. To avoid the previously described hurdle 
(Figure 7.3B) of unintentionally amplifying 2 bands in the PCR producing the recombineering 
fragment, an elongated reverse primer, extending 6bp (total 90nt) beyond the loxP site was 
employed. Nevertheless, two bands were obtained (data not shown). This was most likely due to 
the 5’-3’ nuclease activity of the utilized proofreading polymerase that cuts off the nucleotides 
from the 3’ end of the reverse primer, thus reducing priming specificity. The obvious solution 
would be to extend the already 90nt long reverse primer even further or to place it outside the 
loxP site. Primer extension is limited by oligonucleotide synthesis. Whilst 120-140bp can be 
achieved, synthesis becomes less efficient beyond 50-100mers with more side products being 
created and purification is difficult resulting in significant cost. Placing the primer outside of the 
targeting area results in the introduction of bacterial DNA sequences into the final construct as 
amplification  occurs  from  a  plasmid  vector.  The  presence  of  bacterial  DNA  in  genetically 
modified animals has been linked to silencing effects (Chada et al., 1985; Clark et al., 1997). 
 
Nonetheless  a  sufficient  amount  of  the  targeting  fragments  for  recombineering  could  be 
obtained by gel purifying the larger band. 75 and 21 resistant E. coli colonies were generated for 
Marco and Msr1 respectively. Colonies for Marco, however, could only be obtained after the 
third attempt, when the amount of the targeting fragment iCre2-loxP-Neo-loxP transformed into 
the  E.coli  strain  harbouring  BAC  bMQ294K23  was  quadrupled  from  the  standard  50ng  to 
200ng. Colonies were small, and only 4 of 29 colonies that were inoculated could be expanded. 
 
29 of the potential Marco knock-in clones and all 21 of the potential Msr1 knock-in clones 
underwent PCR screening. Initial PCRs were carried out using E.coli colonies as template. The 
locus specific primer pairs and product sizes are shown in Figure 7.11A,B&E for Marco and 
Msr1 respectively. This initial PCR (Figure 7.11C for Marco, Figure 7.11F for Msr1) revealed 
that the large 3.3-3.6kb band indicating successful recombination could not be observed in any 
of the samples with exception of the positive control. Shorter fragments using one locus- and 
one iCre2-specific primer, however, were amplified in several reactions, indicating potential 
BAC  knock-ins.  These  clones  were  expanded,  BAC  DNA  was  purified  and  the  PCR  was 
repeated (Figure 7.11D&G). One knock-in BAC per target gene, clone 9 for Marco and clone 
19 for Msr1, could be verified. 
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clone i
1112 1193 1120 1130 1140 1150 1160 1170 1180 (1112)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC iCre2 (415)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC splice site MiCre2 icrecheck2_reverse (1065)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC splice site seq iCre2b iCrecheck2_reverse (1097)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC splice site seq mtiCre iCrecheck2_reverse (780)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC Consensus (1112)
566 644 580 590 600 610 620 630 (566)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT crex (433)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT iCre2 (426)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pSP72-iCre2-pApNeoLox (465)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pSP72-iCre2-pApNeoLox_3 (465)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT puC19 iCre2 Pact targeting vector VIIIi PactF (565)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pUC19 iCre2 Pact targeting VIIIp PactF (566)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT Consensus (566)
reference cre(x)
566 644 580 590 600 610 620 630 (566)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT crex (433)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT iCre2 (426)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pSP72-iCre2-pApNeoLox (465)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pSP72-iCre2-pApNeoLox_3 (465)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT puC19 iCre2 Pact targeting vector VIIIi PactF (565)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pUC19 iCre2 Pact targeting VIIIp PactF (566)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT Consensus (566)
reference iCre2
iCre2b
1112 1193 1120 1130 1140 1150 1160 1170 1180 (1112)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC iCre2 (415)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC splice site MiCre2 icrecheck2_reverse (1065)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC splice site seq iCre2b iCrecheck2_reverse (1097)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC splice site seq mtiCre iCrecheck2_reverse (780)
GCTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATC Consensus (1112)
566 644 580 590 600 610 620 630 (566)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT crex (433)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT iCre2 (426)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pSP72-iCre2-pApNeoLox (465)
CGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pSP72-iCre2-pApNeoLox_3 (465)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT puC19 iCre2 Pact targeting vector VIIIi PactF (565)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT pUC19 iCre2 Pact targeting VIIIp PactF (566)
CGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTT Consensus (566)
clone p
consensus
mtiCre2
A B
A
B
 
 
 
 
 
 
 
 
Figure 7.8 Cryptic Splices Sites 
A The reference sequences for Cre(x) and iCre2 were compared to sequencing results obtained 
from  the  plasmid  vectors  iCre2b,  mtiCre2  and  the  BAC  VIII  derived  pUC19  Itgb2l  iCre2 
targeting  vector  clones  i  and  p.  Only  mtiCre2  no  longer  carries  the  cryptic  splice  site.  All 
sequencing reactions were carried out using primer iCrecheck2, which binds in exon 2. B shows 
the Cre coding sequence after the insertion of heterologous introns with boxes  representing 
exons and numbers indicating the length of individual units. The nucleotide sequences of the 
new exon/intron boundaries are specified below; upper case letters indicate exons, lower case 
letters introns. The cryptic splice site activated by intron insertion is shown above together with 
the correcting point mutations. Figure 7.8B is taken from (Lacy-Hulbert et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9 Removal of the Cryptic Splice Site 
A details the strategy employed in repairing the vector carrying iCre2-loxP-Neo-loxP. B shows 
sequencing data for 3 isolated clones compared to the iCre2 reference. Repair was successful in 
all clones. Sequencing was carried out using a standard SP6 primer.   108 
A
B
556 626 570 580 590 600 610 (556)
CTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGAT iCre2 (416)
CTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGAT clone b (pot. repaired pUC19 pactiCre2) icrecheck 2... (437)
CTCTAGCGTTCGAACGCACTGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGAT pUC19 iCre2 Pact targeting VIIIp PactF (556)
CTCTAGCGTTCGAACGCACTGATTTCGACCAAGTTCGGTCACTCATGGAAAATAGCGATCGCTGCCAGGAT Consensus (556)
reference iCre2
clone b
clone p
consensus
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10 Repair of the Cryptic Splice Site 
A illustrates the cloning strategy used for repairing the pUC19 Itgb2l iCre2 targeting vector. B 
shows sequencing data comparing clone p (prior to repair) and clone b (following repair) to the 
iCre2 reference sequence. Sequencing was carried out using primer iCrecheck2. 
 
 
7.11  Construction of Plasmid Vectors from Marco and Msr1 knock-in BACs 
 
The two knock-in BACs were subjected to a second round of recombineering in order to insert 
the  iCre2-loxP-Neo-loxP  flanked  by  4kb  &  7kb  gene  specific  homology  arms  into  pUC19. 
Primer sequences are given in Figure 7.12A. The insertion points were chosen in a manner that 
unique restriction enzyme sites for linearization lie immediately upstream. For Marco this site is 
SmaI, for Msr1 SalI. PUC19 based targeting vectors are descendants of BAC knock-in clones 
Marco iCre2 9 and Msr1 iCre2 19. Several hundred resistant colonies were obtained for both 
target genes. 15 colonies were expanded and analyzed for the former, as were 10 colonies for 
the  latter.  Analytical  restriction  digests  using  XbaI  (Figure  7.12B&D)  and  BamHI  (Figure 
7.12C&E)  respectively,  identified  a  number  of  correctly  recombined  targeting  vectors.  For 
Marco clones b, c, d, i and l show the correct restriction pattern of 8.5kb, 5.5kb and 2.8kb. For 
the other 10 clones digested plasmid amounts were too low to yield visible bands. In case of 
Msr1, clones 1, 2, 3, 5, 6, 7, 8 and 10 reveal expected product sizes (9.2kb, 4.4kb and 3.1kb) 
upon digestion. Two clones were chosen for further work: pUC19 Marco iCre2 9d and pUC19 
Msr1 iCre2 19_10. 
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Figure 7.11 Generation of Marco & Msr1 iCre2 Knock-in BACs  
Targeting  primer  pairs  (A)  consisting  of  50nt  homology  regions  (black)  corresponding  to 
sequences immediately adjacent to the respective start codon are fused to annealing regions 
(red) complementary to either iCre2 or the 3’ loxP site. In an attempt to reduce non-specific 
priming, the terminal targeting primer was extended by 6nt into the PGK promoter. Successful 
recombineering  occurs  when  the  iCre2-loxP-Neo-loxP  fragment  replaces  the  start  codon  of 
either  Marco  (B)  or  Msr1  (E).  Three  PCRs  were  carried  out  on  bacterial  colonies  grown 
overnight to establish which ones harboured BAC knock-ins (C & F). Candidate colonies were 
expanded and 10% of the purified DNA isolated from a 6ml overnight TB culture was used for 
another PCR to verify recombination (D & G). 
BAC: unmodified BAC; -: no template; +: previously generated, faulty knock-in BAC; M1: 1kb 
marker; M2: 100bp marker. 
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Figure 7.12 Generation of Marco & Msr1 Plasmid Based Targeting Vectors 
A Primer pairs contained 50nt homology arms (black) corresponding to sequences 4kb upstream 
and 7kb downstream of the respective start codon and 24bp pUC19 complementary sequence 
(red) bordering the insertion point. Colonies derived from the Marco (B) and Msr1 (C) knock-in 
BACs were expanded, and isolated plasmid DNA was subjected to XbaI (B & D) or BamHI (C 
& E) digests. Patterns indicating successful recombination were 8.5kb, 5.5kb, 2.8kb for Marco 
and 9.2kb, 4.4kb, 3.1kb for Msr1 respectively. Unmodified pUC19 served as a control.   112 
7.12  Summary of Targeting Vector Construction 
 
Target 
Gene 
No. of 
generated 
BAC knock-
ins/of those 
screened 
No. of 
verified BAC 
knock-ins/in 
percent 
Targeting 
vector based 
on BAC 
knock-in 
clone 
No. of 
generated 
targeting 
vectors/of 
those 
screened 
No. of 
verified 
targeting 
vectors/in 
percent 
Clone used for ES 
cell transfection  
Itgb2l  151/10  7/70%  VII 
IV 
VIII 
800/20 
600/20 
550/20 
3/15% 
1/5% 
13/65% 
 
 
b* 
Marco  75/29  1/4%  9  250/15  5/33%  9d 
Msr1  21/21  1/5%  19  120/10  8/80%  19_10 
* derived from BAC knock-in VIII 
 
Table 7.2 Summary of Targeting Vector Construction 
Summary of key steps during the targeting vector creation process, such as the total number of 
colonies generated, fractions shown to be correctly recombined BACs and plasmid targeting 
vectors, and the respective clones used in ES cell work (Chapter 8). 
 
7.13  Comprehensive Restriction Digests of Targeting Vectors 
 
Comprehensive restriction digests were carried out following large scale preparation of all 3 
pUC19  based  targeting  vectors  to  verify  the  overall  structure  of  the  insert  and  exclude  the 
potential loss or re-arrangement of important sequences flanking iCre2-loxP-Neo-loxP. Figure 
7.13A;B;C show the results for the targeting vectors for Itgb2l, Marco and Msr1 respectively. 
Restriction patterns observed confirmed the correct structure of all targeting vectors. 
 
7.14  Sequencing of Targeting Vectors 
 
The targeting vectors were sequenced to ensure no significant mutations had been introduced 
during  the  recombineering  process.  The  entire  Cre  coding  sequence,  the  pause  and  polyA 
signals, the Neo
R gene with its promoters and flanking loxP sites as well as a short stretch of 
vector specific bordering DNA was sequenced. With 5 independent sequencing primers, 80-
100% of the 3010bp large insert could be covered. An overview of the results is given in Figure 
7.14A. The targeting vectors for Itgb2l and Marco have no significant mutations. The Msr1 
targeting vector, however, contains 2 potentially problematic sequence changes. A nucleotide 
(C) is deleted in the reverse loxP site at position 5 of the inverted repeat (Figure 7.14B). Similar 
to what was described in chapter 7.7, this is a mutation introduced by the reverse primer. There 
is also an additional mutation in exon 1 of the Cre coding sequence, changing codon 157 from 
ATG to ACG which results in an amino acid exchange from methionine to threonine (Figure 
7.14C). 
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Figure 7.13 Comprehensive Restriction Digest of Targeting Vectors 
Several restriction digests were carried out for each of the targeting vectors, results are shown in 
A, B and C for Itgb2l, Marco and Msr1 respectively. The number of restriction sites per vector 
and the expected fragment sizes are given on the right. 1µg of plasmid DNA was digested per 
lane using 10U of the appropriate enzyme for one hour at 37˚C. Samples were electrophoresed 
on a 0.7% agarose gel for one hour before being photographed. Fragments smaller than 250bp 
are not visualized. 
M1: 1kb marker; M3: λHindIII marker 
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Figure 7.14 Illustration of Sequencing Coverage & Results 
A shows the structure of the iCre2-loxP-Neo-loxP insert flanked by locus specific homology 
arms. The sequencing coverage is indicated by a black line for each individual vector. Sequence 
errors (compared to the reference) found are represented by black dots. B shows the fragment of 
the 3’ loxP site carrying a 1bp deletion. C illustrates the sequence alignment for three codons of 
exon 1 of the Cre coding sequence (left), the 1bp exchange leads to a Thr at position 157 instead 
of a Methionine (right). Primers used for sequencing were PactF, MaF, Msr1F, iCrecheck2, 
NeoExcF, NeoLoxFSeq, PactR, MaR and Msr1R. 
 
7.15 Discussion 
 
7.15.1  The Choice of iCre2 Insertion Points 
 
Targeting  experiments  were  designed  such  that  the  incoming  iCre2  sequence  replaces  the 
endogenous  translation  start  codon  to  ensure  minimal  interference  with  the  target  gene’s 
regulatory elements. Whereas Itgb2l has one identified start codon (Aftring and Freeman, 1995) 
that was consequently used as insertion point, both Marco and Msr1 have two possible in-frame 
ATGs. For each gene, the most likely translation start codon was chosen, according to data 
published in the literature (see below).  
 
7.15.1.1  Marco 
 
Initial Marco cDNA analysis revealed two potential translation initiation codons (Figure 7.15) 
(Elomaa et al., 1995). Both are located towards the end of the first exon, approximately 10bp 
and 100bp downstream from a conserved TATA box required for transcription initiation. An 
additional TATA-like sequence is found further upstream. Both ATG codons agree with the 
Kozak consensus in positions -3 and +4, making them strong initiation sites (Kozak, 1984). The 
downstream ATG additionally exhibits a consensus at position -5. Primer extension analysis, S1 
nuclease  mapping  and  rapid  amplification  of  5’  complementary  DNA  ends  (RACE)  have 
indicated the main transcription start point as being 27-28bp downstream of the TATA box 
(+1).  A  minority  of  clones  exhibited  transcription  initiation  at  -63  to  -66.  As  the  main   115 
transcription  initiation  start  point  is  downstream  from  the  first  ATG,  the  second  ATG  was 
suggested as the main initiator of translation, whereas the more seldomly used upstream sites 
can give rise to alternative Marco variants with longer cytoplasmic domains (Kangas et al., 
1999). In accordance with this data, the second translation initiation codon was selected as the 
insertion point for iCre2.  
 
 
 
 
 
 
 
 
 
Figure 7.15 Marco 5’ cDNA Nucleotide Sequences 
Sequences upstream and downstream from the in-frame ATGs of Marco (top) are illustrated. 
The  possible  transcription  start  sites  are  indicated  by  asterisks  with  the  main  site  being 
designated +1. Preceding TATA sequences are boxed. The two translation initiation codons are 
marked red, with nucleotides matching the Kozak consensus sequence (bottom) underlined. R: 
Purine nucleotide. Figure modified from (Kangas et al., 1999). 
 
7.15.1.2  Msr1 
 
Msr1 also carries two possible in-frame translation start codons, which are only 3 codons apart 
in the cDNA. The first is located towards the end of exon 1, the second at the beginning of exon 
2. Upstream of either ATG, one cluster of transcription initiation sites lacking a TATA box but 
preceded  by  a  GATA  transcription  factor  binding  side,  has  been  identified  (Figure  7.16) 
(Aftring and Freeman, 1995). The start codons have relatively weak Kozak sequences, both 
agreeing at -3 and the first ATG also at -5 with the consensus (Kozak, 1984). The in-frame 
ATG in exon 1, which was used as iCre2 knock-in site, is only found in the mouse genome but 
not in the human, rabbit and bovine genes (Ashkenas et al., 1993), suggesting an extended 
murine gene product. 
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Figure 7.16 Msr1 5’ cDNA Nucleotide Sequences 
Sequences  5’  upstream  and  downstream  from  the  in-frame  ATGs  of  Msr1  are  shown.  The 
possible transcription start sites are indicated by asterisks with the main site being designated 
+1. A preceding GATA transcription factor binding site is boxed. The two translation initiation 
codons are marked red, with nucleotides matching the Kozak consensus sequence underlined. 
Figure adapted from (Aftring and Freeman, 1995). 
 
7.15.2  Vector Creation and Verification 
 
Overall,  the  application  of  the  Red/ET  recombineering  system  was  very  successful  as  both 
knock-in BACs and retrieval plasmid vectors could be generated for all three loci. Efficiency 
(Table  7.2),  however,  varied  widely  between  target  genes.  The  main  factors  influencing 
recombineering efficiency are both quality and purity of the PCR product and BAC; presence of 
repeats in the targeting region; secondary recombination and the used bacteria strain and its 
transformation competency.  
 
The  main  issues  encountered  during  this  work  were  false  positives  and  primer-induced 
mutations. False positives, drug resistant colonies not harbouring the modified vector,  were 
observed at both stages (Table 7.2) of the vector creation process and are most likely due to the 
presence of traces of the respective supercoiled plasmids used in the PCR amplification of 
recombineering  fragments.  Whilst  fragments  were  gel  purified  prior  to  electroporation,  an 
inadvertent carry-over cannot be excluded. For future experiments, an additional DpnI digest of 
the PCR product, to remove traces of methylated template, is advisable. 
 
Mutations in the final vector were another repeatedly encountered obstacle. Several sequence 
changes were introduced by the primers utilized in amplifying the targeting fragment (Figures 
7.6 & 7.14). In both cases, single or double base pair deletions were observed in a part of the 3’ 
loxP site that originates from the incoming PCR primer. Primers used for recombineering are 
relatively long (>74bp) and thus more likely to contain truncated or deleted side products after 
synthesis.  Whilst  primers  used  in  this  work  were  purified  by  capillary  gel  electrophoresis 
(CGE),  achieving  >90%  purity  (details  provided  by  manufacturer),  unintended  sequence 
changes  could  not  be  avoided  entirely.  In  case  of  Itgb2l  (Figure  7.6),  this  was  simply 
circumvented by using a different BAC knock-in clone that had incorporated a correct primer 
molecule. For Msr1, however, only one targeting was available carrying a mutation (Figure 
7.14) located at position 5 of the loxP site’s inverted repeat. Mutations of the first 5 bp of said   117 
repeats have been described (Missirlis et al., 2006), so the site is likely to be functional. In 
addition,  the  Msr1  targeting  vector  harbours  a  single  base  pair  mutation  in  the  Cre  coding 
sequence caused by a PCR error that occurred despite using a proofreading polymerase with an 
average error rate of 4.8*10E-5 or 1 mutation every 20.000 synthesized base pairs (Cline et al., 
1996).  The  mutation,  however,  causes  an  amino  acid  exchange  outside  of  Cre’s  active  site 
(Gopaul et al., 1998) and should therefore not interfere with protein function. Both sequence 
changes  were  considered too  minor to justify repair, which  would have necessitated  a new 
round of BAC recombineering exacerbated by low PCR yields and knock-in frequencies.  
 
7.15.3  Summary 
 
BAC knock-ins and shorter plasmid targeting vectors were obtained for all three target genes 
Itgb2l,  Marco  and  Msr1  in  two  successful  rounds  of  Red/ET  recmbinogenic  engineering. 
Discovered  sequence  discrepancies  were  corrected.  Comprehensive  restriction  digests  and 
sequencing ensured the integrity of the iCre2-loxP-Neo-loxP cassette as well as the absence of 
major re-arrangements in the final targeting vectors prior to the following embryonic stem cell 
work.   118 
CHAPTER 8: CREATING 2
ND GENERATION EMBRYONIC STEM CELL KNOCK-
INS 
 
The three newly created plasmid vectors targeting iCre2 to Itgb2l, Marco and Msr1 were used 
in a second round of ES cell transfection. G418 resistant clones were subjected to a screening 
regime  similar  to  the  one  successfully  applied  in  Chapter  6  in  order  to  identify  knock-ins. 
Briefly,  the  number  of  clones  to  be  assessed  was  first  reduced  by  a  PCR  covering  the  5’ 
homology arm, which allows the exclusion of random integrants. Candidates were confirmed as 
knock-ins by Southern Blots and further PCRs. Eventually, homologous recombinants could be 
successfully identified for Itgb2l and Marco, but not for Msr1. Subsequent Cre mediated Neo
R 
deletion was achieved, proving the functionality of the repaired loxP sites. Isolating individual 
Neo
R deleted clones, however, was associated with technical difficulties. 
 
8.1  Transfection and Preliminary 5’ PCR Screening 
 
From two independent transfections, approximately 650 drug resistant colonies (summarized in 
Table 8.1) were isolated. Of those 48 each for Itgb2l and Marco and 24 for Msr1 were analysed 
by PCR. The preliminary PCR screen equals the one described in Chapter 6.4. A gene specific 
external primer outside of the 4kb 5’ homology region was paired with an iCre2 specific primer 
(see maps in 8.1A & 8.2A). Only clones having undergone correct homologous recombination 
will amplify a product of the right size. As amplification occurs directly from the lysed cells of 
one half of a mES cell colony, the 5’ PCR was optimized to detect the recombination event 
using low copy numbers (10.000 copies equalling 2pg of BAC) as a template (data not shown). 
 
Results for Itgb2l and Marco are shown in Figures 8.1B and 8.2B. 5 potential Itgb2l iCre2 
knock-ins exhibited the 4.8kb band indicating homologous recombination: clones 8, 15, 17, 20 
and 43. This gives a preliminary targeting efficiency of 10%. The band for Itgb2l iCre2 43, 
however, is very faint and needed further analysis. For suspected Marco iCre2 recombinants, 10 
clones: 10, 11, 23, 25, 29, 33, 37, 43, 44 and 48, resulted in the expected 4.8kb knock-in PCR 
band. If all of these clones were true knock-ins, this would correspond to a targeting frequency 
of  21%.  Again,  the  bands  for  clones  11  and  43  were  very  weak,  necessitating  additional 
investigation. For Msr1 iCre2, 24 clones were assessed. Despite trying several primer pairs, 
polymerases and reaction conditions, no products, not even for the positive control knock-in 
BAC could be amplified (data not shown). Therefore, the following screenings focus on Marco 
iCre2 and Itgb2l iCre2.   119 
Figure 8.1 Diagnostic PCR Spanning the Upstream Homology Arm of Itgb2l 
The structure of the correctly targeted locus for Itgb2l iCre2 is illustrated in A, a forward primer 
(Paext) was placed just outside of the 4kb long upstream homology arm, the reverse primer 
(iCrecheck2) sits in the iCre2 gene.  Amplification is thus only expected if  a knock-in  was 
successful,  resulting  in  a  4.8kb  PCR  product  (B).  Lanes  where  a  product,  indicating 
homologous recombination, was observed are labelled red. 
M1: 1kb marker; M3: λHindIII marker; + Itgb2l iCre2 knock-in BAC; - 129 DNA 
 
Figure 8.2 Diagnostic PCR Spanning the Upstream Homology Arm of Marco 
The structure of the  correctly targeted locus for Marco iCre2 is illustrated in A, a forward 
primer (Maext) was placed just outside of the 4kb long upstream homology arm, the reverse 
primer (iCrecheck2) sat in the iCre2 gene. Amplification is thus only possible if a knock-in was 
successful,  resulting  in  a  4.8kb  PCR  product  (B).  Lanes  where  a  product,  indicating 
homologous recombination, was observed are labelled red. 
M1: 1kb marker; M3: λHindIII marker; + Marco iCre2 knock-in BAC; - 129 DNA   120 
8.2  Secondary 3’ PCR 
 
After verifying the integrity of the upstream homology arm, the same PCR strategy was applied 
to the downstream area. The Itgb2l iCre2 and Marco iCre2 clones screened recombinant in the 
first PCR were re-assessed. A reverse primer was designed to bind just outside of the 7kb 3’ 
arm, to amplify a ~7kb large PCR product when used in conjunction with a primer annealing to 
the Neo
R gene. Similar to the process described in 8.1, only correctly targeted loci will provide 
the  template  for  a  successful  amplification  (see  maps  in  8.3A&B).  The  length  of  the  PCR 
product  also  indicates  whether  any  large  fragments  were  deleted  during  the  recombination 
event. All of the 5 Marco iCre2 knock-ins assessed showed a strong band corresponding to the 
expected  7.4kb  fragment  (8.3B&C).  Working  PCR  conditions  could  not  be  established  for 
Itgb2l iCre2 (map shown in 8.3A, data not shown). Instead, a Southern Blot was used for those 
clones (see 8.3.2). 
 
8.3  Southern Blots  
 
Whilst the previously described PCR data is promising, a separate method was needed to verify 
homologous recombination. Therefore several Southern Blot strategies, covering both ends of 
the targeting zone, were designed to both confirm suspected knock-ins and exclude random 
integrants. 
 
8.3.1  Southern Blot Analysis at the 5’ End  
 
Southern Blot strategies analyzing the 5’ end of the targeted gene were devised for all 3 loci. 
Maps, chosen enzymes and expected fragments are illustrated in Figure 8.4A-C. Enzymes were 
selected for their ability to cut just outside of the 5’ homology arm and the probe was also 
placed external to the targeted region. This method allows bands corresponding to either wild 
type or knock-in to be distinguished. 
 
The  EcoRI  Southern  Blot  for  Itgb2l  iCre2  is  shown  in  Figure  8.5A  and  the  EcoRV/XhoI 
Southern Blot for Marco iCre2 in Figure 8.5B.  Expected fragment sizes for Itgb2l iCre2 were 
9.6kb for the knock-in and 6.3kb for the wild-type locus. Clones 8, 15, 17 and 20 showed those 
bands in accordance with their PCR result. Clone 43, having shown a very weak PCR band, 
only had the wild type band and is thus not a knock-in. In case of Marco iCre2, all 8 assayed 
clones showed the correct combination of a 5.2kb wild type and a 6.2 knock-in band. 
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Figure 8.3 Diagnostic PCR Spanning the Downstream Homology of Marco  
A and B show maps, primer locations and expected product sizes for the diagnostic 3’ PCR for 
Itgb2l iCre2 and Marco iCre2 respectively. Working PCR conditions could only be established 
for Marco iCre2 clones (C). 5 clones were tested; 50ng purified genomic DNA was amplified 
using primer pair Ma3’F/Ma3’B. Negative controls were 129 DNA (wt) or water (-). The Marco 
specific knock-in BAC was used as a positive control. (+)  
M1: 1kb marker; M3: λHindIII marker   122 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 8.4 5’ End Southern Blot Maps 
Target loci for Itgb2l (A), Marco (B) and Msr1 (C) are shown before (top) and after (bottom) 
iCre2 knock-in. The border of the 4kb upstream homology arm is marked, bold black lines 
represent  probes  and  the  coloured  lines  indicate  the  expected  product  sizes.  Probes  were 
amplified from wild-type 129 genomic DNA using gene specific primer pairs and had a size of 
approximately 500bp. 
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Figure 8.5 5’ Southern Blot results for Itgb2l iCre2 and Marco iCre2 
Two separate Southern Blots are shown for both the Itgb2l (A) and Marco (B) locus. Probes, 
amplified from 129 wild type DNA, had sizes of 442bp and 444bp respectively. Wild type 129 
genomic DNA served as a control. Marco iCre2 clones 10 and 44 lost their ability to proliferate 
and could not be included in the Southern Blot.    124 
8.3.2  Southern Blot Analysis at the 3’ End 
 
Additional Southern Blotting strategies were employed to probe the 3’ end of the knock-in loci. 
Maps,  chosen  enzymes  and  expected  fragment  sizes  are  illustrated  in  Figure  8.6.  Briefly, 
restriction enzymes that cut within the 7kb 3’ homology arm and just beyond the border point 
were selected. The internal site was at least 3.5kb upstream of said point, which marks the 
boundaries of the targeting vector insert, in order to cover a significant piece of the 3’ homology 
arm. Membranes were probed with both an internal and an external probe. 
 
Figure 8.7A represents the result for the 4 Itgb2l iCre2 knock-in clones hybridised with an 
external probe. Only one band, identical to the wild type, is visible. The same Southern Blot for 
Marco iCre2 was unsuccessful (data not shown). No bands were visible, possibly due to low 
probe specificity. The PCR described in 8.2, however, produces equivalent data. Figure 8.7B 
and 8.7C show the outcomes of hybridization with an internal probe for Itgb2l iCre2 and Marco 
iCre2, respectively. In both Southern Blots, only one band was visible; that of the wild type.  
 
8.4  Overview of 2
nd Generation Targeting 
 
Target 
Genes 
No. of G418 
Resistant Clones 
Isolated* 
No. of PCR 
Screened 
Clones** 
No. of PCR 
Positive 
Clones 
Of those 
Confirmed by 
Southern Blot 
Targeting 
Frequency 
Itgb2l  224  48  5  4  8% 
Marco  224  48  10  5***  10% 
Msr1  200  24  n/a  n/a  n/a 
* of two independent transfections/target gene ** all derived from 1
st transfection *** no data available for other 5 clones 
Table 8.1 Distribution and Screening Results for 2
nd Generation iCre2 Knock-ins 
 
Out of a total of ca. 650 resistant colonies, 120 clones were screened to identify 9 confirmed 
knock-ins;  4  for  Itgb2l  iCre2  and  5  for  Marco  iCre2.  This  corresponds  to  total  targeting 
frequencies  of  8%  and  10%  respectively.  Msr1  iCre2  clones  were  not  further  assayed,  as 
working conditions for the initial PCR screening could not be established. 
 
8.5  Neo
R Deletion  
 
In a final step of mES cell work, attempts were made to remove the floxed G418 selection 
marker in order to avoid deleterious influences of the expression unit on Cre function in the 
mouse  model  (see  Chapter  2.3).  To  that  end,  several  knock-in  clones  were  transiently 
transfected  with  the  Cre  expressing  vector  pCre-Pac  The  procedure  is  identical  to  the  one 
described in 6.5. In bulk cultures, the resistance gene could be deleted effectively, as assayed by 
PCR and Southern Blot. The isolation of individual clones, however, presented some technical 
challenges.   125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6 Southern Blot Strategies for the 3’ Homology Arm 
The Itgb2l (A) and Marco (B) loci are shown before (top) and after (bottom) targeting. Bold 
black lines represent probes and coloured lines indicate expected fragment sizes. Probes were 
amplified from wt 129 DNA using gene specific primer pairs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7 3’ Southern Blot Results for Itgb2l-iCre2 and Marco-iCre2 
The Itgb2l iCre2 clones were digested with XbaI and hybridized with an external probe (A) or, 
after  stripping  the  same  membrane,  with  an  internal  probe  (B).  Probes  (884bp  or  881bp 
respectively) were amplified from wild type DNA. C Marco iCre2 clones were digested with 
BamHI and hybridized with an internal probe (844bp).   126 
8.5.1  Successful Neo
R Deletion in Bulk Culture 
 
Knock-in clones Itgb2l iCre2 17 and Marco iCre2 25 were transfected with 20µg pCre-Pac and 
DNA was isolated from bulk cultures after 48h. A diagnostic PCR was designed to generate a 
2.5kb fragment for non-deleted DNA and a 1kb fragment in case Neo
R was excised successfully 
(Figure 8.8A). The bulk PCR (Figure 8.8B) showed the presence of both bands in either clone, 
indicating successful deletion in a fraction of the cells. 
 
8.5.2  Isolating individual ΔNeo
R colonies 
 
Following a positive result in the bulk PCR, transfected cells were plated at low densities (500 
cells/ml) onto feeder layers to isolate individual subclones. Unfortunately the plating efficiency 
was very low, with less than 2% of the cells forming colonies. Colonies were very small and 
failed to proliferate after isolation. Another transfection, using less (2µg) pCre-Pac plasmid to 
exclude potential Cre toxicity, yielded no viable clones either. Nor did a new batch of growth 
serum (pre-tested for embryonic stem cells) improve embryonic stem cell survival. Eventually, 
the  failure  of  mES  cells  to  expand  when  plated  at  low  density  was  traced  to  a  protracted 
Mycoplasma infection, which was most likely transmitted from a batch of contaminated feeder 
cells in the initial stages of mES cell targeting. Cells were treated successfully with BM-Cyclin 
(Roche), and remain Mycoplasma-free to date. 
 
Once individual colonies could be expanded, they were subjected to colony PCR (an example is 
shown in Figure 8.9). A summary of all pCre-Pac transfections, from which approximately 320 
separate subclones were isolated, is given in Table 8.2. The efficiency of Neo
R excision, i.e. the 
fraction of isolated colonies showing the deletion PCR product, varied between 7 and 25%, 
depending on the amount of pCre-Pac used and the transfected clone.  
 
Clone  Amount 
pCre-Pac 
Clones deleted/Clones 
Isolated 
Fraction  Cell Plating 
Density in cells/ml 
Marco iCre2 25  20µg  5/33  15%  500 
Marco iCre2 25  5µg  6/72  8%  200 
Marco iCre2 29  5µg  3/48  6%  100 
Marco iCre2 37  5µg  6/48  12.5%  50 
Itgb2l iCre2 17  5µg  12/48  25%  500 
Itgb2l iCre2 20  5µg  5/72  7%  200 
Table 8.2 Overview of Transient Cre Transfection Experiments 
 
Following identification by PCR, aliquots of several clones (descendants of Marco iCre2 29; 
Marco iCre2 25; Itgb2l iCre2 17 and Itgb2l iCre2 20) were subjected to G418 selection as a 
control. 1000 cells per clone were plated in 12 well (12w) plates on gelatin and selected with 
250µg/ml  G418  for  5  days.  With  removal  of  the  Neo
R  gene,  cells  should  have  become   127 
susceptible to G418. Interestingly, the majority of tested clones were not killed by G418. Only 
one clone, designated Marco iCre2 29ΔNeo20, exhibited the expected behaviour and did not 
expand under these conditions. 
 
To analyze the clones further, a Southern Blot was designed for both the Itgb2l and Marco loci. 
A  BamHI  (Figure  8.10A&B)  digest  liberates  fragments  differing  in  size  depending  on  the 
presence or absence of the Neo
R gene. In case of Itgb2l iCre2 fragment sizes were 4.5kb or 
2.9kb, for Marco iCre2 they were 6.2kb or 4.5kb. The Southern Blot revealed two surprising 
results. For the descendants of the two Itgb2l iCre2 knock-in clones (8.10C), no subclone had a 
pure deleted genotype with only the 2.9kb band present. On the contrary, 6 of the assayed 9 
subclones  only  showed  the  4.5kb  band  indicating  the  presence  of  the  Neo
R  gene.  Three 
subclones, two derived from Itgb2l iCre2 17 and one from Itgb2l iCre2 20, resulted in both 
bands, indicating partial deletion of about 75% of the population (Figure 8.10D) as evidenced 
by measuring the Southern Blot signal intensity. 
 
Subclones descended from Marco iCre2 knock-in clones 25 and 29, exhibited a similar result 
(Figure 8.10E). 3 out of 4 subclones had mixed deleted and non-deleted genotypes, with the 
deleted population encompassing about 25% (Figure 8.10F). Subclone Marco iCre2 29ΔNeo20, 
however,  showed  a  pure  deleted  genotype,  as  expected  from  its  susceptibility  to  G418. 
Curiously,  the  non-deleted  control  DNA  isolated  from  Marco  iCre2  knock-ins  expanded 
without  G418  before  pCre-Pac  transfection,  also  presented  both  bands,  indicating  partial 
deletion.  
 
8.6  Discussion 
 
8.6.1  Identification of Homologous Recombinants 
 
The previously designed iCre2 vectors for Itgb2l, Marco and Msr1 were used to target murine 
embryonic stem cells. From two independent transfections, around 200 G418 resistant colonies 
were  isolated  per  gene  (sum:  650),  to  ensure  obtaining  several  homologous  recombinants. 
Significantly more colonies were isolated than for the BAC targeting vectors used earlier, as the 
targeting frequencies of the new shorter plasmid vectors were unknown and could have been 
much lower than the 8% observed for Itgb2l in Chapter 6. The total number of drug resistant 
colonies  generated  for  both  independent  Itgb2l  iCre2  and  Marco  iCre2  transfections  was 
roughly the same with about 300-500 per experiment. For the first Msr1 iCre2 transfection, only 
around  50  colonies  were  obtained,  in  the  second  round,  however,  this  increased  to 
approximately 400.   128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.8 Neo
R Deletion in Bulk Culture 
An iCre2 specific forward primer binding in exon 2 (NeoExcF) was paired with a gene specific 
reverse primer (PaNeoExcB or MaNeoExcB) to enable screening for deletion. 2.5kb or 1kb 
PCR fragments (A) are generated depending on the locus structure. Bulk DNA from clones 
transiently transfected with 20µg pCre-Pac was subjected to PCR after 48h (B). Both bands are 
visible, suggesting the deletion of the floxed selection marker. A fraction of the cultures was 
subjected to a 24h transient puromycin (Puro) selection. DNA isolated from non-transfected 
knock-ins served as a positive control (+) and only showed the 2.5kb band. M1: 1kb marker; 
M2: λHindIII marker; - no template 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.9 Colony PCR for Neo
R Deletion 
This figure shows an example of the colony PCR employed to screen for Neo
R deletion. Itgb2l 
iCre2 20 had been transfected with 5µg pCre-Pac, plated at a density of 200 cells/ml for 10 days 
before 24 clones were subjected to PCR. DNA from non-transfected cells served as a positive 
control (+). 
M1: 1kb marker; M3: λHindIII marker; - no template   129 
 
Figure 8.10 Southern Blot Analysis of Neo
R Deletion 
Both Itgb2l (A) and Marco (B) knock-ins before (top) and after (bottom) Cre mediated deletion 
are shown. BamHI fragments probed with a Cre-specific PCR product were used to screen the 
potentially Neo
R deleted clones of Itgb2l iCre2 (C) and Marco iCre2 (E). c marks control DNA 
samples isolated prior to deletion. For lanes having two visible bands, signal intensities were 
quantified using ImageJ (D&F). 
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The shorter upstream homology arm (4kb) allowed skipping the PCR exclusion strategy applied 
in Chapter 6 and enabled the pre-selection of clones by a 5’ PCR. For Itgb2l iCre2 and Marco 
iCre2, the PCR was very efficient in selecting knock-in candidate clones (Figures 8.1 and 8.2). 
Consequently, it sufficed to assess just 96 of the total 448 clones. As working PCR conditions 
could not be established for the 24 tested Msr1 iCre2 clones, all following work focused on 
Marco and Itgb2l. All Msr1 iCre2 clones, however, are archived for future tests. Alternative 
options to identify homologous recombinants among Msr1 include using different primers (so 
far three forward primers binding just outside the upstream homology arm were tested together 
with  the  Cre  specific  reverse  primer  iCrecheck2),  using  different  polymerases  (a  Taq/Pfu 
combination 25:1 was used in all samples), performing the initial screening using a 3’ PCR, 
narrowing down clone numbers by excluding those harbouring the vector backbone or skipping 
initial PCR analysis and focusing on Southern Blots (Figure 8.4C). 
 
All Itgb2l iCre2 and Marco iCre2 knock-in candidates were subjected to a 5’ Southern Blot 
with  an  external  probe  (Figure  8.5).  The  placement  of  the  restriction  enzyme  sites  and  the 
utilization  of  a  probe  external  to  the  targeting  area  ensures  that  only  clones  in  which 
homologous  recombination  occurred  are  visualized.  The  shorter  length  of  the  upstream 
homology arm enabled a greater choice of restriction enzymes and simplified the screening 
considerably.  All clones assessed,  with the exception of Itgb2l iCre2 43,  were  found to be 
knock-ins with one allele of the respective target gene being modified and the other representing 
the wild type locus. 
 
Gene  targeting  with  sequence  replacement  vectors,  such  as  those  used  herein,  requires  two 
reciprocal recombination events, one at each end of the targeting vector (Deng et al., 1993; Li et 
al., 2001; Sorrell and Kolb, 2005). Both crossing over incidents entail breaking and re-joining of 
DNA molecules. 5’ PCR and 5’ Southern Blot have assessed genetic integrity of the upstream 
homology arm, but further tests were needed to confirm the downstream homology arm. To that 
end, 3’ Southern Blots and 3’ PCRs were employed. In the 3’ Southern Blot restriction enzymes 
cutting within the downstream homology region and just outside of the targeting area were 
utilized. Knock-in clones should, when hybridized with an external probe, only exhibit the wild 
type  band,  indicating  that  no  gross  re-arrangements  or  deletions  have  occurred  in  the 
downstream homology area. The blot for Itgb2l iCre2 (Figure 8.7A) showed this very result, 
with none of the 4 knock-ins revealing any gross abnormalities. Results for Marco iCre2 clones 
were  inconclusive  as,  possibly  due  to  low  external  probe  specificity,  bands  could  be  not 
distinguished. In lieu thereof, the 3’ PCR for Marco iCre2 clones (Figure 8.3) serves to exclude 
the presence of major deletions. 
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The 3’ Southern Blot, re-probed with an internal probe, also helped to verify the absence of 
additional random integration (Figure 8.7B&C). The presence of only one band, equivalent to 
the wild type, is the expected result in the absence of random integrants. Clones that have the 
vector integrated randomly within their genome carry the same upstream restriction site, but the 
closest downstream restriction site would be dependent on the random locus and likely result in 
additional bands of different sizes. Similarly, if vector concatemers had recombined into the 
locus additional bands of different sizes would occur. Neither Itgb2l nor Marco Southern Blots 
reveal  any  additional  bands  beyond  the  wild  type.  Insert  duplication  or  additional  random 
integration can thus be excluded. Those findings are consistent with reports in the literature that 
homologous recombination and random integration do not frequently happen in the same cell, 
due to either low probability of two such rare events occurring simultaneously  (estimated at  
10
-9 per cell) (Waldman, 1992) or the cellular pathways involved in homologous recombination 
(double strand break repair; DSBR) and random integration (non-homologous end joining; NEJ) 
not being directly competitive (Ng and Baker, 1999; Reid et al., 1991).  
 
One drawback of the 3’ Southern is that, due to the absence of suitable restriction sites, it does 
not cover the entire 3’ homology arm. Also, though there is no indication of additional random 
integration, the employed technique cannot distinguish random bands of the same size as the 
wild type. Alternatives in excluding random integrations are further quantitative Southern Blots 
that allow establishing the knock-in gene copy number. Options include the use of restriction 
sites and probes internal to the incoming sequences to allow the quantitation of band intensities 
(as has been done in Chapter 6) or utilization of a copy number standard (by including the 
vector). 
 
When all screenings were taken together, homologous recombinants could be identified for both 
the Itgb2l and Marco loci, the results are summarized in the following Table 8.3. 
 
8.6.2  Targeting Frequency 
 
The targeting frequency for the Itgb2l locus was 8%, identical to the value observed in Chapter 
6, when the Itgb2l iCre2 BAC vector was utilized.  For Marco, a 10% targeting frequency was 
established. Several candidate clones, however, lost their ability to proliferate in culture before 
all screenings could be performed. If all 8 clones assessed as homologous recombinant during 
the 5’ Southern Blot were actually knock-ins, the frequency would be a high 17%.  
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    HR Confirming Result in   
Targeting 
Construct 
Clones selected 
by 5’ PCR  
3’ PCR  5’ Southern 
Blot 
3’ Southern 
Blot 
Considered Knock-
in Clone 
8  NDA  YES  YES  YES 
15  NDA  YES  YES  YES 
17  NDA  YES  YES  YES 
20  NDA  YES  YES  YES 
Itgb2l iCre2 
43  NDA  NO  NA  NO 
10  NDA*  NDA*  NDA*  NO** 
11  NDA*  YES  NDA*  NO** 
23  NDA*  YES  NDA*  NO** 
25  YES  YES  YES  YES 
29  YES  YES  YES  YES 
33  NDA*  YES  NDA*  NO** 
37  YES  YES  YES  YES 
43  YES  YES  NDA*  NO** 
44  NDA*  NDA*  YES  YES 
Marco 
iCre2 
48  YES  YES  YES  YES 
Table 8.3 Identification of Knock-ins for Itgb2l and Marco  
The table lists the screening results for the Itgb2l iCre2 and Marco iCre2 samples that were 
selected  as  candidates  by  5’  PCR  and  whether  they  were  eventually  considered  to  be 
homologous recombinants.  NDA – no data  available; NA – not assessed; NDA* – no data 
available due to clones loosing ability to proliferate in culture; NO** – not considered knock-
ins as not all screenings could be performed, HR Homologous Recombination 
 
 
Targeting frequencies depend on the locus (Hasty et al., 1994), the length of total homology 
(Hasty et al., 1991) and the selection strategy applied (Mansour et al., 1988). The presented 
work used a total homology of 11kb and a simple positive selection approach. Table 8.4 lists 
several  similar  experiments,  lengths  of  homologies  utilized  and  the  corresponding  targeting 
frequencies.  Overall,  frequencies  observed  in  this  work  are  in  the  same  (8%  for  Itgb2l)  or 
slightly higher (10-17% for Marco) range, which can be explained by using homology arms 
almost two times longer than those listed. The results indicate that the Marco locus is more 
amenable for homologous recombination than Itgb2l. Targeting frequencies could have been 
further increased by using an additional negative selection marker (HSVtk), which typically 
provides a 2-5 fold enrichment for correctly targeted clones (Sedivy and Dutriaux, 1999). 
 
Targeted Locus  Sum 
Homology  
Upstream   Downstream   Targeting 
Frequency 
Reference 
Various  5-8kb  n/a  n/a  1-5%  (Sorrell and 
Kolb, 2005) 
Fgr (src kinase)  6kb  2kb  4kb  5% 
Fah (fumarylaceto-
acetate hydrolase) 
6kb  1.4kb  3.6kb  7.5% 
(Hasty et al., 
1994) 
Table 8.4 Overview of Targeting Efficiencies 
Summary of targeting frequencies obtained when autosomal mouse genes were targeted with 
sequence replacement vectors carrying single positive selection markers. 
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8.6.3  Technical Obstacles in Removing the G418 Resistance Marker 
 
In bulk culture, deletion of the Neo
R gene by transient Cre expression could be verified for all 
six assessed knock-in clones (Figure 8.8). Genomic DNA isolated from such cells amplified 
deleted and non-deleted products. The non-deleted band appeared stronger, which coincides 
well  with  the  assumption  that  only  a  fraction  of  cells  is  successfully  transfected  by 
electroporation.  In  an  earlier  experiment,  using  an  EGFP  expressing  reporter  plasmid,  the 
transfection efficiency was around 15% (data not shown). Subclones assessed by colony PCR 
(Figure 8.9) established the fraction of deleted colonies to be in the same range (Table 8.2), 
corresponding to values between 2-15% reported in the literature (Abuin and Bradley, 1996; 
Sauer and Henderson, 1989). 
 
Subclones screened as deleted, however, were not killed by G418 selection. Whilst massive cell 
death  was  observed  around  day  4,  a  significant  fraction  of  the  cells  continued  to  thrive. 
Unmodified embryonic stem, grown under the same conditions, died within 7 days. A Southern 
Blot (Figure 8.10) revealed that the majority of samples exhibited a mixed genotype of Neo
R 
containing and ΔNeo genomic DNA. There are two possibilities to explain these results: 
1.  Isolated colonies derive from more than one cell and are not actually clonal, but mixed 
populations containing both cells successfully transfected by pCre-Pac and those that 
were not. 
2.  Colonies are derived from single cells, but transfected pCre-Pac became active during 
or after cell division, which led to an asymmetric distribution of Neo
R deletion. 
 
The second option appears plausible in the transfections of Marco iCre2 25 and Itgb2l iCre2 17, 
as cells were diluted and plated for clonal expansion immediately after electroporation, when 
considering the short doubling times of murine embryonic stem cells of around 12h (Udy et al., 
1997). For all other transfections (Table 8.2), however, cells were plated as bulk for 48h before 
being  cloned.  After  two  days  recombination  should  be  complete,  and  since  the  enzymatic 
equilibrium favours the deletion of Neo
R, the process is irreversible. 
 
The first option, colonies not being of clonal origin, appears more likely. Embryonic stem cells 
tend to clump together, despite taking great care to plate dilute single cell suspensions. The 
number of cells plated per 10cm feeder plate was stepwise reduced from 5000 to 1000. Those 
numbers resulted in a low density of colonies evenly spaced across the entire dish allowing easy 
isolation. However, as no selection is applied and pCre-Pac transfection is relatively inefficient, 
the possibility of colonies deriving from more than one cell and harbouring different genotypes 
cannot be excluded.  Subclone  Marco iCre2 29ΔNeo20, which has  a pure deleted genotype, 
shows that the method’s general principle is sound.   134 
The  PCR  utilized  to  identify  deleted  subclones  (Figure  8.8)  inadvertently  encouraged  the 
expansion  of  mixed  colonies.  Whilst  faithfully  amplifying  the  1kb  deleted  band;  the  larger 
2.5kb non-deleted band could not be obtained reliably thus largely precluding the identification 
of mixed populations at this stage. As one lysed half of a picked colony served as template, this 
is  likely  due  to  cellular  debris  and  low  template  copy  number  inhibiting  polymerase 
amplification. The complete Neo
R cassette spans about 1.5kb, so placing the primer pair slightly 
closer together, for example by choosing a forward primer that aligns within exon 3 of iCre2 
instead of exon 2 (Figure 8.8A), could have improved this PCR screen, though the final product 
size cannot be reduced much beyond 2kb. 
 
Re-cloning of mixed cell lines at a lower density (500 cells per 10cm plate yielding a few dozen 
colonies) and scoring isolates by PCR, Southern Blot and G418 selection largely alleviated the 
problem for Itgb2l. Whilst some samples remained mixed populations, several colonies of a 
pure deleted genotype were obtained. Subcloning of Marco samples, however, only resulted in 
G418 resistant colonies. Colony PCRs only exhibited the 2.5kb Neo
R containing bands. The 
reason for the apparent loss of the deleted cell fraction is unclear, but may be related to its low 
proportion of just one quarter among the  whole population (Figure 8.10D). For  Itgb2l, this 
fraction was more than three quarters (Figure 8.10F), which seems to indicate that the locus is 
more accessible for Cre mediated recombination. 
 
By  and  large,  the  problem  of  mixed  genotypes  is  mainly  caused  by  low  transient  Cre 
transfection efficiency. Increasing the frequency of Cre mediated recombination and thus the 
proportion of the ΔNeo population would help to reduce the appearance of mixed genotype cell 
lines, even for non-clonal colonies arising from several cells. Utilizing alternative methods to 
ensure a higher efficiency of Cre delivery to ES cells in vitro would be a sensible choice in 
future experiments. Adenoviral Cre, for example, successfully infected and recombined 91% of 
an embryonic stem cell population. This high fraction meant that the isolation of clones was not 
necessary. Mixtures of deleted and non-deleted cells were used directly for blastocyst injection 
20h after infection, allowing significant time savings. Chimeras reliably transmitted the deleted 
genotype  to  their  offspring  (Shui  and  Tan,  2004).  Similarly,  varieties  of  cell  permeant  Cre 
protein have been used to treat cultured cells, including mES cells. Depending on the chosen 
Cre  protein,  cell  line  and  recombination  target,  between  20%  and  80%  of  all  cells  were 
recombined successfully (Jo et al., 2003; Lin et al., 2004; Patsch and Edenhofer, 2007). 
 
In conclusion, ΔNeo subclones were eventually isolated for both Marco and Itgb2l knock-ins. 
Due to the hurdles encountered, however, embryonic stem cells were kept in culture for an 
extended period of time and manipulated frequently. The stock of ES cells used in this work 
was passage 12. Resistance marker containing knock-in clones are around passage 20, whereas   135 
confirmed deleted clones are between passages 35-40. A high number of passages have been 
reported  to  reduce  mES  ability  to  contribute  to  the  mouse  germ  line,  likely  due  to  an 
accumulation of genetic and epigenetic changes influencing pluripotency (Fedorov et al., 1997; 
Kondoh et al., 1999; Liu et al., 1997). Therefore, it may be prudent to use earlier passage Neo
R 
containing knock-ins for blastocyst injection and remove the resistance marker in vivo. Possible 
methods are discussed in Chapter 10. 
 
8.6.4  Basal iCre2 Expression in Marco Knock-in Clones 
 
The Southern Blot aimed at confirming Neo
R deletion, also revealed the presence of low level 
Cre activity within Marco knock-ins. Control DNA of both tested clones 25 and 29, grown 
without  G418,  exhibited  deletion  of  the  resistance  marker  in  the  absence  of  transiently 
expressed Cre (Figure 8.10E) in 25% of the population. Therefore the activity must have arisen 
from  within those cells through iCre2 expression from the  Marco locus.  Whilst this shows 
principle functionality of the iCre2  coding sequence and protein, it  also indicates promoter 
leakiness as Marco has thus far only been described as active during macrophage development 
(see Chapter 3.2.3). Contrariwise Itgb2l, the candidate for neutrophil specific Cre expression 
(see Chapter 3.2.1), showed no such behaviour in undifferentiated embryonic stem cells (Figure 
8.10C). The observed activity could have several reasons: 
1. Low level Marco activity is a part of basal embryonic stem cell gene expression. 
2. Marco plays a role in embryonic development that is yet to be described. 
3. Marco, and consequently iCre2 expression, are dysregulated by the presence of Neo
R 
within the locus. 
 
The finding that embryonic stem cells express 50% more genes than differentiated adult cells 
supports the first theory (Golan-Mashiach et al., 2005). Similarly, genome wide gene trapping 
in embryonic stem cells has shown that around 2/3 of all mouse genes are expressed to a high 
enough level to be trapped by promoterless vectors (Nord et al., 2006; Schnutgen et al., 2008; 
Skarnes et al., 2004). It has been suggested that embryonic stem cells maintain a broad basal 
level of gene expression as a preface for cell fate determination. Major transcriptional changes 
occur  during  differentiation,  a  large  number  of  genes  are  down-regulated,  whereas  tissue 
specific expression is increased (Fathi et al., 2009; Ivanova et al., 2002; Sharova et al., 2007). 
Thus gene expression in the undifferentiated state in vitro is not necessarily an accurate model 
for assessing tissue specific gene activity in the adult in vivo. 
 
A recently discovered link between pluripotent stem cells and macrophages sustains the second 
assumption. Murine embryonic stem cells were found to share macrophage abilities, such as 
phagocytosis – a process in which Marco is involved. In addition, peritoneal macrophages and   136 
embryonic stem cells were shown to have remarkable similarities within their transcriptome 
(Charriere et al., 2006). Likewise, a multipotential subpopulation of peripheral macrophages has 
been discovered. These cells can, if stimulated with appropriate growth factors, differentiate 
into  neuronal,  hepatic,  endothelial,  epithelial  and  lymphocytic  cells  and  thus  resemble 
embryonic stem cells (Kuwana et al., 2006; Ruhnke et al., 2005; Zhao et al., 2003). 
 
Thirdly, wide spread expressional dysregulation by the selection cassette has been reported. The 
Neo
R gene, due to its procaryotic origin, carries numerous cryptic splice sites that can cause 
aberrant splicing (Ren et al., 2002). Also, a high CpG content can adversely affect expression in 
cis (Jin and Mann, 2005).  The strong promoter (PGK1) has the potential to influence gene 
expression across several 100kb (Olson et al., 1996; Pham et al., 1996) (Chapter 2.3).  
 
On  the  whole,  iCre2  expression  in  undifferentiated  ES  cells  could  be  detrimental  to  the 
envisaged  macrophage  specific  conditional  mouse  model  if  the  activity  persists  throughout 
embryonic  development  at  a  high  enough  level  to  mediate  recombination  in  vivo.  Partial 
recombination in the blastocyst would lead to a mosaic adult genotype, negating the objective of 
tissue specificity. Nevertheless, the actual iCre2 expression pattern can only be verified in the 
mouse model in vivo. 
 
8.6.5  Summary 
 
In  conclusion,  the  herein  reported  findings  confirm  that  the  use  of  homology  arms  of  4kb 
upstream  and  7kb  downstream  is  a  good  compromise  between  obtaining  high  targeting 
frequencies and facilitating straightforward screening. The utilized shortened plasmid vectors 
are therefore superior to the BAC vectors employed in Chapter 6. iCre2 knock-ins with no 
obvious chromosomal rearrangements or additional random insertions were generated for both 
Itgb2l and Marco loci. The number of individual knock-in clones (4 for Itgb2l and 5 for Marco) 
should  be  sufficient.  General  recommendations  are  that,  when  working  within  the  129 
background,  3  independent  clones  per  target  gene  should  be  injected  to  obtain  sufficient 
numbers of high-level coat colour chimeric mice to ensure germ line transmission (Ware et al., 
2003).  The  problematic  positive  selection  cassette  removal  suggests  the  exploration  of 
alternative methods to accomplish this feat in vitro or moving it to a later stage of the mouse 
production process in vivo. The general expressibility and protein functionality has been shown 
in Marco knock-ins as the Southern Blot designed to detect selection marker removal indicated 
deletion in the absence of extraneous Cre recombinase. However, as it also raises the question 
of  potential  Marco  promoter  leakiness,  Itgb2l  iCre2  clones  may  be  the  first  choice  for 
producing mice at this stage.   137 
CHAPTER  9:  GENERATING  EMBRYONIC  STEM  CELL  DERIVED 
MACROPHAGES 
 
In a final part of the project, an attempt was made to assess iCre2 expression specificity in vitro. 
To that end, a protocol was adapted to differentiate knock-in embryonic stem cells along the 
haematopoietic pathway.  As macrophages are  easier  to obtain than neutrophils, the primary 
focus lay on Marco iCre2 knock-in lines. Differentiated cells were identified using specific 
surface markers; expression of Marco and iCre2 was analyzed on the total RNA level and with 
the  help  of  a  newly  created  reporter  cell  line  able  to  switch  on  GFP  expression  after  Cre 
mediated recombination.  Whereas macrophages could be created successfully, expression of 
iCre2 could not be verified. 
 
9.1  Conditions for Haematopoietic Development 
 
Initially, conditions were established that permit haematopoietic differentiation of IB10 murine 
embryonic  stem  cells.  The  three-dimensional  embryoid  body  (EB)  method  was  applied  to 
induce early mesodermal differentiation (Keller et al., 1993; Wiles and Keller, 1991). Three 
approaches were used to form EBs: culture in hanging drops (Wang and Yang, 2008), dilute 
culture in suspension and methyl cellulose based semisolid culture (Keller, 1995). 
 
The  suspension  culture  protocol  involved  dilute  suspensions  of  ES  cells  (100-500  cells/ml) 
plated  onto  bacteriological  grade  dishes.  Within  a  week,  small  EBs  became  apparent. 
Efficiencies were relatively low. On average, only about 10% of all cells formed EBs in this 
culture system.  Further growth of such EBs was also hampered by their strong tendency to 
adhere to all tested types of culture dishes. Early adherence and spreading of EBs significantly 
reduces  the  development  of  haematopoietic  and  other  tissues  by  hindering  orderly  three-
dimensional differentiation (Bautch et al., 1996; Dang et al., 2002).  
 
Semi-solid culture was attempted by plating the dilute ES cell suspension (100 cells/ml) into 
differentiation  medium  containing  1%  methylcellulose.  With  this  method,  however,  EB 
formation took almost two weeks and the formation frequency was lower than 25%. In addition 
EBs tended to adhere, as was observed in suspension culture, and the gel like quality of the 
medium hampered the removal of grown EBs without damage. 
 
For the hanging drop culture 20µl drops containing 100 or 1000 cells per drop were plated into 
the lid of 10cm bacteriological grade culture dishes. After two days of culture, one embryoid 
body was typically formed per drop with a frequency of 63±8% for 100 cells/drop and 85±6% 
for  1000  cells/drop.  On  day  3,  individual  embryoid  bodies  contained  1050±210  cells  or   138 
6800±450 cells respectively (Figure 9.1). Thus, owing to its ease of use and high EB formation 
efficiency,  the  hanging  drop  method  (1000cells/drop)  was  eventually  adapted  for  all 
haematopoietic differentiation assays.  
 
After 48h in hanging drop culture, EBs were transferred into suspension culture containing the 
appropriate growth factors to induce macrophage development (see below) (Keller et al., 1993; 
Wiles and Keller, 1991). In cases where excessive adherence of EBs occurred, non-adherent 
embryoid bodies were transferred onto a fresh dish. With a plating density of 30-40 EB/ml, the 
medium needed replacing every 2-3 days. Stages of development observed are described in the 
next section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 Embryoid Body Formation in Hanging Drop Culture 
Two cell densities, 100 and 1000 cells/drop were tested for the frequency of EB formation after 
48h (A). The cell number per EB after 3 days (B) was measured by pooling a defined number of 
EBs,  trypsinization  and  counting  in  a  haemacytometer.  Values  given  represent  5  individual 
experiments±standard deviation of the median. 
 
 
9.2  Stages of Development in Differentiation Cultures 
 
Undifferentiated ES cells (Figure 9.2A) can be induced to form early embryoid bodies (Figure 
9.2B)  within two days,  which recapitulates the stages of early embryonic development (see 
Chapter 4). Three-dimensional development is necessary to induce haematopoietic commitment. 
The initial stages of differentiation, up to the formation of mesodermal precursors, are growth   139 
factor  independent  (Keller  et  al.,  1999).  Further  haematopoietic  development,  however,  is 
dependent on the presence of appropriate cytokines. Cultures were consequently supplemented 
with 5ng/nl MCSF and 1ng/ml IL-3 from day 2 onwards. Was this supplementation performed 
too late (i.e. after day 10), development of detectable amounts of embryonic macrophages did 
not occur (data not shown). EBs, transferred from hanging drop into suspension culture, grow in 
volume and the majority undergo globinization, the development of primitive and definitive 
erythrocytes, from day 7 onwards (Figure 9.2C&D). Early myeloid precursors are thought to be 
present  by  day  6  (Wiles,  1993).  When  suspension  EBs  were  transferred  into  tissue  culture 
plates,  they  attached  within  48h  (Figure  9.2E)  and  spread,  forming  several  poorly  defined 
tissues.  Left  in  suspension  culture,  EBs  kept  growing  and  began  to  shed  cells,  under 
supplemented conditions the majority of these cells are believed to be macrophages (Wiles, 
1993). By day 15, a large proportion of EBs had transformed into liquid-filled cystic embryoid 
bodies reminiscent of the in vivo blastocyst stage (Figure 9.2F).  When suspension EBs (no 
earlier than day 7) were disrupted using trypsin or collagenase IV and plated onto tissue culture 
dishes, clusters of embryonic macrophages began appearing after about 5 days, indicating the 
presence of haematopoietic precursors in the three-dimensional structures. Survival of these 
precursors and formation of macrophages, however, varied greatly as disruption of EBs required 
long protease incubation times and strong physical shear force. Attached whole EBs also began 
forming embryonic macrophages after about 5 days, which typically appear as halos around the 
individual colonies (Figure 9.2G).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.2 Stages of Development (see following page) 
Undifferentiated  mES  cells  were  grown  on  gelatin  in  the  presence  of  Leukemia  Inhibitory 
Factor (LIF) (A) before being subjected to EB formation in hanging drops for 48h (B). By day 7 
the majority of EBs have turned red at the centre due to globinization (C&D). When left to 
attach to tissue culture plastic, several tissues appear within a few days, E shows such an EB on 
day 13. EBs left in suspension culture begin to turn into liquid filled cystic embryoid bodies 
from day 10, such a large structure, on day 15, is shown in F. Embryonic macrophages (G) can 
be derived from EBs de-aggregated from day 7 onwards, here EBs were broken apart on day 12 
and left to grow for 6 days. Embryonic macrophages can also appear as halos (H) around EBs 
left to adhere and spread for 5-7 days. Magnification: 40x (B; C; E; F; H); 200x (A; D; G)   140 
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9.3  The Appearance of Macrophage Differentiation Markers 
 
CD11b and F4/80 were used as markers for murine macrophages (see Chapter 4.1) (Moore et 
al.,  1998).  Cells  were  analyzed  by  flow  cytometry  at  different  stages  of  the  differentiation 
process. The gating strategy applied to all samples is shown in Figure 9.3B. In order to avoid 
cellular debris and clumps of cells, only events of medium forward scatter and low to medium 
side scatter were gated. Debris and clumps in the samples could not be avoided entirely due to 
the physical force (i.e. prolonged protease treatment and passaging through a needle) needed to 
break apart embryoid bodies or differentiated cells prior to staining. 
 
Figure 9.3A details the differentiation protocols assessed in the pilot experiment. EBs  were 
either kept in suspension culture beyond day 9 or were, from then onwards, attached to tissue 
culture plastic as whole structures (4-6EB/well of a 12w plate) or single cell suspension (10E5 
cells/well of a 12w plate). In addition, EBs were grown in semisolid culture for 9 days before 
attaching them to tissue culture plates as a whole. Samples for staining were taken on days 9; 
14; 17 and 21. 
  
CD11b/Mac-1 was used as the first indicator for monocyte/macrophage development. On day 9 
in suspension culture, only trace expression of CD11b could be observed (Figure 9.3C). By day 
14, independent of culture method, about 11% of all cells expressed this marker. Beyond that, 
for both suspension and attached cultures, the value fell to about 4% on day 17 and 0.9% or 
2.6% respectively on day 21. For de-aggregated cells, expression levels peaked later, on day 17 
with a value of 14%, before falling to 5% on day 21. In semisolid culture, 5% of all cells stain 
positive for CD11b on day 17 (only data point available). 
 
Similar data was obtained for the second macrophage marker F4/80 (Figure 9.3D). No trace 
expression could be picked up in suspension culture on day 9, but up to 10% of all cells cultured 
as attached EBs express F4/80 after 14 days. As with CD11b, the expression was reduced after 
that  in  suspension  and  attached  cultures.  For  the  de-aggregated  culture  method,  expression 
peaked at day 17 with about 13% before being reduced to 5% on the last assayed day 21. In 
semisolid culture, about 2% of all cells expressed F4/80 on day 17. 
 
Overall, the combination of forming EBs in hanging drops, further growth in suspension and 
attached de-aggregated single cell culture proved to be most efficient and straightforward in 
generating embryonic macrophages. Technical problems encountered were primarily related to 
breaking  apart  the  embryoid  bodies.  Prolonged  incubation  of  up  to  15min  in  0.1%  trypsin 
resulted in poor viability (less than 50% of the cells, by Trypan Blue) and excessive force was 
needed to generate single cell suspensions.   142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.3 CD11b and F4/80 Expression in Pilot Differentiation Cultures 
A illustrates the differentiation protocols applied to the ES cells. Cells of medium forward and 
low to medium side scatter were gated to avoid debris and clumps of cells (B). CD11b (C) and 
F4/80 (D) expression is plotted as the fraction of cells expressing the respective marker in the 
total sample depending on the applied culture method. Expression levels of parallel experiments 
varied greatly. Antibodies used were CD11b-PE and F4/80-FITC.    143 
Consequently, few of the cells attached and differentiated further. Switching to collagenase IV 
largely alleviated the problem. Collagenase is not inhibited by serum proteins and could be 
added (at 0,2%) straight to the  medium.  After  a 30min incubation  with pipetting in 10min 
intervals and finally passing the cells through a needle, the majority of cells was in single cell 
suspension and viability was greater than 90%. 
 
After establishing the general parameters, the differentiation process was repeated using the 
selected suspension/de-aggregation method. EBs were disrupted slightly earlier on day 7 (as 
opposed to 9) and cultured as single cells until day 15. Earlier time points were included in the 
analysis, days 0; 4; 7 (Figure 9.4A). Day 0 represents undifferentiated ES cells, cultured in the 
presence of LIF, which are CD11b and F4/80 negative. As before, CD11b expression appears 
initially  on  day  7  (with  approx.  3.5%  of  all  cells),  slightly  earlier  than  in  the  previous 
experiment. The fraction of cells expressing CD11b increases to 11% on day 10 and 15% on 
day 15. F4/80 cell surface expression appeared later than CD11b, with 1.6% of cells expressing 
the marker after 10 days and 12.5% of all cells staining positive after 15 days. The double 
staining shows that the majority of stained cells (12.5%) expressed both markers after about 2 
weeks (Figure 9.4B). Isotype matched controls (Figure 9.4C&D) did not indicate any significant 
non-specific staining. 
 
Levels of CD11b and F4/80 expression varied greatly between experiments (i.e. compare to 
wild type differentiation in 9.3), but 10-15% embryonic macrophages in the total cell population 
after two weeks of differentiation were considered to be sufficient to attempt detection of iCre2 
expression. Several trials were made to expand embryonic macrophages beyond days 15-17. 
Upon  harvesting  and  re-plating  of  the  cells,  no  further  expansion  could  be  achieved.  Cells 
generally failed to attach and propagate further. Again, detaching differentiated cells from tissue 
culture plastic needed long proteinase incubation times and excessive force. 
 
9.4  Further Markers Assessed in Wild Type Differentiation Cultures 
 
To further dissect the process of differentiation, several other markers were used for staining. 
Those  include  an  endothelial  (CD31),  a  haematopoietic  (CD117),  a  B  cell  lineage 
(CD45R/B220) and a neutrophil (Gr1) marker. Culture conditions were as described before. 
Following EB formation, cells were kept in suspension culture until day 7 before being plated as 
single  cells  until  day  15.  The  majority  of  undifferentiated  ES  cells  (day  0;  Figure  9.5A) 
expressed CD31  when they were attached to gelatin (Figure 9.2A). CD31 expression levels 
continuously fell over the course of haematopoietic differentiation, from 98% on day 0 to less 
than  10%  on  day  15.  The  majority  of  undifferentiated  cells  (84%)  also  expressed  CD117 
(Figure 9.5B).   144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  9.4  Macrophage  Development  in  Wild  Type  Cultures  Using  the  Suspension/de-
aggregation Method 
Wild-type  mES  cells  were  differentiated  for  15  days  (A)  and  stained  for  CD11b/F4/80 
expression at regular intervals (B). Isotype matched controls (tinted) for F4/80 (C) and CD11b 
(D) showed no significant non-specific staining when compared to their respective antibodies 
(bold). Antibodies used were CD11b-PE and F4/80-FITC.   145 
CD117  expression  was  reduced  almost  10  fold  in  suspension  culture  EBs  by  day  7.  De-
aggregated  and  re-attached  cells  showed  a  slight  increase  by  day  15.  Expression  of  the 
neutrophil marker Gr1 and the B cell marker CD45/B220 could not be observed at any stage of 
the haematopoietic development process nor in undifferentiated ES cells (data not shown).  
 
9.5  Generation of a Reporter Cell Line Based on Marco iCre2 
 
With macrophage differentiation conditions having been established, a system allowing the live 
read-out of iCre2 activity had to be set up. The read-out is based on the activation of GFP 
expression by Cre mediated recombination – both an appropriate vector and reporter cell lines 
were thus created. 
  
9.5.1  Creation of a Cre-inducible GFP Reporter Vector 
 
In order to obtain a Cre-inducible version of the vector pEGFPN1_int (an intron improved 
version EGFP termed iGFP) (Lacy-Hulbert et al., 2001), the XhoI fragment from pS3 containing 
a floxed stop sequence (FLST) was cloned into aforementioned vector (Figure 9.6A). FLST 
contains a pause signal and polyA site flanked by loxP sites and is able to suppress expression 
when placed between a promoter and the gene to be blocked. Out of 50 screened colonies 3 (9, 
46 and 47) contained FLST as evidenced by a SalI/NotI digest (Figure 9.6B). Two of those (46 
and 47) carry FLST in the same orientation as iGFP. The resulting pEGFPN1-int-FLST (FLST-
iGFP) can be used as reporter construct, in which iCre2 mediated FLST deletion switches on 
iGFP expression from the CMV promoter. 
 
9.5.2  Creation of Stable CMV-FLST-iGFP Transfectants  
 
The AflIII linearized reporter plasmid was used to generate stable transfectants from knock-in 
clone  Marco  iCre2  29ΔNeo20.  To  establish  reporter  functionality  before  differentiation,  a 
transient Cre expression was performed. Five resistant clones were analysed at 24h and 48h post 
electroporation. Three of the clones tested showed a small (2%), but distinct, population of 
green fluorescing cells (Figure 9.7), with no background activity observable in the controls. 
Transfection of an iGFP expressing plasmid served as a control. Reporter clone 12 was used for 
subsequent differentiation assays as it had the highest and brightest fraction of green fluorescing 
cells after 24h (2.05%). After 48h, 1.79% of cells were still fluorescent. 
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Figure 9.5 CD31 and CD117 Expression in Wild Type Differentiation Cultures 
Fractions of CD31+ (A) and CD117+ cells (B) are shown as bold lines compared to the isotype 
matched controls (tinted) over the differentiation time period of 15 days. 
Antibodies used were CD31-PE and CD117-PE. 
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Figure 9.6 Production of Cre-inducible Reporter Vector 
A  illustrates  the  structure  of  iGFP  before  (top)  and  after  (bottom)  FLST  insertion.  As 
unidirectional cloning was used with only one restriction enzyme (XhoI), FLST can insert in 
both orientations. A SalI/NotI digest identified clones carrying FLST and the orientation (B). 
SalI (S), NotI (N) and XbaI (X) linearize the vector (5.3kb). SalI and NotI create fragment sizes 
of  947bp  and  4361bp  or  1358bp  and  3951bp  respectively,  depending  on  the  orientation  of 
FLST. M1: 1kb Marker; M3: λHindIII Marker 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.7 Cre-mediated GFP Expression in Reporter Cell Lines  
G148 resistant clones were electroporated with 5µg pCre-Pac. Cells were analyzed before (0h, 
left)  and  24h  (middle)  and  48h  (right)  after  transfection.  Wild-type  ES  cells,  transiently 
transfected with 5µg pEGFPN1-int (top) served as a positive control for GFP expression   148 
9.6  Haematopoietic Differentiation of Marco iCre2 Knock-ins 
 
Thus far, all differentiations had been carried out using wild type mES cells. In order to analyze 
iCre2  expression,  these  methods  needed  to  be  reproduced  for  the  Marco  iCre2  knock-ins. 
Several of the  Marco iCre2 knock-in clones  were  consequently subjected to the previously 
described  culture  regime.  Clones  assayed  were  Marco  iCre2  29;  Marco  iCre2  29 
CMVFLSTiGFP12 (the reporter line) and Marco iCre2 48. Various attempts at differentiating 
the first 2 clones did not result in any CD11b or F4/80 expression and thus no macrophage 
production (see Figure 9.8), even though wild type cells assayed at the same time differentiated 
into embryonic macrophages. 
 
The  CMVFLSTiGFP  reporter  clone  also  showed  no  GFP  expression  at  any  stage  of  the 
differentiation cycle (data not shown). Morphologically, however, the differentiation process 
appeared to be similar to that observed with wild type mES cells. EB formation frequencies 
were around 80% and EBs turned red. The only difference was that the EB size for Marco-
iCre2 29 knock-in clones was consistently lower than for the wild type. This is reflected in a 
lower cell number per EB. On day 7, wild type EBs contained about 12180±1731 cells per EB; 
compared to 8180±841 for Marco iCre2 29. Extending the time in suspension culture to 10 days 
before generating single cell suspensions, gave Marco iCre2 29 EBs the chance to grow further 
(Marco  iCre2  29  EB:  9480±1099;  wild  type  EB:  11700±1421),  but  did  not  improve  the 
formation of macrophages  
 
Following  the  attachment  of  EB-derived  single  cells,  the  typical  morphology  of  ES 
macrophages (Figure 9.2G) did not appear. Instead, some clusters of cells began looking more 
like undifferentiated ES cells (Figure 9.2A) again. CD31 and CD117 expression throughout the 
differentiation (Figure 9.9) was similar to that observed in wild type cells (Figure 9.5), until day 
15 – macrophages should have been present by then – when both markers were up-regulated. 
 
In order to establish whether the failure to produce embryonic macrophages was a feature of 
these particular  clones or of knock-ins in general, another  Marco iCre2  clone, no. 48,  was 
differentiated in the same manner. From this particular clone, macrophages could finally be 
generated (Figure 9.10A). Again, the EBs appeared to be smaller after a week in suspension 
culture when compared to the wild type, but on day 14 circa 4% of all gated cells expressed 
both  CD11b  and  F4/80.  This  fraction  is  lower  than  before,  however,  in  this  particular 
experiment, the wild type also only yielded a distinct embryonic macrophage population of 
about 3%. At this stage, cells were also stained for Marco, the receptor whose gene served as 
the iCre2 knock-in target (Figure 9.10B). Interestingly the majority of cells, more than 75% in 
case of Marco iCre2 48, expressed the marker.   149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.8 F4/80 and CD11b Expression in Marco iCre2 29 and Reporter Differentiation 
Cultures 
A shows CD11b/F4/80 double stainings for wild type and Marco iCre2 29 cells differentiated 
according to the protocol described in Figure 9.3A on day 17. B represents the same staining 
data, but for the Marco iCre2 29 reporter cell line from the ES cell stage through to day 15. For 
the parallel wild type staining, please see Figure 9.4B. 
Antibodies were CD11b-PE and F4/80-FITC in A and CD11b-PE and F4/80-Bio/CyC in B. 
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Figure 9.9 CD31 and CD117 Expression in Marco iCre2 Reporter Differentiation Cultures 
Fractions of CD31 (A) and CD117 (B) are shown as bold lines compared to the isotype matched 
controls (tinted). Antibodies used were CD31-PE and CD117-PE. Equivalent stainings for the 
wild type are found in Figure 9.5.    151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  9.10  Expression  of  Macrophage  Markers  on  Day  14  in  Marco  iCre2  48 
Differentiation Cultures 
Marco iCre2 48 and wild type mES cells were differentiated as previously described. On day 
14, cells were stained for CD11b and F4/80 (A). Separately, cells were labelled with a Marco-
specific antibody and a fluorescent 2
nd AB (B). Unstained cells are tinted red, 2
nd AB only 
labelled cells are blue, cells labelled with both antibodies are black. 
Antibodies used are F4/80-FITC, CD11b-PE, Marco and Star69-FITC. 
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9.7  RT PCR for Marco and iCre2 Expression 
 
A RT PCR strategy was designed to analyse the expression of Marco, iCre2 and, as internal 
standard, HPRT in the macrophage differentiation cultures on the RNA level. Cell samples for 
RNA isolation, reverse transcription and PCR had been taken at regular intervals during the 
differentiation of Marco iCre2 29 (Figure 9.11B); Marco iCre2 25 (Figure 9.11C), Marco iCre2 
48  (Figure  9.11D)  and  wild  type  controls.  All  samples  were  assessed,  whether  or  not 
macrophage markers could be identified by flow cytometry. Product sizes, for genomic and 
cDNA,  and  primer  locations  are  shown  in  Figure  9.10A.  For  the  HPRT  internal  standard, 
previously published primers (Kieusseian et al., 2006) were used. Marco primers were newly 
designed and amplify across exons 9 to 12. For iCre2, two primer pairs were utilized. Both 
amplify across exons 1 to 3 but produce different product lengths. The first, Cre141f/Cre1045R, 
was previously described  and applied in 9.11B  and  9.11C (Lacy-Hulbert et al., 2001).  The 
second, novel, set of primers, CrecDNAF/CrecDNAR, was used in 9.10D. 
 
As  expected,  expression  of  the  housekeeping  gene  HPRT  could  be  detected  in  all  samples 
tested.  The  expression  pattern  for  Marco  varied  between  wild  type  cells  and  Marco  iCre2 
knock-ins. 
 
For wild type cells Marco could only be detected after differentiation had taken place for at 
least 7 days – in both independent differentiations (Figure 9.10B&D) assayed. Curiously, for all 
Marco iCre2 knock-ins (clones 25; 29 and 48; Figure 9.10BDC) analysed, Marco expression 
was detectable from the undifferentiated ES cell level (day 0) onwards. Unfortunately, no iCre2 
expression could be detected in any of the samples, even though the positive control shows that 
cDNA synthesis and PCR themselves worked. For Marco iCre2 clones 25 and 29 this may be 
explained by the absence of macrophages in the differentiation cultures (data not shown and 
Figure  9.6).  Marco  iCre2  clone  48,  however,  had  shown  a  small  fraction  of  embryonic 
macrophages after 2 weeks of differentiation, and even here no PCR product corresponding to 
Cre cDNA/RNA was detected. 
 
The  Cre  coding  sequence  contained  in  Marco  iCre2  clones  25  and  37  was  recently  re-
sequenced.  No  mutations could be identified in the  iCre2 exon-intron structure and several 
adjacent 100bp up- and downstream. The apparent lack of iCre2 expression cannot be explained 
at this stage. 
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Figure 9.11 RT PCR Data for 3 Differentiated Marco iCre2 Knock-in Clones 
A illustrates the gene structure (exons as black squares, introns as dotted lines), primer pairs and 
product sizes for the genes assessed. Three different Marco iCre2 knock-ins were differentiated, 
together with wild type controls. RT PCR results are shown for wild type, Marco iCre2 25 (C); 
Marco iCre2 29 (B) and Marco iCre2 48 (D).  
no RT: non reverse transcriptase treated sample, gDNA: genomic DNA of respective clone; +:  
RNA isolated from wild type mES transiently transfected with 5µg pCre-Pac and harvested 
after 48h.   154 
9.8  Discussion 
 
The  goal  of  this  chapter  was  the  development  of  an  embryonic  stem  cell  differentiation 
procedure that, in conjunction with flow cytometry, RNA analysis and a reporter system, allows 
tracking  tissue  specific  iCre2  expression  from  the  Marco  locus  in  vitro.  The  approach  is 
essentially similar to the one presented in (Faust et al., 1994), where in vitro differentiation 
enabled tracing the activity of a chicken lysozyme transgene in murine embryonic macrophages. 
The  ideal  model  system  provides  a  mixture  of  easily  identifiable  differentiated  tissues 
(macrophages vs. non-macrophages) that closely resemble those of the adult knock-in mouse 
model. Ultimately, iCre2 expression could not be verified – possible explanations are discussed 
in  the  following  sections.  Two  issues  are  key  when  considering  the  applied  experimental 
approach: the suitability of the differentiation culture method and the utilized reporter systems. 
 
9.8.1  IL-3 and MCSF Are Sufficient to Obtain Macrophages from IB10 ES 
Cells 
 
Initially, a system needed to be developed, which allowed the straightforward production of 
embryonic macrophages from the murine ES cell line IB10 that had thus far never been used for 
differentiation.  A  minimal  protocol  (Figure  9.4A),  based  on  embryoid  body  formation  in 
hanging drops and expansion in the presence of IL-3 and MCSF modelled after (Keller, 1995; 
Wassarman and Keller, 2003; Wiles, 1993), was found to be suitable, if occasionally variable. 
 
The main advantages of the adapted differentiation protocol are that it is relatively quick (2 
weeks), cheap (relies only on two recombinant cytokines) and creates a mixture of differentiated 
tissues – containing sufficient amounts of the desired cell type (10-15% macrophages) but also 
other cell types, which is ideal for the assessment of a promoter’s specificity. Disadvantages 
include the variability of macrophage yield, the limited amount of differentiated cells obtained 
and the possibility that cells differentiated in vitro have different characteristics than their adult 
counterparts. 
 
Though there are currently no accepted benchmarks for EB formation, observations during this 
work agree well with published reports for other murine embryonic stem cell lines. EBs formed 
with high efficiency from drops of 1000 cells (Figure 9.1) and reached cell numbers comparable 
to reported figures. On day 3, IB10 EBs contained 6800 cells on average, which corresponds to 
values of 6000 cells observed for the CCE line (Dang et al., 2002). Later stage cell numbers on 
day 10 were slightly lower with 11700 cells/IB10 EB compared to around 20000 cells/CCE EB 
(Dang et al., 2002). Differences in EB formation capacity and overall differentiation potential 
between murine embryonic stem cell lines have been documented (Wiles and Keller, 1991).   155 
Common  milestones  of  EB  development,  such  as  globinization  (Doetschman  et  al.,  1985) 
(Figure 9.2D) – regarded as a success criterion for  haematopoietic potential – formation of 
cystic cavities (Figure 9.2F) or the appearance of beating cardiomyocytes (Keller, 1995), were 
all met during the first two weeks of differentiation.  
 
Targeted expansion of embryonic macrophages, defined by the appearance of CD11b and F4/80 
in the presence of IL-3 and MCSF, was successful. The pilot experiment (Figure 9.3) revealed, 
that  macrophage  marker  expression  is,  in  line  with  early  mesodermal  development  and  the 
appearance of myeloid pre-cursors, induced after about 9 days in suspension culture. Marker 
expression  is  maintained  irrespective  of  culture  method,  but  reaches  highest  values  when 
individual EBs are broken apart and cultured as single cells. Marker levels eventually taper off 
for all culture methods, likely caused by reduced cellular survival due to terminal differentiation 
or  the  lack  of  further  developmental  cues  (Odegaard  et  al.,  2007).  Subsequent  experiments 
(Figure  9.4)  were  then  optimized  by  more  frequent  media  changes,  avoiding  the  early 
attachment of EBs by replating, and the use of Collagenase IV, overall increasing cell survival 
and  proliferation.  Two  weeks  sufficed  to  obtain  around  15%  macrophages  expressing  both 
CD11b and F4/80 in the total differentiated cell population. 
 
The CD11b marker appears first, followed by F4/80 (Figure 9.4B), resulting in a distinct doubly 
stained population once cells become terminally differentiated. The stepwise marker emergence 
mirrors macrophage maturation in vivo, where CD11b is a broader spectrum label for myeloid 
cells, including, but not restricted to, monocytes, macrophages, granulocytes and dendritic cells, 
possibly appearing as early as on the clonogenic myeloid progenitor found in the fetal liver or 
adult bone marrow (Akashi et al., 2000; Leenen et al., 1994; Traver et al., 2001). Similarly, 
F4/80  is  recognized  as  a  later  marker  mainly  being  expressed  on  mature  macrophages 
(Anderson et al., 1999; Leenen et al., 1994; Lloyd et al., 2008). Differentiation cultures did not 
show neutrophilic Gr-1 or lymphoid CD45R/B220 expression at any stage, reflecting both the 
later induction of those cell types in vivo and the lack of necessary growth factors in the herein 
utilized culture conditions (Cho and Zuniga-Pflucker, 2003; Lieber et al., 2004). 
 
In  general,  the  yield  of  macrophages  obtained  from  wild  type  IB10  ES  cells  was  variable 
(compare  Figures  9.4B  and  9.8A  to  Figure  9.10A).  Three  main  factors  influencing  the 
reproducibility of differentiation attempts include the utilized serum (Bruce et al., 2007) and 
growth factors, the culture method and the quality of the ES cells. Analyses have shown that 
serum free conditions can increase reproducibility and benefit differentiation as the medium 
composition can be defined exactly (Keller, 2005; Kubo et al., 2004; Ng et al., 2005). The 
utilized culture method may also have contributed to the variability. While embryoid bodies all 
have the same size and developmental status after hanging drop culture, transfer in suspension   156 
culture  causes  de-synchronisation  of  differentiation. This  is  primarily  due  to  EBs  randomly 
fusing together creating a heterogeneous population. When EBs grow larger they are prone to 
necrosis  and  diminished  differentiation  potential  (Dang  et  al.,  2002)  and  EB  size  has  been 
associated with varying myeloid potential (Ng et al., 2005). One way to avoid EB fusion and 
maintain  synchronous  growth  is  the  use  of  methylcellulose  medium.  In  this  work,  it  was 
observed that IB10 ES had a low plating and EB formation efficiency in semisolid medium. 
Handling was problematic. However, forming EBs in hanging drops first before transferring 
them into methylcellulose medium, may improve performance.  
 
The  method  described  herein  was  geared  towards  allowing  straightforward  macrophage 
production. While it works satisfactorily, there are several options to increase both yield and 
specificity of macrophage formation. These either target the initial EB growth period or the 
expansion  of  myeloid  progenitors.  Recent  advances  in  EB  production  include  the  use  of 
polymeric  non-adherent  or  hydrophobic  substrates  and  matrices  other  than  methylcellulose 
(Fathi et al., 2009; Koike et al., 2005; Konno et al., 2005; Valamehr et al., 2008), rotary cell 
culture (Carpenedo et al., 2007; Wang et al., 2006), ES cell encapsulation in alginate beads 
(Rohani  et  al.,  2008)  and  growth  in  lithographic  microwells  (Moeller  et  al.,  2008)  or 
microfluidic chambers (Torisawa et al., 2007) – all aimed at enabling synchronized growth and 
reduced attachment.  
 
Additional  cytokines  –  together  with  IL-3  and  MCSF  –  can  improve  the  expansion  and 
differentiation of myeloid precursors. IL-1, for example, can boost macrophage yield up to two 
fold (Wiles and Keller, 1991). IL-11 and the kit ligand (KL) increase the overall number of 
haematopoietic progenitors (Keller et al., 1993). Vascular endothelial growth factor (VEGF) 
and stem cell factor (SCF) are also beneficial for early haematopoietic development (Nakayama 
et al., 2000; Orlovskaya et al., 2008).  
 
Other improvements may allow the long term production of embryonic macrophages. The most 
common approach uses EBs grown for at least 10 days, which are then attached to tissue culture 
plastic.  In  the  presence  of  appropriate  cytokines,  myeloid  cells  can  be  harvested  from  the 
supernatant after two to three weeks for several weeks running (Karlsson et al., 2008; Moore et 
al., 1998). Such floating cells were not readily observed in this work – possibly due to the 
shorter culture periods. Another innovative experiment incorporated the overexpression of the 
oncoprotein HoxA9 to immortalize myeloid progenitors isolated from EBs, that could then be 
differentiated into macrophages indefinitely (Odegaard et al., 2007).  
 
A  way  to  influence  macrophage  purity  is  to  isolate  haematopoietic  progenitors  early  on  in 
differentiation  through  FACS  or  MACS,  followed  by  selective  maturation.  Three  suitable   157 
purification  markers  are  Flk-1  (fetal  liver  kinase),  CD34  and  CD45,  representing  stepwise 
development from the early mesodermal through to early haematopoietic stages respectively 
(Faloon et al., 2000; Fehling et al., 2003; Kabrun et al., 1997; McKinney-Freeman et al., 2009; 
Nakayama et al., 2000; Wang et al., 2005). 
 
Lastly, the question remains whether in vitro produced macrophages are an accurate model to 
predict iCre2 expression from the Marco locus in adult mouse macrophages. Haematopoietic 
differentiation from embryonic stem cells essentially recapitulates yolk-sac haematopoiesis and 
is thus a process separate from adult bone marrow haematopoiesis (Keller, 2005; Murry and 
Keller, 2008). Notwithstanding, no gross variances have been found in either morphology or 
cellular  metabolism  between  embryonic  and  adult  macrophages  to  date.  Marker  expression 
(CD11b, F4/80,  CD68, CD36,  CD14, scavenger  receptors) (Odegaard  et al., 2007), cellular 
processes such as phagocytosis or cytokine secretion upon stimulation (Clarke  et al., 2000; 
Moore et al., 1998) and gene expression profiles (Lindmark et al., 2004) have all been found to 
be  very  similar.  One  group,  however,  found  that  fetal/embryonic  macrophages,  both  those 
generated in vivo as well as those differentiated in vitro had lower expression levels of a chicken 
lysozyme  transgene  than  their  adult  counterparts  derived  from  the  bone  marrow,  spleen  or 
peritoneal cavity due to differential promoter activity (Faust et al., 1999; Huber et al., 1997). 
 
Overall, macrophages generated from Marco iCre2 knock-in cells should be a good model for 
the adult mouse. It has to be noted, however, that the adult macrophage population is very 
diverse (Lloyd et al., 2008). Any in vitro differentiation attempt is therefore likely to only model 
a fraction of adult cells.  
 
9.8.2  Marco iCre2 Knock-in Lines Show Reduced Differentiation Potential  
 
When  the  optimized  differentiation  protocol  was  applied  to  Marco  iCre2  knock-in  cells, 
macrophages failed to develop from clones 25; 29 and the reporter line (based on 29), as judged 
by  marker  expression  and  general  morphologic  appearance.  For  clone  25,  used  in  pilot 
experiments  (data  not  shown)  this  is,  retrospectively,  likely  due  to  growth  factor 
supplementation  occuring  too  late  (after  day  10)  to  promote  significant  macrophage 
development.  
 
However,  clone  29  and  its  GFP-reporter  descendant,  also  consistently  failed  to  produce 
macrophages  expressing  CD11b  and  F4/80,  unlike  wild  type  cells  differentiated  in  parallel 
under the same conditions (Figure 9.8). While there were no apparent differences in plating 
efficiency, EB formation or globinization; EB size and marker expression varied between clone 
29 and  wild type cells.  Wild type  EBs had reached their maximum cell number of  around   158 
12.000 cells on day 7; whereas clone 29 EBs were 33% smaller with around 8.000 cells. Three 
days later, knock-in EBs still had 22% less cells (9.500) than wild type structures (12.000).  
 
The expression of surface markers CD31 and CD117 during late myeloid differentiation also 
varied between knock-in cells (Marco iCre2 clone 29; Figure 9.9) and wild type (Figure 9.5). 
CD31 (Pecam-1; platelet endothelial cell adhesion molecule 1) is a widely used murine marker, 
primarily found on endothelial cells of the vascular system, but also on certain haematopoietic 
cells such as platelets, neutrophils, monocytes and selected  T  cells (Ilan  and Madri, 2003). 
CD31 was intended to enable the identification of endothelial cells within the differentiation 
culture in order to, in conjunction with macrophage markers, test the tissue specificity of iCre2 
expression. More than 90% of all undifferentiated embryonic stem cells, whether iCre2 knock-
ins or wild type, express this marker (day 0 Figures 9.5A and 9.9A). Other studies found similar 
expression levels, primarily located at the cell-cell junctions and designated the presence of 
CD31 as a constitutive feature of undifferentiated embryonic stem cells, which reflects in vivo 
CD31 appearance in the inner cell mass of pre-implantation embryos (Li et al., 2005; Redick 
and Bautch, 1999; Robson et al., 2001). Furthermore, CD31 expression has been positively 
correlated with pluripotency as such cells show higher levels of pluripotency markers Oct3/4 
and Nanog and greater differentiation potential (Furusawa et al., 2006). During differentiation, 
CD31 levels are sharply down regulated and become restricted to distinct endothelial lineages 
and subsets of haematopoietic cells (Li et al., 2005; Redick and Bautch, 1999). In this work, 
such reduction could only be observed for wild type cells (days 4 to 15, Figure 9.5A). Marco 
iCre2 knock-in clone 29 showed an up-regulation of CD31 expression on day 15 (Figure 9.9A).  
 
CD117 (Figures 9.5B and 9.9B) expression levels, follow a similar pattern. CD117 (c-kit) is a 
widely  used  stem  cell  marker  involved  in  haematopoiesis,  pigmentation  and  fertility 
(Fleischman,  1993).  It  is  broadly  expressed  in  adult  tissues  and  promotes  cell  survival, 
particularly  for  pluri-  and  multipotent  stem  cells  (Ashman,  1999).  It  has  been  found  on 
embryonic stem cells, where it is essential to avoid apoptosis after differentiation is induced in 
vitro,  but  not  in  vivo  (Bashamboo  et  al.,  2006).  Accordingly,  the  majority  of  both 
undifferentiated  wild  type  and  knock-in  cells  (day  0;  Figures  9.5B  and  9.9B)  express  the 
marker. As CD117 is linked to the maintenance of pluripotency, it also becomes rapidly down-
regulated  during  differentiation  in  vitro,  under  appropriate  growth  conditions  CD117  is 
eventually restricted to many types of stem cells including those facilitating haematopoiesis 
(McKinney-Freeman et al., 2009; Palmqvist et al., 2005). The wild type cells (days 4-15; Figure 
9.5B) accurately match these observations whereas CD117 in the knock-in clone (Figure 9.9B) 
is up regulated on day 15.  
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The high levels of CD31 and CD117 observed on both wild-type and knock-in undifferentiated 
cells support that these cultures were in good condition when differentiation was induced. The 
increase of both markers in the knock-in cells at the end of the differentiation period – when 
macrophages  should  have  been  present  –  seems  to  suggest  that  this  particular  clone  either 
reverts  to  a  less  differentiated  state  or  predominantly  forms  cell  types  expressing  CD31  or 
CD117.  The former seems unlikely, as  LIF  withdrawal has been shown to result in a near 
complete loss of pluripotency after 72h (Palmqvist et al., 2005). The latter would be surprising, 
as apart from serum, IL-3 and MCSF, there were no other growth factors present that would 
favour either endothelial or stem cells in the differentiation culture. Another possibility is, as 
marker expression is measured in the whole cell population, relatively higher survival of CD31 
and CD117 expressing cells. Though why other cell types (i.e. myeloid lineages) would not be 
supported in the knock-in cultures remains unexplained. 
 
The final differentiation experiment seems to suggest that the failure to produce macrophages is 
a phenomenon restricted to Marco iCre2 knock-in clone 29. Clone 48 (Figure 9.10A) produced 
approximately the same amount of macrophages after 2 weeks as wild-type cells – though these 
amounts were lower than observed in other experiments. Again, EBs appeared smaller, though 
in this case this did not seem to interfere with myeloid potential. 
 
At this stage it can only be speculated about the reasons of clone 29 not being able to produce 
macrophages. Several options are conceivable, like the epigenetic state or age/quality of that 
particular clone. Further experiments are needed to establish whether clone 29 is less pluripotent 
– despite its CD117/CD31 profile and its ability to form EBs. It may be wise to focus on the 
other Marco iCre2 knock-in clones for injection. Knock-in EBs reaching a smaller size than 
their wild type counterparts can also not be easily explained at present. It may also be a feature 
of embryonic stem cell age/passage number, but could theoretically mean that Marco exerts an 
unknown dose-dependent role during development, as there is only one active copy in the iCre2 
knock-in cells. 
 
9.8.3  Results from the Reporter GFP System Remain Inconclusive 
 
In line with the previous findings, the failure to detect iGFP activity (Figure 9.8B) induced by 
recombination in differentiated cells can potentially be attributed to the inherent inability of 
clone 29 to form macrophages and thus not switching on iCre2 expression. 
 
The reporter system has generally been shown to work in a transient transfection assay (Figure 
9.7). Nevertheless there may be room for improvement. One of the most important features in a 
reporter construct is the promoter utilized. The herein used reporter vector (Figure 9.6A) is   160 
based on pEGFPN1 (Clonetech) and is driven by a standard cytomegalovirus (CMV) promoter. 
The CMV promoter has long been widely used to drive reporter expression in a wide variety of 
tissues and cells, both in vivo and in vitro, and is generally considered to be constitutively active 
(Makrides, 1999). In the system presented here, it is essential that the promoter driving the 
reporter is active during the undifferentiated ES cell stage to distinguish leakiness of iCre2 
expression, during the EB differentiation process to detect when iCre2 expression is switched 
on, and finally in terminally differentiated embryonic macrophages.  
 
Whilst  the  CMV  promoter  has  been  successfully  used  in  haematopoietic  cells  in  general 
(Keating  et  al.,  1990)  and  macrophages  that  were  either  monocyte  (He  et  al.,  2006)  or 
embryonic stem cell derived (Stevenson et al., 2000) in particular, its suitability to drive gene 
expression in undifferentiated and differentiating embryonic stem cells has been controversially 
discussed. It has been reported, active in transient expression systems by several groups (Kim et 
al., 2007; Wang et al., 2008b; Ward and Stern, 2002), but inactive in mouse ES cells and EBs 
by others (Chung et al., 2002; Kawabata et al., 2005). In stably transfected mouse ES cells, 
CMV promoter activity can usually be seen in ES cells and throughout development, including 
in differentiated cells such as vascular progenitors, cardiomyocytes, mesodermal and neuronal 
cells and fibroblasts (Alexopoulou et al., 2008; Bagchi et al., 2006; Hong et al., 2007).  
 
Some studies noted a variability of expression,  with the CMV promoter being dynamically 
switched on and off throughout development (Stevenson et al., 2000), down regulated after 
longer culture periods (Wang et al., 2008b; Xia et al., 2007) or specifically activated (Chung et 
al.,  2002;  Hong  et  al.,  2007)  or  de-activated  (Bagchi  et  al.,  2006)  in  certain  terminally 
differentiated tissues such as neurons. These widespread differences have been attributed to 
varying vector delivery methods (i.e. virus versus electroporation), the utilized ES cell line, 
vector design (i.e. use of an internal ribosomal entry site) and chromosomal location of stably 
transfected reporters. Taken as a whole, it would appear that the CMV promoter should provide 
sufficient activity for the herein designed reporter system.  
 
Several  studies,  however,  have  suggested  that  other  promoters  may  provide  stronger,  more 
sustainable  reporter  expression,  especially  in  undifferentiated  ES  cells  and  during  the  EB 
formation  process,  though  not  necessarily  in  terminally  differentiated  cells.  Those  are  in 
particular the elongation factor 1 α (EF), the phosphoglycerate kinase (PGK) and the hybrid 
CMV chicken β actin promoters – though the latter has often been reported as only marginally 
more active than the CMV promoter (Chung et al., 2002; Kim et al., 2007; Wang et al., 2008b). 
Whilst the alternative promoters also have been associated with reporter silencing (Xia et al., 
2007) and variable expression levels (Hong et al., 2007) and therefore do not guarantee better   161 
expression,  they  may  be  worth  testing  if  the  herein  described  reporter  system  was  to  be 
improved.  
 
One surprising result is that none of the reporter lines show any significant activation of iGFP 
expression in undifferentiated ES cells (Figure 9.8; 0h). The basal level of iCre2 expression 
noted in Chapter 8.6.4 does not translate into reporter activation. It is conceivable, however, that 
basal  expression  levels  are  too  low  to  mediate  efficient  recombination  of  the  randomly 
integrated reporter construct at its particular chromosomal location or that the  reporter gets 
silenced rapidly. 
 
9.8.4  iCre2 Expression Cannot Be Observed; Marco Appears to Be 
Dysregulated 
 
The utilized RT PCR failed to detect iCre2 expression in all three assayed clones (Figure 9.11). 
While the result is understandable for Marco iCre2 clones 25 and 29, which failed to develop 
measurable amounts of macrophages, clone 48 was expected to switch on expression in the 
differentiated macrophage subpopulation. 
 
Even more surprising is, that Marco expression was both detected by RT-PCR and by flow 
cytometry (Figure 9.10A). Wild type cells showed Marco mRNA from day 7 onwards, when 
macrophage  markers  also  began  appearing,  underlining  the  expected  tissue  specificity.  In 
knock-in cells, however, Marco was constitutively expressed even at the undifferentiated cell 
level indicating a degree of dysregulation. As all assessed clones still harbour the resistance 
gene, this may well be due to Neo
R disturbing expression across the locus, i.e. through its effect 
on the endogenous promoter. To further illuminate this, Marco mRNA expression would need 
to be assessed in a ΔNeo knock-in cell line. The one that is available to date had not been tested 
as it consistently failed to produce macrophages.  
 
When differentiated cells were stained with a Marco specific antibody on day 14, a much larger 
population of differentiated cells (70%), for both knock-in and wild type, show the marker than 
would have been expected from the level of CD11b+/F4/80+ macrophages (3%). If this staining 
was specific as suggested by unstained controls and cells stained with the secondary antibody 
only, it would indicate that Marco is actually not exclusively restricted to macrophages in the 
differentiation culture. In depth analysis of Marco expression through the entire developmental 
process is needed to clarify this. 
 
Due to its knock-in status the recombinase should be mirroring the host gene’s expression. The 
failure to detect amplification of iCre2 cDNA when Marco mRNA is clearly present is therefore   162 
puzzling. The reasons for this finding are speculative at this point, though several options are 
imaginable: 
 
1. PCR and or cDNA synthesis failed: This scenario appears unlikely as both the housekeeping 
gene  control  (HPRT)  and  the  Cre  positive  control  consistently  provided  PCR  products.  All 
shown PCRs (Figure 9.11) were carried out after total RNA had been reverse transcribed using 
a oligodT primer. The utilization of random primers did not facilitate iCre2 amplification either 
(data not shown). 
 
2. iCre2 mRNA copy number too low: PCR failure due to low copy number is imaginable as the 
Cre control utilizes mRNA from a transient transfection that may be more abundant than those 
expressed from the single copy endogenous locus and the RT PCR has not been quantified. 
iCre2, however, should be expressed at the same level/copy number as Marco mRNA as it 
utilizes the same promoter – and therefore produce roughly the same number of transcripts/RT 
PCR templates. The amount of macrophages among the total cell population was quite low (3% 
in the Marco iCre2 48 sample) and therefore restricting the template amount if expression is 
specific. Increasing the number of macrophages in the cultures or cDNA synthesis using an 
iCre2 specific primer may help to increase DNA copy numbers and sensitivity of the assay. It 
is,  however,  also  possible  that  iCre2  mRNA,  for  unknown  reasons,  suffers  from  transcript 
instability. 
 
3. iCre2 is not expressed at all: iCre2 has thus far been functionally tested in CHO and NIH/3T3 
cells  in  vitro  and  the  rat  brain  in  vivo,  expression  in  murine  embryonic  stem  cells  should 
therefore be possible as well (Lacy-Hulbert et al., 2001). As potential expression failure is not 
due to any mutations in the coding sequence (data not shown), two scenarios are conceivable. 
The first is epigenetic silencing during culture, i.e. by methylation, which could be illuminated 
by carrying out a methylation specific PCR. Secondly, iCre2 may have been inserted in the 
wrong place.  As discussed in Chapter 7.15, Marco  contains two potential translational start 
codons (Figure 7.15) and iCre2 was inserted into the one identified as the main translation 
initiation point in macrophages (Kangas et al., 1999). It may be possible that this data is not 
accurate and that the exact location of the translation start codon either needs re-assessing or 
iCre2 has to be inserted to replace the second ATG to function. On the other hand, it seems 
surprising that there should be a complete exclusion of translation from start codons only 100bp 
apart when known mRNA species would support protein synthesis from either one. 
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9.8.5  Summary and Conclusion 
 
Collectively, this chapter establishes a framework for analyzing the expression characteristics of 
the recombinant Cre recombinase before investing resources into creating a mouse model. For 
the pilot study, macrophages and therefore the expression of Marco iCre2 were chosen, as it is 
relatively straightforward to differentiate them in vitro compared to protocols for the generation 
of neutrophils required for the assessment of Itgb2l iCre2. The ability of the tested embryonic 
stem cell lines to form embryoid bodies, beating cardiomyocytes and the expression patterns of 
CD31 and CD117 support they are indeed pluripotent. When it came to the selective expansion 
of  myeloid  progenitors,  however,  only  one  Marco  iCre2  knock-in  was  able  to  produce 
measurable  numbers  of  macrophages  under  the  experimental  conditions  applied.  It  may  be 
necessary to further optimise haematopoietic growth conditions. Non-differentiating clones may  
have acquired genetic aberrations during culture that reduce their pluripotency – the ultimate 
test for this will be their ability to differentiate in vivo, i.e. the generation of chimeric mice. The 
failure  to  detect  iCre2  expression  remains  unexplained  as  the  coding  sequence  is  intact. 
Considering the many unknown factors and evidence of expressional dysregulation pertaining 
to Marco iCre2 clones, it may be prudent to focus the mouse creation process on Itgb2l iCre2 
knock-in clones until the Marco samples can be scrutinized further.   164 
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CHAPTER 10: FUTURE WORK AND THE APPLICATION OF MACROPHAGE AND 
NEUTROPHIL SPECIFIC iCre2 KNOCK-IN MOUSE MODELS 
 
With Itgb2l and Marco iCre2 knock-in cell lines having been established and verified, the next 
step  is  to  create  the  Cre  mice  by  either  blastocyst  injection  or  morula  aggregation.  In  this 
context, alternative ways for removing the G418 selection marker during the mouse production 
process  are  discussed.  Also,  current  methods  for  assessing  iCre2  tissue  specificity  and 
expression levels are recommended, as the mouse models will need to be thoroughly tested 
before they can become useful tools in immunology. Finally, as the envisaged mouse models 
are based on 129, the challenges of choosing an appropriate genetic background are explored 
and  several  possibilities  for  the  long  term  application  of  the  novel  myeloid  iCre2  mice  in 
studying innate immunity in health and disease are suggested. 
 
10.1  Future Work 
 
10.1.1  The G418 Selection Marker Can Be Removed During the Mouse 
Creation Process  
 
As described in Chapter 8.6.2, the G418 resistance marker could not be removed from some of 
the knock-in embryonic stem cell lines due to difficulties in obtaining ES cell subclones. There 
are, however, several methods to enable marker deletion with high efficiency in vivo during or 
after the mouse production process. 
 
The first is removal of Neo
R at the zygote/embryo stage, which requires an additional mouse 
generation and is technically complex; but helps maintain the mice’s genetic background. In one 
study 16 cell stage morulae were isolated, infected with adenoviral Cre, cultured in vitro until 
the early blastula stage and re-implanted into foster mothers. The majority of offspring were 
mosaic  for  the  deleted  marker  and  several  were  able  to  transmit  the  deletion  to  the  next 
generation.  Genomic  integration  of  the  virus,  and  therefore  the  potential  of  insertional 
mutagenesis, was not observed (Kaartinen and Nagy, 2001).  
 
Alternatively,  injection  can  deliver  a  Cre  expressing  plasmid  directly  to  the  pro-nucleus  of 
fertilized  eggs.  Two  studies,  where  a  floxed  Neo
R  marker  was  removed  after  homologous 
recombination, reported 1 or 3 correctly deleted offspring per 160 or 176 (Sunaga et al., 1997; 
Xu et al., 2001b) injected zygotes respectively. In an experiment where the same method was 
used to eliminate a floxed sequence from a strongly expressed transgene, correct genotypes 
were obtained in 18 offspring after the injection of 206 zygotes (Araki et al., 1995). Similarly, 
in  vitro  transcribed  Cre  mRNA  has  been  injected  into  the  zygote  cytoplasm  to  reduce  the   166 
number of floxed transgene copies in a highly efficient manner (de Wit et al., 1998). Most 
recently, zygote injection of a maltose binding protein (MBP) Cre fusion protein (Kolb and 
Siddell, 1996) resulted in efficient marker removal depending on protein concentration. The 
deletion was transmitted to the offspring (Luckow et al., 2009). The use of protein or mRNA is 
advantageous  as  there  is  no  risk  of  insertional  mutagenesis  caused  by  accidental  genome 
integration of plasmid or adenoviral vectors, an event that is not routinely screened for but can 
affect the phenotype. 
 
Secondly, the marker can be removed in vivo by mating the proposed iCre2 knock-in mouse to 
a deleter strain. This method does not require sophisticated embryo manipulation, but needs at 
least two generations and may result in mixed genetic backgrounds. It can, however, be easily 
incorporated into a breeding programme. Deleter strains carry either ubiquitously active Cre – 
often controlled by a viral promoter – or germline specific Cre. A variety of choices are listed in 
Table 10.1.  
 
Two possible transgenic Cre strains designed for ubiquitous expression are EIIa-Cre (Lakso et 
al., 1996) and Meu40Cre (Leneuve et al., 2003). In the former, recombinase expression occurs 
from  an  adenoviral  promoter  whereas  the  latter  utilizes  a  minimal  human  cytomegalovirus 
(CMV) promoter. Both strains facilitate recombination during early embryonic development. F1 
offspring are either completely deleted or mosaic for the floxed target gene. EIIa-Cre produced 
50% complete deletions in F1 when crossed to a mouse carrying a single copy loxP-Neo-loxP 
targeted insert in the immunoglobulin light chain kappa constant region locus (Lakso et al., 
1996). When the desired total deletion cannot be obtained in F1, further crossing of individuals 
exhibiting strong mosaicism reliably creates such individuals in F2. Owing to strong expression 
of EIIa in oocytes, deletion is most efficient when Cre is inherited from the mother. Meu40Cre 
is similarly effective and recombination levels do not differ between maternally and paternally 
transmitted Cre (Holzenberger et al., 2000a).  
 
Numerous alternative ubiquitous Cre models exist, including, other CMV promoter controlled 
strains (Schwenk et al., 1995; Su et al., 2002; Zinyk et al., 1998), β-actin-Cre (Lewandoski and 
Martin, 1997), c-kit-Cre (Bergqvist et al., 1998) as well as a strain expressing a GFP-Cre fusion 
transgene from a prion promoter (Scheel et al., 2003).  
 
Germline-specific  elimination  of  the  resistance  marker  is  sufficient  to  transmit  the  Δneo 
genotype to the offspring. Various transgenic models direct Cre expression to spermatocytes, 
for  example  Sycp1-Cre  (Chung  et  al.,  2004)  or  Prm-Cre  (O'Gorman  et  al.,  1997).  In  the 
transgenic Syn-Cre model, originally produced for neuronal-specific recombination, efficient 
floxed  target  gene  deletion  was  recently  discovered  in  the  testes  during  spermatogenesis,   167 
ultimately resulting in knock-out phenotypes for male progeny (Rempe et al., 2006). Equally, 
there are several Cre systems expressing the recombinase in the female germline, such as Zp3-
Cre, GDF-9-iCre and Msx2-Cre, all of which are active during different stages of oogenesis 
(Lan et al., 2004). 
 
To  summarize,  there  are  a  number  of  alternative  approaches  that  allow  the  removal  of  the 
resistance marker from the germ line. The suitability of using a particular injection method or 
mouse strain needs to be established experimentally. For an optimal choice, the desired target 
genetic background needs to be considered. 
 
Strain 
Name 
Promoter or 
Locus/Type 
Genetic 
Background(s) 
Activity 
   
Reference 
Ubiquitous Cre 
EIIa-Cre  Adenoviral EIIa 
Promoter/Transgene 
C57BL/6 
129/Sv 
FVB/N 
From oocyte through, 
pre-implantation 
embryo, maternal 
imprinting 
(Lakso et 
al., 1996) 
MeuCre40  Human CMV 
Promoter/Transgene 
C57BL/6 
129/Sv 
From morula stage 
until birth 
(Leneuve et 
al., 2003) 
Deleter  Human CMV 
Promoter/Transgene 
C57BL/6J  Pre-implantation 
embryo, X-linked 
transmission 
(Schwenk et 
al., 1995) 
CMV-Cre  Human CMV 
Promoter/Transgene 
C57BL/6  Pre-implantation 
embryo 2-8 cell stage 
(Zinyk et al., 
1998) 
X-linked 
CMV Cre 
Human CMV 
Promoter/Knock-in 
hprt locus 
129S5/SvEvBRd  Early embryonic 
development, X-
linked transmission 
(Su et al., 
2002) 
Prion-
GFPCre 
Prion Promoter/ 
Transgene 
129S6/SvEvTac  Early embryonic 
development 
(Scheel et 
al., 2003) 
c-kit-Cre  c-kit 
Promoter/Transgene 
C57BL/6  Early embryonic 
development 
(Bergqvist et 
al., 1998) 
Germline Cre 
Sycp1-Cre  Sycp1 
Promoter/Transgene 
C57BL/6  Spermatogenesis, 
paternal imprinting 
(Chung et 
al., 2004) 
Syn-Cre  Rat Synapsin I 
Promoter/Transgene 
C56BL/6  Neurons, during 
spermatogenesis 
(Zhu et al., 
2001) 
Prm-Cre  Protamine 1 
Promoter/Transgene 
129/SvJae  During 
spermatogenesis 
(O'Gorman 
et al., 1997) 
Zp3-Cre  Zona pellucida 
protein 3 
Promoter/Transgene 
C57BL/6J  Postnatal oocytes  (de Vries et 
al., 2000) 
GDF-9-
iCre 
Mouse Growth 
Differentiation 
Factor 9 
Promoter/Transgene 
C57BL/6SJ  Postnatal oocytes  (Lan et al., 
2004) 
Msx2-Cre  Msh Homeobox 2 
Promoter/Transgene 
C57BL/6  Postnatal oocytes  (Sun et al., 
2000) 
Table 10.1 Overview of Possible Cre Strains for Selection Marker Deletion in vivo 
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10.1.2  Verification of Tissue-Specific Expression  
 
If iCre2 expressing mouse models were created from the verified knock-in mES cell clones 
described in this work, the tissue specificity and expression levels, as well as potential leakiness 
of the Cre recombinase would need to be assessed before the mouse can be a useful tool in 
immunological research.  
 
In  recent  years,  reporter  mice  have  become  popular  tools  for  the  exploration  of  these 
characteristics.  A  range  of  available  mice  is  summarized  in  Table  10.2.  Such  animals  are 
genetically engineered to express a reporter, such as β-galactosidase, a fluorescent protein or, 
most recently, luciferase, following Cre mediated recombination. The Cre strain is crossed to 
the reporter strain and the offspring are assessed, tissue by tissue, for reporter gene activity. 
Some systems rely on only one reporter, which is activated by the deletion of a floxed stop 
cassette placed between the coding sequence and cooperating promoter (Constien et al., 2001; 
Kawamoto et al., 2000; Luche et al., 2007; Mao et al., 2001; Soriano, 1999). This approach is 
similar to the GFP reporter construct created in this work aimed at establishing iCre2 expression 
in differentiated embryonic stem cells (Figures 9.6&7). Such systems have the disadvantage, 
that  there  is  no  way  of  knowing  whether  the  absence  of  the  reporter  reliably  reflects  Cre 
expression or is instead due to the reporter not functioning properly in the particular tissue.  
 
To circumvent this potential problem, models allowing a binary read-out of two reporters have 
been  developed.  The  first  floxed  reporter  is  expressed  independently  of  Cre  and  gives  an 
indication  of  tissues  in  which  its  presence  is  measurable.  Recombinase  catalysed  deletion 
switches  on  the  second  reporter  and  provides  an  estimate  of  Cre  expression.  Various 
combinations of reporters have been established, ranging from β-galactosidase or β-geo and 
EGFP (Novak et al., 2000; Yamamoto et al., 2009) to various colour fluorescent proteins (De 
Gasperi et al., 2008; Muzumdar et al., 2007). 
 
A reporter mouse would ideally allow visualization of iCre2 activity in all tissues. As these 
models  are  genetically  engineered,  chromosomal  positioning  effects,  instability  of  multiple 
transgenes  and  epigenetic  modulation  can  complicate  this  analysis.  Strong,  ubiquitous 
expression  of  the  reporter  requires  an  appropriate  promoter.  Two  strategies  dominate  the 
available  systems  –  the  use  of  the  heterologous  CAG
10  promoter  (Niwa  et  al.,  1991)  in  a 
transgene or the endogenous ROSA26 locus
11 (Soriano, 1999) as a site for reporter knock-in. 
                                                 
10 The CAG promoter combines the CMV early enhancer with the β actin promoter for strong ubiquitous 
expression. 
11  ROSA26  is  a  mouse  locus,  ubiquitously  expressed  throughout  development  and  in  adult  tissues, 
encoding three non-coding transcripts of unknown function.   169 
Despite this, reporter expression varies among the strains. The RA/EG strain (Constien et al., 
2001), for example, was reported non-functional in the brain and liver and only partially active 
in the spleen, whereas Z/EG (Novak et al., 2000) showed no activity in the lung. Several strains 
are unable to report Cre expression in erythrocytes, including Z/AP (Lobe et al., 1999) and 
CAG-CAT-EGFP  (Kawamoto  et  al.,  2000).  Recently,  it  was  found  that  Z/AP,  Z/EG  and 
ROSA26-EYFP were all equally effective during early embryonic development. When it came 
to assessing Cre activity in adult haematopoietic cells however, both Z/AP and Z/EG reporters 
showed  a lower fraction of reporter positive cells than ROSA26-EYFP.  These observations 
were made with the LysMCre mouse, a granulocyte specific strain similar to the novel models 
proposed in this work (see Chapter 3.3) (Long and Rossi, 2009). ROSA26-EYFP labelled 85% 
of peripheral granulocytes in the double transgenic animal, compared to only 57% or 36% with 
Z/AP and Z/EG respectively. This effect was traced to transgene methylation and incorporation 
into  heterochromatin,  silencing  the  expression  of  the  reporter  and  inhibiting  Cre  mediated 
deletion. Similar effects were reported for other adult tissues, such as kidney, liver, lung and 
retina (Jullien et al., 2007; Zhang et al., 2005).  
 
Alternatively, recombination specificities and levels can be established by Southern Blot. To 
that end, the new Cre mouse is crossed to a floxed model of choice and tissues are assessed by 
quantitative Southern Blot, similar to what has been done in this work to estimate the copy 
number of the knock-in target locus (Figure 6.4).  This technique  was used to establish the 
recombination frequencies in the original publication of the LysMCre mouse (Clausen et al., 
1999).  Southern  Blot  and  fluorescence  measurements,  have  been  reported  to  be  sometimes 
conflicting. In the assessment of the functionality of the CD11b-Cre transgene, a  monocyte 
targeted Cre and thus similar to the macrophage Cre presented here, Southern Blot analysis 
showed close to 100% recombination in peritoneal macrophages but only 38% for the reporter 
EGFP  (Ferron  and  Vacher,  2005).  These  experiments  were,  however,  carried  out  using the 
Z/EG reporter, which has since been identified as being of limited use for haematopoietic cells 
(Long and Rossi, 2009).  
 
Collectively, these experiences show that the choice of reporter is a crucial factor in assessing 
the  usefulness  of  the  proposed  macrophage  and  neutrophil  specific  iCre2  lines.  First,  the 
reporter  must have sufficient  activity in the haematopoietic lineage.  The  ROSA26 knock-in 
constructs appear to be the  most promising candidates. Second, in order to get an accurate 
impression of potential leakiness, several reporter strains may be necessary to guarantee truthful 
reporter read-out across all tissues. Thirdly, recombination levels deduced from reporter gene 
expression  should  be  verified  by  an  independent  method,  i.e.  Southern  Blot.  Lastly,  as  the 
recombination  efficiency  depends  on  the  chromosomal  location  of  the  loxP  sites,  levels   170 
established in the reporter strain may not always be an accurate representation for all potential 
floxed target genes. 
 
Strain Name  Reporter  Locus or 
Promoter 
Activa-
table by 
Reporter Activity 
Verified in 
Reference 
 
Z/AP  β-geo, 
Alkaline 
phosphatase 
Transgene, 
CAG 
promoter 
Cre  Embryo, most 
adult tissues 
(Lobe et al., 
1999) 
ROSA26-βgeo  β-geo  Gene 
trapped 
ROSA26 
Cre  Early embryo, 
haematopoietic 
tissues, germ line 
(Mao et al., 
1999) 
R26R  β-geo  Gene 
trapped 
ROSA26 
Cre  Embryo  (Soriano, 1999) 
CAG-CAT-
EGFP 
EGFP  Transgene, 
CAG 
promoter 
Cre  Most adult tissues  (Kawamoto et 
al., 2000) 
Z/EG  β-gal, EGFP  Transgene, 
CAG 
promoter 
Cre  Most adult tissues  (Novak et al., 
2000) 
RA/EG  EGFP  Knock-in 
RAGE 
Cre  Embryo, most 
adult tissues 
(Constien et al., 
2001) 
ROSA26-
EGFP 
EGFP  Gene 
trapped 
ROSA26 
Cre  Embryo, 
haematopoietic 
tissues 
(Mao et al., 
2001) 
ROSA26-
EYFP 
ROSA26-
ECFP 
EYFP 
ECFP 
Knock-in 
ROSA26 
Cre  Embryo, brain  (Srinivas et al., 
2001) 
Z/RED  RFP  Transgene, 
CAG 
promoter 
Cre  Embryo, ES cells, 
most adult tissues 
(Vintersten et al., 
2004) 
mT/mG  Tomato, 
EGFP 
Knock-in 
ROSA26 
& CAG 
promoter 
Cre  Most adult tissues  (Muzumdar et 
al., 2007) 
ROSA26-RFP  RFP  Knock-in 
ROSA26 
Cre  Most adult tissues, 
T lymphocytes 
(Luche et al., 
2007) 
GNZ  GFP/β-gal 
fusion 
Knock-in 
ROSA26 
Cre  Embryo  (Stoller et al., 
2008) 
IRG  RFP, EGFP  Transgene, 
CAG 
promoter 
Cre     Most adult tissues  (De Gasperi et 
al., 2008) 
Tg(CAG-luc)  Luciferase  Transgene, 
CAG 
promoter 
Cre  Induced gliomal 
and lung tumors 
(Woolfenden et 
al., 2009) 
R26
NZG  β-gal, EGFP  Knock-in 
ROSA26 
& CAG 
promoter 
Cre, Flp  Most adult tissues  (Yamamoto et 
al., 2009) 
Table 10.2 Reporter Mice for the in vivo Assessment of Site Specific Recombination 
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10.1.3  Considering the Genetic Background of Mouse Models 
 
10.1.3.1  129 or C57BL/6 in Immunology 
 
Inbred mouse strains have initially been generated to achieve certain phenotypes. As such, they 
differ significantly and also lack the genetic diversity found in wild derived mice (Salcedo et al., 
2007; Yoshiki and Moriwaki, 2006). Therefore the genetic background is a crucial factor that 
needs  to  be  considered  when  designing  experiments.  129  mice,  for  example,  have  lower 
breeding efficiencies, and show significant differences in immune response (McVicar et al., 
2002) and behaviour (Crawley et al., 1997) when compared to another commonly used strain 
C57BL/6. Furthermore, the 129 inbred strain has a complex and poorly documented genetic 
history. Deliberate and accidental out crossings have created several distinctive substrains and 
high levels of genetic variation (Simpson et al., 1997; Threadgill et al., 1997). 
 
Nevertheless, the first mouse embryonic stem cell lines were isolated from the 129 background 
(Evans and Kaufman, 1981; Martin, 1981) and have become widely used. They are robust in 
culture, exhibit good homologous recombination efficiency, chimera formation and germline 
transmission frequencies. Consequently and in spite of the associated drawbacks; 129 ES cells 
remain a  major resource for generating mice and numerous  models established in the past, 
particularly Cre producer and responder strains, are based on this background.  
 
129P2 ES cells were also chosen as the starting point for the project presented here because they 
matched the background of a floxed responder strains previously generated in the lab (Cazac 
and Roes, 2000). Thus, when both models are crossed to obtain novel conditional knock-outs, 
there  is  no  mixing  of  the  genetic  background.  Mixed  backgrounds  can  be  detrimental  to 
phenotypic analysis for reasons described below. However, even though the targeting vectors 
created in this work are derived from a 129 BAC library (more specifically 129S7/SvEvBrd-
Hprt
b-m2) (Adams et al., 2005), they could easily be used to target C57BL/6 ES cells, as there 
are no known SNPs in either the 4kb upstream or 7kb downstream homology arms
12. 
 
Which mouse strain is best suited for experimental models remains a controversial issue. In 
immunology, in recent years the pure C57BL/6 background has been established as the de-facto 
gold standard (Rivera and Tessarollo, 2008). Notably, C57BL/6N embryonic stem cell lines 
have also been chosen as the base for recently established high-throughput mouse mutagenesis 
programmes (see Chapter 2.6) and C57BL/6  is also the reference strain of the mouse genome 
project (Waterston et al., 2002). 
                                                 
12 As ascertained by carrying out a SNP query comparing the respective sequences between 129/Sv and 
C57BL/6  using  the  Mouse  Genome  Database  (MGD),  Mouse  Genome  Informatics,  The  Jackson 
Laboratory, Bar Harbor, Maine. World Wide Web (URL: http://www.informatics.jax.org). (March 2010)   172 
The shift from 129 to C57BL/6 has primarily been facilitated by the recent expansion of the ES 
cell repertoire. It is now possible to generate mice directly from C57BL/6 lines, thus avoiding 
lengthy periods of backcrossings onto the target genetic background (Auerbach et al., 2000; 
Kontgen et al., 1993; Pettitt et al., 2009; Schuster-Gossler et al., 2001). It should be noted that in 
general  C57BL/6  embryonic  stem  cell  lines  are  less  robust  in  culture  than  129  lines.  For 
example, Bruce4 ES cell clones are four times more likely to be aneuploid than those of the 129 
line E14Tg2a.4. Aneuploidy reduces the ability to re-populate the mouse germ line (Hughes et 
al., 2007). C57BL/6 ES cells also showed a 40% diminished ability to form chimeras as judged 
by coat colour when injected into BALB/c blastocysts compared to 129 ES cells injected into 
C57BL/6. Five independent clones needed to be injected, as opposed to three, to obtain the 
same number of chimera (Ware et al., 2003). Lower germ line transmission frequencies have 
also been reported (Auerbach et al., 2000).  
 
Conversely there are published findings in which C57BL/6 embryonic stem cell lines have been 
shown to be as efficient as those derived from 129. A newly isolated line from C57BL/6NHsd 
mice,  for  instance,  displayed  only  insignificantly  lower  targeting  and  chimera  formation 
frequencies than an established 129SvJ line (GSI-1), apart from exhibiting slower growth. In 
terms  of  germline  transmission,  the  C57BL/6  line  was  almost  3  times  more  efficient  when 
considering the necessary chimera breeding time (Keskintepe et al., 2007). Similarly, isogenic 
BAC  vectors  targeted  to  Ap3b2  and  Lmna  loci  showed  comparable  levels  of  homologous 
recombination  in  both  C57BL/6  (Bruce4  line)  and  129  (CJ7  and  W9.5  lines).  Though  the 
proportion of chimeras born from C57BL/6 ES cells was about 50% lower, all tested chimera 
transmitted to the germline, compared to only 30% from the 129 background (Seong et al., 
2004). Better C57BL/6 lines are in development and may replace 129 in the future (Pettitt et al., 
2009). 
 
There  are,  however,  limitations  of  rigidly  restricting  immunological  research  to  one  inbred 
background.  C57BL/6  does  possess  some  features  that  preclude  the  analysis  of  certain 
questions, for example a low tumor incidence, a skewing towards a T helper 1 (Th1) responses 
(O'Neill et al., 2000) or the inability to model human asthma accurately (Herz et al., 2004). It is 
also unwise to try and develop models of complex human disease in just one inbred mouse 
strain,  given  that  human  populations  display  extreme  genetic  heterogeneity  (Rivera  and 
Tessarollo, 2008). 
 
This problem may be overcome by the ever increasing number of available embryonic stem cell 
lines.  Lines  derived  from  DBA,  C3H,  FVB  and  BALB  sub  strains  have  been  isolated 
(Schoonjans et al., 2003).  Most recently, a line originating from MSM/Ms, an inbred  wild-
derived  strain  phylogenetically  separated  from  the  common  laboratory  mouse  by  about  1   173 
million years, has joined the repertoire (Araki et al., 2009). The rapidly increasing selection 
should enable the creation of  mouse models in any desired genetic background in the near 
future. 
 
10.1.3.2  Mixed Backgrounds and Appropriate Controls 
 
Should  it  become  necessary  to  cross  the  herein  proposed  129  iCre2  producer  mice  onto 
C57BL/6 responder mice, the loss of the congenic background means that appropriate controls 
are needed. Due to linkage, sequences flanking the modified target gene will always reflect the 
donor ES cell strain even after 10 or more backcrosses achieving a more than 99.9% identity 
with the desired recipient genome (Figure 10.1A). Linked loci are only segregated following 
recombination, which is a stochastically unlikely event (Crusio, 2004). Linked regions can be 
very large in size and have been reported to influence the phenotype. For example, a knock-out 
of Cd38 carried out in 129 cells, backcrossed onto C57BL/6 for 10 generations, still carried 
about 40Mb of linked 129-dervied DNA, which is equivalent to about 400 genes (Leiter, 2002). 
 
Optimal control animals in mixed background phenotypic analyses are those that are identical at 
all loci. If the introduced modification is dominant, a co-isogenic
13 129 heterozygote (created by 
mating  the  chimera  to  the  strain  from  which  the  ES  cells  were  derived)  can  be  crossed  to 
C57BL/6 wild type mice (Figure 10.1B). Control crosses are more complicated if the modified 
locus  is  recessive  (Figure  10.1C),  a  co-isogenic  129  heterozygote  needs  to  be  crossed  to  a 
congenic
14 C57BL/6 homozygote created by at least 10 backcrosses. Offspring will be either 
homozygous or heterozygous for the targeted loci and flanking genes (Wolfer et al., 2002).  
 
Attempts have been made to reduce the time needed for backcrossing. Recently created mouse 
SNP  and  micro  satellite  databases  are  useful  tools  in  order  to  identify  the  origin  of linked 
flanking genes and locate those possibly impacting on the mutant phenotype (Ridgway et al., 
2007). In conventional set-ups, ten backcrosses take 2-4 years on average. Speed congenics uses 
genome-wide polymorphic markers (microsatellites or SNPs) to identify offspring with minimal 
linked gene content that are selected for continued breeding. In several studies, the number of 
backcrosses required to achieve more than 99% congenicity could be halved to 4-5 generations. 
This method, however, comes with the need for extensive genotyping of all offspring, beyond 
just  the  traditional  test  for  the  presence  of  the  engineered  locus,  which  creates  its  own 
significant  cost  (Armstrong  et  al.,  2006;  Collins  et  al.,  2003;  Wong,  2002).  Lately,  speed 
congenics were combined with speed mating. Spermatids were isolated from immature mixed 
background males at 22-25 days of age and injected into C57BL/6 donor oocytes.  
                                                 
13 Genetically identical to the parent inbred strain except for the mutation in one defined gene. 
14 Genetically identical to the parent inbred strain except for a limited genetic region, i.e. the mutated 
gene and flanking alleles.   174 
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Figure 10.1 Linked Genes and Controls 
A illustrates the chromosomal makeup of several generations of crosses between gene-targeted 
(black dot) 129 mice and pure C57BL/6 animals. By F2 chromosomes will be of mixed origin, 
genes linked to the modification (black lines), however, will always represent the 129 donor 
strain.  In  order  to  exclude  the  phenotype  arising  from  linked  genes,  control  animals  are 
necessary. For dominant modifications (B), a co-isogenic 129 heterozygote can be crossed to a 
wild type pure C57BL/6 mouse. Offspring are either homozygous wild type or heterozygous for 
the modification. Any observed phenotype must derive from the modification as the animals are 
otherwise genetically identical. In case of recessive modifications (C), heterozygous co-isogenic 
targeted 129 mice are crossed to homozygous congenic C57BL/6 mutants. Offspring, whether 
homozygous or heterozygous, is identical at all loci, including the flanking genes of the targeted 
locus, thus influence from linked alleles can be eliminated. 
Adapted from (Crusio, 2004).   175 
After selecting appropriate offspring based on genome markers, congenicity could be achieved 
after approximately 6 months with 4-5 accelerated generations (Ogonuki et al., 2009). 
 
In general, there seems to be no ideal genetic background choice for the introduction of targeted 
modifications  (Frankel,  1998).  All  available  inbred  strains  have  certain  disadvantageous 
phenotypic traits due to a lack of genetic variability (Linder, 2006). The mixing of backgrounds 
can further confound the analysis of observed phenotypes and should either be avoided by using 
ES cells co-isogenic to the inbred strain chosen for analysis or by carefully monitoring with the 
appropriate  controls.  Ideally  mutant  phenotypes  should  be  analyzed  in  different,  well-
characterized, genetic backgrounds. In many cases this labour and cost-intensive approach may 
not be feasible, though it could be beneficial in dissecting complex phenotypes originating from 
the function of numerous genes.  
 
In conditional knock-out experiments, an additional Cre-only control – a mouse carrying the 
recombinase but not the target of choice – should be considered. Most Cre donor strains appear 
phenotypically normal, though some researchers consider this a surprising feat in light of the 
ongoing potential of Cre toxicity. It has been postulated that Cre mice, due to developmental 
adaptation, possess a more active DNA repair machinery, which is particularly relevant if genes 
involved in DNA repair are to be assessed (Schmidt-Supprian and Rajewsky, 2007). There are 
also Cre producers whose phenotypic abnormalities have complicated the investigation of the 
conditional knock-out. The RIP-Cre model, for example, was eventually shown to be glucose 
intolerant – problematic in a model primarily used for diabetes research (Lee et al., 2006). 
Therefore, the inclusion of a Cre control in all experiments ensures that observed variances, 
especially subtle ones, can indeed be attributed to the gene investigated.  
 
10.2  Application of the Envisaged iCre2 Models 
 
10.2.1  Dissecting the Function of the TGF-β Receptor in the Myeloid System 
 
The TGF-β cytokine system plays roles in tissue homeostasis, disease and development. It is 
involved in diverse cellular processes, such as differentiation, proliferation and apoptosis (Kang 
et al., 2009). As conventional TβR knock-outs are lethal (Oshima et al., 1996) and organism 
wide deletion of the  receptor’s agonist isoforms  results in complex, difficult to dissect  and 
potentially also lethal phenotypes (Dunker and Krieglstein, 2000); conditional models are the 
best way to examine transforming growth factor β receptor type II (TβR) function in individual 
immune  cells.  TGF-β  function  is  considered  to  be  of  major  regulatory  importance  in  the 
immune system in general and a large body of research focuses on its anti-inflammatory impact   176 
as a potential treatment route for immune disorders (Moore et al., 2008; Schmidt-Weber and 
Blaser, 2006; Taylor, 2009; Wahl et al., 2006). 
 
One of the aims of this thesis is to utilize the novel iCre2 mice for the myeloid specific in-
activation of TβR as relatively little is known about the role of the TGF-β system in neutrophils 
and macrophages and prior research has been predominantly focused on creating conditional 
knock-outs in either B cells or in the entire haematopoietic system. 
 
A mouse model where loxP sites flank exon 3 of the gene encoding the TGF-β receptor’s ligand 
binding domain has been created in the lab (Cazac and Roes, 2000). Previous use of the floxed 
TβR mouse, in conjunction with CD19-Cre, enabled the B cell specific ablation of TβR, which 
identified  important  roles  for  TGFβ  in  B  cell  homeostasis,  maintenance  of  an  appropriate 
immune response level and the control of IgA production (Cazac and Roes, 2000). Furthermore, 
TGF-β  receptor  induced  inhibition  of  antigen  and  Toll-like  receptor  signalling,  as  well  as 
increased calcium flux and suppression of apoptotic factors, were shown to be main elements in 
avoiding autoimmunity (Roes et al., 2003).  
 
A similar mouse model, in which exon 4 of the TβR gene is flanked by loxP sites, is available. 
Deletion resulted in receptor inactivation as exon 4 encodes the majority of the receptor kinase 
and the entire transmembrane domain (Leveen et al., 2002). A widespread conditional knock-
out in the haematopoietic system, achieved with the interferon inducible Mx1-Cre strain (Kuhn 
et  al.,  1995),  caused  an  inflammatory  disorder  characterised  by  multifocal  tissue  leukocyte 
infiltration that typically was lethal after 8-10 weeks (Leveen et al., 2002) and mirrored the 
conventional knock-out phenotype (Oshima et al., 1996). The same model was used to show 
that  TβR  deficiency  does  not  influence  thymic  T  cell  differentiation,  though  there  was  an 
increase in CD8+ T cell proliferation (Leveen et al., 2005). 
 
10.2.1.1  TGF-β and Neutrophils 
 
Neutrophils, like most tissues in the body, express TGF-β receptors and are capable of storing 
and  secreting  TGF-β  (Fava  et  al.,  1991).  The  effect  of  TGF-β  signalling  on  neutrophil 
recruitment and activation in vivo remains unclear. On the one hand, TGF-β can act as a very 
potent chemoattractant for neutrophils in vitro (Brandes et al., 1991; Reibman et al., 1991) as 
well as in vivo after being injected into rat knees resulting in an arthritis like phenotype (Allen 
et al., 1990; Fava et al., 1991) or applied via the intra-bronchial route of rats experiencing E.coli 
induced  pneumonia  (Cui  et  al.,  2003).  These  findings  are  confirmed  by  reduced  neutrophil 
migration in mice where the TGF-β signalling molecule Smad3 is knocked-out (Yang et al., 
1999). On the other hand, TGF-β has been demonstrated to impair IL-8 dependent neutrophil   177 
transendothelial migration (Smith et al., 1996), reduces neutrophil adhesion to endothelial cells 
isolated from the umbilical vein (Gamble and Vadas, 1988), inhibits neutrophil response when 
co-injected with LPS into rat trachea (Ulich et al., 1991) and also impairs  neutrophil migration 
to the peritoneum after stimulation with thioglycollate (Gresham et al., 1991). One study found 
an  increased  neutrophil  influx  into  the  lungs  when  TGF-β  function  was  suppressed  by  an 
antibody in a guinea pig model of tuberculosis, even though an adequate immune response 
failed to develop (Allen et al., 2008). 
 
Many of the downstream signalling targets relevant to TGF-β chemotaxis in neutrophils are 
poorly characterised. Weak activation of the p38 MAP kinase (Hannigan et al., 1998) and a 
unique subset of G proteins (Haines et al., 1993) are involved in signalling, as is the modulation 
of L-Selectin expression (Malipiero et al., 2006). Adhesion and migration in response to TGF-β 
is dependent on fibronectin deposition in the extracellular matrix (Parekh et al., 1994). TGF-β 
signalling in  conjunction  with  other  inflammatory  stimuli  such  as  LPS,  does  not,  however, 
activate neutrophil processes such as the respiratory burst or de-granulation (Haines et al., 1993; 
Shen et al., 2007), though one study infers such activation when neutrophils are attached to 
fibrinogen in vitro (Balazovich et al., 1996) 
 
Recent findings suggest that TGF-β receptor induced neutrophil suppression can have adverse 
effects  on  disease  outcome.  In  a  mouse  model  of  meningitis,  the  inactivation  of  TβR  on 
leukocytes  promoted  host  defense  and  reduced  brain  damage  and  was  accompanied  by  an 
increased  number  of  neutrophils  in  the  central  nervous  system  (Malipiero  et  al.,  2006). 
Similarly, tumor infiltrating neutrophils assumed capabilities that enabled them to arrest tumor 
growth  and  kill  tumor  cells  in  conjunction  with  CD8+  T  cells  when  the  TβR  kinase  was 
inhibited  by  a  small  molecule  (Fridlender  et  al.,  2009),  The  exact  mechanisms  of  these 
processes are unknown, but could provide novel treatment options.  
 
10.2.1.2  TGF-β and Monocytes/Macrophages 
 
As with neutrophils, the knowledge about TGF-β function in monocytes and macrophages is 
limited. Resting monocytes constitutively express TGF-β receptors and react to their stimulation 
by chemotaxis (Wahl et al., 1987).  Activation and differentiation of monocytes results in a 
marked down-regulation of cell surface receptor concentration which reduces the sensitivity to 
TGF-β (McCartney-Francis and Wahl, 1994).  
 
The role of TGF-β signalling in the macrophage context is somewhat unclear. Pro-inflammatory 
effects include the recruitment to sites of injury, secretion of cytokines, for example IL-1β and 
TNF-α (Wahl et al., 1987), expression of macrophage integrins for endothelial adhesion and   178 
matrix metalloproteinases (MMP) for the dissolution of vascular basement membranes (Wahl et 
al., 1993), induction of Fc gamma receptor 3 (FcγRIII) to recognize bound IgG and stimulate 
phagocytosis (Welch et al., 1990) and priming of bone marrow derived macrophages to produce 
more nitric oxide in response to some parasites (Lin et al., 1995). In vivo studies support this 
pro-inflammatory impact. Blocking TGF-β receptor associated kinase function, for example, 
lowered macrophage TNF-α production and reduced levels of tissue damage and lethality in 
mouse models of septic shock (Chen et al., 2008). In activated human macrophages, TGF-β 
stimulation  resulted  in  a  pattern  of  inflammatory  gene  activation  similar  to  that  found  in 
macrophages associated with atherosclerotic lesions (Gratchev et al., 2008). 
 
Yet, TGF-β receptor signalling in macrophages also has powerful anti-inflammatory effects. 
These include the deactivation of macrophages, i.e. terminating the production and release of 
antimicrobial  substances  such  as  reactive  oxygen  intermediates  (ROI),  reactive  nitrogen 
intermediates (RNI) and inflammatory cytokines (Bogdan and Nathan, 1993; Ding et al., 1990; 
Langermans et al., 2001; Tsunawaki et al., 1988) or the suppression of pro-coagulant activity 
(Jungi et al., 1994). Macrophages produce TGF-β after phosphatidylserine receptor mediated 
ingestion  of  apoptotic  cells  (McDonald  et  al.,  1999)  and  downregulate  themselves  in  an 
autocrine  manner.  Inflammatory  cytokine  production  is  reduced  through  the  sequential 
activation of TβR and ERK and ultimately inhibition of p38 MAPK (Xiao et al., 2002). The 
same  process,  though  meant  to  prevent  excessive  inflammation,  is  also  associated  with 
pathological  fibrosis  (Nacu  et  al.,  2008).  In  general,  the  dampening  effects  of  TGF-β  on 
macrophages are believed to be essential to resolve inflammation and prevent tissue damage. 
 
A link between TGF-β signalling in macrophages and cancer has been established, similar to 
that found with neutrophils, though the findings appear to be contradictory. One study observed 
that reduced TGF-β receptor activity in advanced colon cancer is accompanied by a higher 
fraction of infiltrating tumor associated macrophages and worsened clinical prognosis (Bacman 
et al., 2007). TGF-β receptor suppression by a dominant negative mutant, however, rendered the 
murine macrophage cell line RAW264.7 more cytotoxic towards co-cultured carcinoma cell 
lines  due  to  the  increased  production  of  TNF-α,  IFN-γ  and  induced  nitric  oxide  synthase 
(iNOS). This study postulated that TGF-β resistant macrophages have a higher tumour killing 
ability, though this comes at the price of increased systemic autoimmunity (Lee et al., 2007). 
 
10.2.1.3  Summary 
 
An overall view is emerging that TGF-β function in the immune system in general, and in 
neutrophils and macrophages in particular, is of bipolar nature (summarized in Figure 10.3). 
Whether TGF-β receptor signalling will be pro- or anti-inflammatory seems to depend on the   179 
cellular differentiation status, local levels of TGF-β, its receptor and other cytokines as well as 
the stage of the inflammatory process (Ashcroft, 1999; Wahl, 2007). The role of TGF-β appears 
to be the establishment of an adequate immune response early on in inflammation, but also the 
resolution of the late inflammatory process. The overzealous dampening of immune excitability 
by TGF-β, however, plays an important role in disease.  
 
Much of the current knowledge about TGF-β function in innate immunity has been obtained by 
systemic blockade using anti-TGF-β or anti TGF-β receptor antibodies, TGF-β decoy molecules 
or TGF-β serine/threonine kinase inhibitors (Malipiero et al., 2007). All these strategies affect 
multiple  tissues  and,  due  to  the  widespread  influence  of  TGF-β,  bear  the  risk  of  creating 
complex phenotypes that may preclude discovering effects on individual immune cell types. 
The herein proposed neutrophil and macrophage specific iCre2 deleter strains, however, are 
ideally suited to produce superior models in which receptor function is only switched off in the 
murine  myeloid  compartment.  Combining  such  novel  conditional  knock-outs  with  murine 
disease models may help to clarify the role of TGF-β in the innate immune system. 
 
Figure 10.2 Multiple Effects of TGF-β on Neutrophils and Macrophages 
TGF-β receptor function exerts varied influences neutrophils (top) and macrophages (bottom), 
which are often of bipolar nature and cause cells to react either pro- (left) or anti-inflammatory 
(right). 
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10.2.2  Assessing the Role of Macrophages and Neutrophils in Health and 
Disease 
 
Despite being primarily intended to create conditional TGF-β receptor knock-outs, the proposed 
iCre2 models can be applied to facilitate the tissue specific ablation of any gene of interest for 
which floxed mouse models are either already available or can be produced. As such they will 
significantly expand the toolbox available for immunological research by allowing the somatic 
mutagenesis  of  widely  expressed  genes  to  elucidate  their  role  in  health  and  disease  (Roes, 
2007). This concluding section is aimed at suggesting an overview of areas for which the novel 
iCre2 mice may be useful. 
 
The  Msr1  iCre2  mouse  is  anticipated  to  mediate  deletion  in  all  populations  of  murine 
macrophages.  As  such,  it  would  be  ideally  suited  to  study  gene  function  in  conditions 
characterized  by  systemic  dysregulation  of  monocyte/macrophage  activation  processes.  One 
such  disease  is  rheumatoid  arthritis  (RA),  a  multisystemic  autoinflammatory  syndrome  that 
results in the destruction of synovial tissues (Drexler et al., 2008). RA is a highly complex 
disease  with  virtually  all  signalling  pathways,  soluble  mediators  and  cell  surface  proteins 
affecting  macrophages  being  altered  and  contributing  to  pathogenesis  (Kinne  et  al.,  2007). 
Therefore, a virtually endless array of genes that have been implicated in RA, may be suitable 
for conditional knock-out to help and understand disease etiology or identify novel drug targets. 
These may include transcription factors of the fos and jun families (Zenz et al., 2008), whose 
conventional knock-outs largely exhibit lethal phenotypes (Hilberg et al., 1993; Karreth et al., 
2004;  Schorpp-Kistner  et  al.,  1999;  Schreiber  et  al.,  2000);  cytokines,  their  receptors  and 
downstream signalling molecules considered to be novel drug targets such as IL-15, IL-17  or 
IL-18 (Pickens et al., 2010; Ruckert et al., 2009; Shao et al., 2009); or the macrophage matrix 
metalloprotease  MMP12  (Chen,  2004;  Liu  et  al.,  2004)  co-responsible  for  observed  tissue 
damage.  
 
The Marco iCre2 strain, with its more restricted expression pattern and its expected ability to 
catalyse  recombination  in  alveolar  macrophages  in  particular,  will  be  ideally  suited  to 
investigate murine models of airway disease. The role of alveolar macrophage (AM) function in 
asthma, a condition characterized by chronic inflammation and the narrowing of bronchi,   is 
generally considered to be the suppression of airway hyperresponsiveness. How AM control 
this  process,  whether  cell-cell  contacts  or  soluble  mediators  are  involved,  and  how  AM 
behaviour is altered in the disease state is not understood (Peters-Golden, 2004). Murine models 
in which candidate mediators or their up- and downstream targets are inactivated in an AM 
specific manner will help to comprehend disease progression. Currently discussed candidates 
include  IL-17  (Song  et  al.,  2008),  IL-33  (Kurowska-Stolarska  et  al.,  2009),  nitric  oxide   181 
(Esposito  and  Cuzzocrea,  2007;  Mulrennan  and  Redington,  2004)  and  Prostaglandine  E2 
(Huynh et al., 2005).  
 
Finally, the envisaged Itgb2l iCre2 strain, with its anticipated pan-neutrophil expression pattern, 
may help to shed light on neutrophil involvement in chronic illness. In cancer, for example, 
neutrophils  have  recently  been  found  to  play  key,  but  not  well  understood,  roles  in  tumor 
growth and metastasis. Neutrophils can have pro- and antitumor effects, though what regulates 
this switch is not known (Fridlender et al., 2009; Mantovani, 2009). Effector molecules and 
pathways connected to this recently identified behaviour, and therefore prime candidates for 
conditional knock-outs, are soluble mediators and their receptors IL-1, IL-8, IFN-β, MMP-9 as 
well as transcription factors STAT-3 and c-myc (De Larco et al., 2004; Jablonska et al., 2010).  
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CONCLUSION 
 
The main aim of this thesis was to establish novel myeloid specific Cre mice for the application 
in conditional mutagenesis. To that end, three murine target genes, Itgb2l, Marco and Msr1, 
with predicted expression specificities in neutrophils or macrophages respectively, had been 
chosen  and  BAC  knock-in  vectors  harbouring  the  improved  recombinase  iCre2  had  been 
created by Red/ET recombinogenic engineering prior to the start of this project. These vectors 
were used to directly target 129P2 embryonic stem cells as the long BAC homology arms were 
believed to have a beneficial influence on the targeting frequency. However, the length of the 
homology  significantly  complicated  the  screening  regime  without  actually  improving  the 
targeting  efficiency.  When  the  discovery  of  antiparallel  loxP  sites  in  the  original  targeting 
vectors precluded the removal of the G418 selection marker in all targeted cell lines, the project 
was restarted with an overhauled vector design. In the second generation vector construction 
process, after re-creating BAC knock-ins, an additional round of Red/ET recombineering was 
applied to transfer the iCre2-Neo
R cassette flanked by a total homology of 11kb into plasmid 
based vectors. Several additional sequence inconsistencies, including a cryptic splice site in the 
iCre2 coding sequence causing aberrant splicing and errors introduced by PCR amplifications, 
were found and repaired. The second generation targeting vectors were then used to obtain a 
total  of  650  G418  resistant  clones.  Nine  knock-ins  for  Itgb2l  and  Marco,  with  targeting 
frequencies of 8 and 10% respectively, could be confirmed. The plasmid vectors did indeed 
facilitate a straightforward screening regime whilst maintaining good targeting frequencies. The 
repaired loxP sites  were functional, as indicated by  the successful removal of the selection 
marker.  Some  technical  difficulties  were  encountered  in  producing  pure  deleted  cell 
populations, which  may partially be due to the low  efficiency of transiently delivering  Cre 
expression plasmids to the knock-in lines by electroporation. 
 
A  pilot  study  was  carried  out  to  analyse  tissue  specific  iCre2  expression  in  vitro,  before 
investing  significant  resources  in  the  production  of  a  mouse.  To  that  end,  the  ability  of 
embryonic stem cells to differentiate into virtually any tissue can be utilized to assess promoter 
specificity using a reporter system or RNA analysis. Macrophages were differentiated relatively 
quickly  with  a  minimal  protocol  based  on  three  dimensional  aggregation  of  ES  cells  and 
selective outgrowth of myeloid progenitors in the presence of IL-3 and MCSF. The read-out of 
iCre2  expression,  however,  was  hampered  by  the  reduced  ability  of  knock-in  cell  lines  to 
produce macrophages and a certain level of dysregulation in the Marco locus was observed. The 
question remains whether this is a locus specific feature or due to the presence of Neo
R. If the 
former is true, Marco may not be as accurate driving iCre2 expression in vivo as initially hoped. 
The established procedure could be applied to the Itgb2l knock-ins to test expression in vitro in 
the future, though the generation of neutrophils requires a more time and resource intensive   183 
protocol. The differentiation approach may also provide a useful alternative for studying aspects 
of  myeloid  cell  biology  in  vitro,  as  genetically  engineered  ES  cells  can  be  turned  into 
neutrophils or macrophages without having to produce a mouse model. 
 
In essence, this project provides the resource to generate neutrophil and macrophage specific 
iCre2 mice in the near future, which will prove useful in light of the tens of thousands new 
floxed cell lines and mouse models currently being generated by high throughout mutagenesis 
programmes.  Retrospectively,  as  a  lot  of  time  was  required  to  correct  the  sequence 
inconsistencies encountered in the course of this project, it may have been prudent to advance 
the mouse generation process in parallel with the differentiation experiments, and remove the 
Neo
R selection marker in vivo instead of focusing on in vitro deletion. Ultimately, only the 
completed mouse model will accurately predict how useful the new Cre lines are going to be. 
With absolute tissue restricted expression patterns in Cre mice being the exception rather than 
the rule, specificity will need to be very carefully assessed. Compared to conventional Cre, 
iCre2 should provide higher, more consistent, expression and therefore recombination levels. In 
addition, the knock-in loci are genes of the immune system,  which opens up the option to 
induce inflammatory processes to further increase expression levels in vivo. 
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